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ABSTRACT 
Introduction 
Technologies can help older adults live independently in their homes, but innovators often 
struggle to get their technologies in the hands of older people, their families and the systems that 
help to care for them (Naylor et al., 2015). Governments and older adults agree that aging at 
home for as long as possible is the goal. Technologies exist to help health care institutions, older 
adults, and caregivers to manage health and wellbeing of older adults (Quinn, O’Brien & 
Springan, 2018), but the layers of jurisdiction combined with silos across types and levels of care 
settings are complex for innovators to negotiate. To ensure older adults and their caregivers see 
the benefits of innovative technologies as quickly as possible, innovators need to better 
understand the Canadian policy and regulatory landscape, and policy-makers need to better 
understand policy recommendations which could facilitate innovation and adoption of 
technologies. The objectives of this research are to i) document and understand facilitators and 
barriers to health technology adoption in Canada across all stages of innovation; ii) understand 
how these facilitators and barriers might impact technologies for older adults and caregivers; and 
iii) create an evidence-informed policy agenda for health technology innovation for older adults.  
Methods 
A scoping review guided by Arksey and O’Malley (2005) looked at the barriers and 
facilitators to health technology innovation and adoption in Canada in published and grey 
literature. A graphic depiction was developed to explain scoping review results which outlined 
the stages along the innovation pathway (development, assessment, implementation, 
sustainability) and how some facilitators and barriers to technology innovation and adoption 
v 
exist within certain stages, and others are common across stages (Canadian policy context, 
resources, partnerships).  
Forty-six qualitative interviews with innovators, industry representatives, researchers and 
policymakers were analyzed using framework analysis (Ritchie & Spencer, 2003). Deductive 
coding guided by the graphic depiction developed in the scoping review as well as inductive 
coding to further explain phenomena within each theme guided data analysis.  
Through the scoping review and the qualitative interviews, an inventory of facilitators 
and barriers of health technology innovation was developed. Content analysis (Hsieh & Shannon, 
2005) was used to code facilitators and barriers into policy actions. Group concept mapping was 
used as a systematic approach to integrate group brainstorming, sorting, and rating of policy 
action statements on their relevance and feasibility (Kane & Trochim, 2007).  
Results 
The scoping review generated a comprehensive summary of facilitators and barriers to 
technology development, assessment and implementation, and how those stages are crosscut by 
barriers and facilitators in the Canadian policy context, resources and partnerships.  
Qualitative interviews show resource constraints specific to innovation and adoption of 
the home and community care sector. Interviews revealed a complex home and community care 
sector where care delivery activities crowd out the possibility of considering or adopting a 
technology, exacerbated by the lack of funding for evaluation and implementation of 
technologies. 
Group concept mapping identifies which evidence-informed policy options are deemed 
the most relevant and the most feasible to be implemented, based on input from a diverse 
vi 
stakeholder group. Results reflect funding and system constraints in health care, and the value of 
diverse partnerships across all stages of technology innovation.  
Conclusions 
This work generated an understanding of facilitators and barriers to health technology 
innovation and adoption; how aging-related technologies might experience barriers and 
facilitators to health technology innovation and adoption; and expert stakeholders’ perceptions 
about the relevance and feasibility of potential policy options. These results can inform a policy 
agenda to facilitate innovation and safe adoption of health technologies for older adults.  
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CHAPTER ONE: GENERAL INTRODUCTION AND RESEARCH 
OBJECTIVES 
1.1 General Introduction  
Older adults represent ‘the core business of health care’, composing 50% of visits to general 
physicians, 70% of home care visits, and 90% of nursing home care (Mezey, Capezuti & Fulmer, 
2004; Canadian Home Care Association, 2016). Older adults tend to consume more healthcare 
resources because they are commonly the most complex patients (Canadian Institute for Health 
Information, 2011). Nevertheless, over 85% of older adults have expressed their desire to age in 
place in their homes, even if their health status were to change (Canadian Mortgage and Housing 
Company, 2015). Technologies can empower older adults to age in place and delay placement to 
long-term care (Peek et al., 2016). Technologies have supported aging-in-place through their use 
in a variety of disease states including: palliative care, chronic disease management, mental 
health and behavioral health, supports for family caregivers, transitional care for heart failure and 
home-based primary care for frail older adults (Quinn, O’Brien, Springan, 2018). Technologies 
which can support older adults and caregivers to age in place in and delay placement into long-
term care could contribute to health system sustainability by reducing long-term care costs, 
which represented around 13% of total Canadian health expenditures in 2013 (Grignon & 
Spencer, 2018). 
The Canadian government supports technology innovation through investments in research, 
such as a $35 million investment in the AGE-WELL research network, which has funded 
projects on technological innovation, policy innovations and service innovations to facilitate 
aging in place, and increase quality of life for older adults and their caregivers (AGE-WELL, 
2018). Industry Canada’s $2 billion investment in a Strategic Innovation Fund is open to 
innovators operating in any sector, including health (Government of Canada, 2018). Innovation 
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may be a national priority, but innovators developing health technologies innovators find it 
difficult to navigate multiple sets of policies and regulations across Canadian jurisdictions to 
bring their technologies to market in Canada (Naylor, Fraser, Girard, Jenkins, Mintz and Power, 
2015). As a response to this network of innovation policy between federal, provincial and 
regional jurisdictions, many Canadian innovators bring their technologies to market in other 
countries. It may take as long as 17 years before innovations integrate into usual practice (Balas 
and Boren, 2000).  
To ensure older adults and their caregivers see the benefits of innovative technologies as 
quickly as possible, a better understanding of the Canadian policy and regulatory landscape is 
required with specific areas for policy innovation. A clearly articulated health technology agenda 
is required with specific actions for different actors at different institutional levels which 
characterize the Canadian health care system (Snowdon, 2017; Padfield, 2017). This work 
responds to calls in the literature for a “whole systems approach” to understanding how 
facilitators and barriers at different institutional levels can be translated into viable solutions for 
policy problems (Greenhalgh et al., 2004). 
1.2 Research Objectives 
The overarching goal of this study is to create an evidence informed policy agenda to support 
health technology innovation for older adults. The main objectives are:  
i. Document and understand facilitators and barriers to health technology adoption in 
Canada across all stages of innovation;  
2 
ii. Understand how these facilitators and barriers might impact technologies for older adults 
and caregivers, (such as those being developed inside the AGE-WELL research network); 
and  
iii. Engage diverse stakeholders to create an evidence-informed policy agenda for health 
technology innovation for older adults.  
The following research questions guided the study in meeting its objectives: 
1. What are the policy and regulatory barriers to, and facilitators of, successful innovation 
and safe adoption of health technologies in Canada? 
2. What do experts (researchers, innovators, industry representatives, policymakers) 
perceive to be the most relevant and feasible policy options to facilitate health technology 
innovation and adoption for older adults? 
3. How do older adults and their caregivers perceive key policy issues relevant to health 
technology innovation and adoption? 
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 CHAPTER TWO: Enabling health technology innovation in Canada: Barriers and 
facilitators in policy and regulatory processes1 
2.1 Introduction 
Canada has a strong reputation in clinical trials, health services research, and evidence-
based medicine, but less so in successfully implementing new knowledge in practice. A recent 
national advisory panel on health care innovation found that “entrepreneurs across Canada are 
ﬁnding it difﬁcult to introduce, sustain and scale up their innovations in the health care system” 
(Naylor et al., 2015). Several contributing factors have been identiﬁed and may include policy 
gaps such as jurisdictional issues in the provision of health care across the country (Ontario 
Health Innovation Council, 2015) and an emphasis on pilot projects that do not transform 
promising and valuable health care innovations and technologies nationally (Snowdon, Zur, & 
Shell, 2011; Bégin, Eggertson, & Macdonald, 2009; Savage et al., 2009). With an aging 
population and more individuals being diagnosed with frailty and multiple chronic conditions, a 
nimble and responsive regulatory and policy environment supporting effective innovation to 
ensure better use of scarce resources becomes imperative (Canadian Institute for Health 
Information [CIHI], 2011).  
Deﬁnitions of innovation are varying, but most emphasize new approaches or products 
that result in meaningful improvements; these can include the generation, development or 
implementation of new or better ideas that produce, policies, products, strategies, services, 
1 This article was published in Health Policy following peer review and can also be viewed on 
the journal’s website at: https://www.sciencedirect.com/journal/health-policy 
MacNeil, M., Koch, M., Kuspinar, A., Juzwishin, D., Lehoux, P., Stolee, P. (2019) Enabling 
health technology innovation in Canada: Barriers and facilitators in policy and regulatory 
processes. Health Policy 123(2), 203-214. doi: 10.1016/j.healthpol.2018.09.018 
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procedures, models, or other solutions that add value over the status quo, such as social or 
economic value (Prada, 2015; Blomqvist & Busby, 2016; Ontario Bioscience Innovation 
Organization [OBIO®], 2013; World Health Organization [WHO], 2015). Within the health care 
context, the Canadian Advisory Panel on Healthcare Innovation (the Naylor Panel), deﬁned 
innovative activities as those that “generate value in terms of quality and safety of care, 
administrative efﬁciency, the patient experience and patient outcomes” (Naylor et al., 2015). 
These definitions reinforce the notion that innovation in health care is not simply invention, and 
this project does not wish to promote a technological imperative in health care- but to better 
understand how to get safe, effective innovations (which generate value for patients and the 
health care system) adopted as quickly as possible. With this broad understanding of health 
technologies the term health technology will be used through out to reflection this broad range of 
innovations in health.  
The deﬁnition of ‘health technologies’ also varies; according to the World Health 
Organization, these refer to “the application of organized knowledge and skills in the form of 
devices, medicines, vaccines, procedures and systems developed to solve a health problem and 
improve quality of lives,” whereas the International Network of Agencies for Health Technology 
Assessment deﬁnes a health technology as “an intervention that may be used to promote health, 
to prevent, diagnose or treat acute or chronic disease, or for rehabilitation, and may include 
pharmaceuticals, devices, procedures and organizational systems used in health care”, (Agency 
for Healthcare Research and Quality, n.d.; International Network of Agencies for Health 
Technology Assessment [INAHTA], 2006).  
Despite the various beneﬁts of many health technologies, some innovations have been 
criticized as a driver of rising health care expenditures (Chandra & Skinner, 2012; Sorenson, 
5 
Drummond, & Bhuiyan-Khan, 2013). Recent reviews have shown this relationship between 
innovation and expenditures may be complicated by the use of cost-ineffective innovations 
(Chandra & Skinner, 2012; Sorenson et al., 2013). Therefore, access to technological innovations 
should be mediated by consideration of which innovations offer the best value-for-money, for 
which patients (Chandra & Skinner, 2012; Sorenson et al., 2013).” 
Factors that foster the adoption of health care innovations have been studied and reported 
on in the context of a range of countries internationally (Keown et al., 2014). With this paper, we 
aim to address a knowledge gap and further the existing body of evidence by describing 
documented policy and regulatory barriers and facilitators to the adoption of health technologies 
and medical devices in Canada. With a small market and a negative trade balance for medical 
devices, the Canadian context is similar to a number of other countries (International Trade 
Administration [ITA], 2016). Canada is geographically adjacent to the United States, which 
represents the largest global medical device market share, similar to smaller countries that border 
larger medical device markets such as those in Germany, France, or Japan (Snowdon et al., 2011; 
ITA, 2016). 
2.2 Methods 
2.2.1 Rationale 
In this scoping review, we utilized a ﬁve-stage methodological framework as outlined by 
Arksey and O’Malley to identify the breadth of key concepts and the main types and sources of 
existing evidence (Arksey & O’Malley, 2005). We selected a scoping review to address a broad, 
complex and exploratory research question that spans a number of diverse disciplines, and 
identiﬁes gaps in the existing literature. This approach also gave us the ﬂexibility to include a 
6 
variety of studies, including grey literature (which is especially relevant to health policy 
research), and studies of varying quality (O’Brien et al., 2016). Additionally, this approach 
allowed us to determine the feasibility of a future systematic review (O’Brien et al., 2016).  
2.2.1 Stage 1: identifying the research question 
Our review aimed to answer the question, what are the policy and regulatory barriers to, 
and facilitators of, successful innovation and safe adoption of health technologies in Canada? 
2.2.2. Stage 2: identifying relevant sources 
We conducted a comprehensive search of all published English language literature using 
both MEDLINE and Scopus databases for the period January 2000–October 2016. Search terms 
were developed via an iterative process, in consultation with a health sciences librarian, and 
included: Canada, technology, medical device, government, policy, regulatory, approval process, 
marketing, decision-making, and health technology assessment (HTA). Grey literature was 
searched using The Canadian Agency for Drugs and Technologies in Health (CADTH) Grey 
Matters Search Tool, a comprehensive checklist of national search websites and databases, drug 
and device regulatory agencies, and health economics resources (Canadian Agency for Drugs 
and Technologies [CADTH], 2014).  
2.2.3 Stage 3: study selection 
All publications (e.g., commentaries, editorials, and reviews) were included if they 
involved a health technology or medical device and discussed the barriers to and/or facilitators of 
pol- icy, regulation, approval processes, marketing, decision making, and health technology 
assessment in Canada. Sources that focused on pharmaceuticals or information–system focused 
e-health technologies (such as electronic medical records or e-prescribing systems) were 
excluded. Both Scott et al. (2015) and Varabyova et al. (2017) have excluded these types of 
technologies from systematic searches as their adoption trajectories are seen to be distinct from 
7 
medical technologies. This also serves to limit the scope of the search and increased the 
feasibility of data extraction for the project. No restrictions were placed on the demographics or 
health status of the study participants. 
Search results were exported to RefWorks, a reference management software, and 
divided into four lists for review by four researchers. Each reviewer screened out publications 
with irrelevant titles and abstracts, and independently evaluated the full texts of the remaining 
sources. Reasons for exclusion were documented for all sources that did not meet the inclusion 
criteria. During this process, a random sample of 10 articles were selected to assess the interrater 
reliability of application of the inclusion criteria among the four researchers using Fleiss ‘Kappa 
Fleiss’ Kappa between the four researchers was 0.73, representing ‘substantial’ agreement 
(Fleiss, 1971; Landis & Koch, 1977). The average percent agreement (McHugh, 2012) between 
the researchers was 95%. 
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Figure 1: Flow diagram of literature search and selection of papers  
2.2.4 Stage 4: charting the data 
Each researcher recorded their results in a summary table in Excel, similar to that of 
Arksey and O’Malley (2005), which included the author(s), year, publication type, context or 
topic of the article, and any listed barriers and facilitators to health technology innovation and or 
adoption found in each reference. This provided data amenable to the theming and summarizing 
characteristic of stage ﬁve. 
2.2.5 Stage 5: collating, summarizing and reporting results 
The researchers adopted a directed approach to content analysis as described by Hsieh 
and Shannon (2005). Within this approach, existing literature can be used to identify key 
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concepts as initial coding categories (Hseih & Shannon, 2005). Based on our knowledge of 
existing innovation frameworks (e.g. Innovation Adoption Journey, The Health Technology 
Innovation Cycle) we considered that the stage of innovation was relevant to the policy and 
regulatory issues encountered (Naylor et al., 2015; Ontario Health Innovation Council, 2015). 
With direct coding, we summarized and organized the barriers and facilitators which were 
extracted in stage four, across three stages of innovation commonly found in the literature (i.e., 
development, assessment and implementation) (Naylor et al., 2015; Ontario Health Innovation 
Council, 2015). Two researchers (MM and MK) read through the extraction table to familiarize 
them- selves with the data, and then independently categorized ﬁndings into one of the three 
categories (stages); the two researchers then discussed the categorizations to achieve consensus. 
The categorizations were then reviewed by other members of the research team (including CS, 
SG and PS). Data that could not be coded within the existing categories were analyzed in a 
second phase; this phase generated three over-arching themes (policy context, resources, and 
partnerships) using emergent coding (Hseih & Shannon, 2005). Literature ﬁndings not 
previously categorized were then coded into these three categories using a process similar to the 
ﬁrst analysis phase. Within each of the now six categories, ﬁndings were then re-labelled as 
barriers or facilitators depending on the part of the extraction table from which they were drawn. 
2.4 Results 
Sixty-seven sources are categorized and displayed in Table 1 as identifying facilitators and/or 
barriers across common stages of the innovation process, including: 
• Development, e.g. research and device prototyping; 
• Assessment, e.g. regulatory approval and health technology assessment (HTA); and 
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• Implementation, e.g. an implementation plan, adoption and diffusion. 
An additional three themes emerged beyond these stages in relation to the Canadian policy 
context, resources, and partner- ships. The concepts found within these themes tended to me 
more overarching, spanning multiple innovation stages. Table 1 summarizes the sources included 
in the review and Fig. 2 indicates the distribution of papers per theme. Examples of source 
excerpts are included in Table 2. 
Table 1. Summary of Included Studies and Identified Themes 
Author,
 Year 
Study/publication  
Type 
Context/Topic 
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n
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Abelson 
(2013)  
Qualitative study  Patient and caregiver 
involvement in HTA 
 
Abelson 
(2016)  
Literature review Public and patient involvement 
in HTA 
 
Agrawal  
(2006)  
Retrospective 
review and 
regression 
analysis  
Licensing for medical devices 
Akpinar  
(2006)  
Review Economic evaluation   
Assasi  
(2014)  
Review Ethical assessment in HTA  
Baltussen  
(2006)  
Review  Multi-criteria decision analysis 
Battista 
(2006)  
Commentary Expanding methodology types in 
HTA 

Bercovitz  
(2007)  
Quantitative 
study 
Technology transfer 
Blomqvist 
(2016)  
Grey literature- 
Institutional 
report  
The Naylor Report and health 
policy in Canada 
  
Bombard  
(2011)  
Mixed-methods 
study 
Ethical and social values in HTA  
Brehaut  
(2005)  
Grey literature- 
Institutional 
report  
Using research evidence in 
policy development 
 
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






Bubela 
(2010)  
Commentary Technology transfer 
Burls 
(2011)  
Survey  Ethical issues in HTA 
Carbonneil 
(2009)  
Review  Access with evidence generation   
Chafe  
(2010)  
Case study Access with evidence generation 
Challinor, 
(2016)  
Grey literature- 
Institutional 
report  
Recommendations to support 
health science sector innovation 
  
Cuyler  
(2014)  
Commentary Cost effectiveness analysis in 
HTA  
 
Health 
Technology 
Assessment 
Task Group 
(2004)  
Grey literature- 
Institutional 
report  
Recommendations to support the 
management of health 
technologies across the lifecycle: 
innovation through obsolescence 

Holmes 
(2012)  
Grey literature- 
Institutional 
report  
Stakeholder consultation to 
develop a medical device 
strategy for Canada 
   
Husereau  
(2015)  
Grey literature- 
Institutional 
report 
Entry of new medical devices 
into Canada’s publically-funded 
health care system 

Husereau 
(2011)  
Grey literature- 
Institutional 
report 
Challenges and opportunities to 
using HTA to develop provider 
fees in Canada 
  
Khayat 
(2015)  
Grey literature-  
Institutional 
report  
Online commentary on health 
technology innovation 
  
Lavis 
(2008) 
Multi-method 
study 
Use of research evidence in 
policymaking  
  
Lavis 
(2010)  
Review Using research evidence in 
health system policy making 

Lee 
(2003)  
Case study Developing a regional HTA 
implementation unit 
  
Lehoux 
(2012)  
Case study Medical devices  
Lehoux 
(2015)  
Qualitative study Venture capital in medical 
innovation 

Lehoux 
(2016)  
Qualitative study Venture capital in medical 
innovation 
 
Lehoux 
(2000)  
Commentary Expanding methodologies in 
HTA  
    
Lehoux 
(2005)  
Case study Dissemination of HTA reports   
Lehoux 
(2008)  
Qualitative 
interviews  
Relationships between evaluators 
and regulators in HTA 
 
Lehoux 
(2008) 
Commentary  Policy research agenda for 
Health innovation 
  
Lehoux 
(2013)  
Practical 
guidance 
Knowledge transfer  
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





Lehoux 
(2013)  
Commentary Health care innovation policy 
Lehoux 
(2014)  
Study protocol Ethical and social issues in HTA 
Lehoux 
(2014)  
Mixed-methods 
study 
Academic spinoff companies    
Levin 
(2015)  
Qualitative study Harmonization of regulation and 
reimbursement 
  
Luczak 
(2012)  
Case study Regulatory approval for medical 
devices 

Martin 
(2016)  
Qualitative study  Hospital-based/Regional HTA   
McDaid 
(2003) 
Interviews  Economic evaluation  
McMillan 
LLP 
(2010)  
Grey literature- 
Institutional 
report
 Overview of legislation related 
to health care in Canada for 
businesses 
 
MDI² 
(2011)  
Grey literature- 
Institutional 
report 
How to improve development 
and commercialization of 
Canadian medical devices to the 
global market  
   
MEDEC  
(2011)  
Grey literature- 
Institutional 
report 
Stakeholder consultation: 
Ontario business sector strategy 
for medical technologies  
 
Menon 
(2009)  
Commentary HTA in Canada: production and 
use, current issues, lessons 
learned 
    
Menon 
(2008)  
Review  Patient involvement in HTA   
Menon 
(2011)  
Survey Patient involvement in HTA  
Miller 
(2009)  
Ethnographic 
Study 
Technology transfer for health 
innovation 
  
Ministry of 
Research and 
Innovation 
(2015)  
Grey literature- 
Institutional 
report  
Ontario's innovation agenda 
Mitton 
(2014) 
Commentary Program budgeting and marginal 
analysis  
 
Mortenson 
(2013)  
Interview 
analysis 
Power mobility in rehab settings 
Naylor 
(2015)  
Grey Literature- 
Institutional 
Report  
Recommendations about how to 
support Canadian health care 
innovation 
  
Ontario 
Health 
Innovation 
Council  
(2015)  
Grey literature- 
Institutional 
report 
Stakeholder consultation: 
Recommendations to enable 
person-centred care and grow 
Ontario’s Health technology 
sector  
    
Prada (2015) Grey literature- 
Institutional 
report 
Research organization: online 
commentary  
  
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Prada  
 (2016) 
Grey literature- 
Institutional 
report
 Research organization report: 
Recommendations about 
applicability of competitive 
dialogue in Ontario and Canada 
 
Prada (2007) Grey literature- 
Institutional 
report 
Research organization report: 
suggestions to improve Canada’s 
capacity for technological 
innovation in health systems  
  
Prada (2011) Grey literature- 
Institutional 
report 
Research organization report: 
suggestions about implementing 
innovative procurement policies 
    
Pratesi  
(2013)  
Review Technology design, 
development, implementation 

Ross  
(2015)  
Literature review Life cycles of medical devices   
Scott 
(2015)  
Literature review  System level adoption and 
diffusion of medical devices 
 
Sebastianski 
(2015) 
Review Innovation in public health care 
systems  
    
Shultz 
(2015)  
Survey Willingness to pay for 
technologies 

Snowdon 
(2011)  
Grey literature- 
Institutional 
report  
Medical devices     
Tarride 
(2008)  
Secondary data 
analysis  
Economic evaluation 
Tesfayohann 
es 
(2007)  
Secondary data 
analysis  
Industrial research and 
development institutions 
  
Tsoi 
(2013)  
Literature review Harmonization of regulatory and 
reimbursement activities 
  
Verma 
(2016)  
Invited essay Policy framework to promote 
health system transformation 
 
Xie 
(2011)  
Expert Review Summary of HTA supporting 
decision-making in Ontario and 
Canada 
  
Figure 2: Distribution of papers per theme 
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Table 2: Examples of source excerpts 
Focus stage or 
theme 
Article example Reference 
Development “Encouragingly, there have been some efforts in recent years 
to curb capital drought through programmatic changes in both 
the public and private sectors. For example, giving special 
attention to those commercialization challenges experienced in 
the development cycle “valley of death”, the government has 
launched initiatives like MaRS Innovation/MaRS Discovery 
District.” 
(Challinor, 2016) 
Assessment “This study addresses this gap by reporting on the 
development and outputs of a comprehensive framework for 
involving the public and patients in a government agency's 
HTA process.” 
(Abelson, 2016) 
Implementation “Regional implementation—While there is a need for a 
coordinated federal and provincial/territorial policy framework 
for innovation procurement, the U.K. experience suggests the 
need for a strong regional focus. Governments should give 
health regions an explicit mandate as health-care innovators 
and should support the development of regional innovation 
hubs.” 
(Prada, 2011) 
Canadian 
Policy Context 
“Decision-makers and administrators complained of policy 
and managerial gridlock, confiding on occasion that attempts 
at reform in the public interest were sometimes co-opted to the 
short-term benefit of providers or politicians. Policy experts 
emphasized the clumsiness of the current fee-for-service mode 
of remunerating physicians, and asked why Canada had failed 
to adopt integrated delivery subsystems, exemplified by 
leading American group health plans. Professionals 
highlighted the ways that cumbersome regulations and 
perverse incentives were stifling their creativity and ability to 
play a bigger role in Canada’s healthcare systems.” 
(Naylor, 2015) 
Resources  “There is a lack of funding opportunities to support successful 
regional initiatives to become national initiatives. While 
economies of scale work in favour of national incentives, lack 
of stable operating funding at the national level impede these 
efficiencies. Turning a successful regional pilot into a 
successful national initiative requires the commitment of a 
stable funder.” 
(Naylor, 2015) 
Partnerships  “Around the world, a feature of successful jurisdictions that 
have fostered a strong medical device industry is the close 
(Snowdon, 2011) 
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collaboration that venture capital firms, universities and other 
academic institutions enjoy.” 
2.4.1 Development  
Development barriers occur when innovations inadvertently exclude groups, reinforce 
hierarchical social arrangements or impede social progress (Lehoux & Blume, 2000). Canadian 
policymakers are often isolated from the practical aspects of health care delivery, resulting in the 
development of innovation policies that are not always reﬂective of the goals and needs of the 
health care system (Ontario Health Innovation Council, 2011). For example, innovations that are 
primarily oriented towards readily commercializable technologies or to the interests of venture 
capitalists may not satisfy the health system or particular user groups (Lehoux, Miller, & 
Daudelin, 2016; Menon & Stafinski, 2009). Also, developers without health care contacts, 
encounter additional barriers when they overestimate the value of their technology; make costly 
and avoidable mistakes; form assumptions on behalf of clinicians, or narrowly focus on 
empowering physicians with their technology (Lehoux & Blume, 2000; Lehoux, Miller, & 
Daudelin, 2013a; Lehoux, Daudelin, Hivon, Miller. & Denis, 2014b; Lehoux, Williams-Jones, 
Miller, Urbach, & Tailliez, 2008b; Ontario Health Innovation Council, 2015). 
Canadian technology developments are often funded by and oriented to American 
markets where the technologies may be more rapidly commercializable and proﬁtable; this 
orientation is potentially inconsistent with the cost-containment and sustainability aims of a 
publicly funded health care system (Challinor, 2016). This orientation may also draw talent, 
technology and tax revenues away from Canada (Challinor, 2016), and lead to the creation of 
innovations which do not respond to the most pressing needs in Canadian health care systems 
(Lehoux et al., 2013a; Lehoux et al., 2016; Lehoux et al., 2014b).  
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Several important approaches were identiﬁed to facilitate further innovation in the 
development phase, including: 
• Providing additional local/national seed funding or venture capital opportunities to spur 
innovation activities and decrease dependence on foreign investment (Tesfayohannes, 2007; 
Conference Board of Canada, 2007);  
• Building awareness and understanding among developers of unmet health system 
priorities (Lehoux, Miller, & Daudelin, (2013a); and 
• Creating opportunities for innovators to consult with clients and health care professionals 
early in the development phase and incorporating their feedback on how technological 
innovations would ﬁt within health systems to facilitate the development of more appropriate 
innovations (Lehoux, et al., 2008b; Lehoux, Gauthier, Williams-Jones, Miller, Fishman, Hivon, 
& Vachon, 2014a; Khayat, 2015). 
2.4.2 Assessment 
Health technology assessments (HTAs) are systematic evaluations of technologies using 
evidence to consider the direct and unintended consequences of the technology (INAHTA, 
2006). The main purpose of conducting assessments is to inform policy decision-making, 
however when HTAs do not meet they take a global perspective, without adequately considering 
how a new technology impacts budgets or care pathways at an individual health care 
organization level (Health Technology Assessment Task Group, 2004; Sebastianski et al., 2015; 
Martin, Polisena, Dendukuri, Rhainds, & Sampietro-Colom, 2016; Lehoux, Denis, Tailliez, & 
Hivon, 2005). Some reports may not adequately target their ﬁndings when they integrate many 
perspectives (social, ethical, legal) from a wide consultation process (Lehoux et al., 2005; 
Bombard, 2011). Since HTA organizations are not responsible for whether their 
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recommendations are applied or not, they may not collect data on implementation for fear they 
may lose credibility if they are perceived to be too close to the policy process (Lehoux et al., 
2005; Lavis, Oxman, Moynihan, & Paulsen, 2008).  
Identiﬁed facilitators in the assessment stage include: 
• Collecting data about the use of HTA reports in decision-making, these data could inform 
efforts of HTA organizations to include implementation of HTA recommendations as part of 
their remit (Martin et al., 2016). Such a database was created in 2014, and contains HTA reports 
from Canada from 1991 on and international HTA reports from 1989 on (Martin et al., 2016; 
University of York, 2018); 
• Encouraging the use of evidence from HTA reports completed in other jurisdictions 
through an information-sharing platform accessible to, and populated by, different regions and 
coordinated by a national HTA agency (Chafe, Merali, Laupacis, Levinson, & Pre-existing HTA 
reports may require contextualization if they lack the speciﬁcity required to be useful for 
decision-makers (Lavis et al., 2010; Martin et al., 2016); 
• Where existing information may not be available on a new technology, ﬁeld evaluations 
and access with evidence generation are techniques that allow for promising technologies to be 
adopted and assessed simultaneously (Health Technology Task Group, 2004);  
• Formalizing the process for patient involvement in HTA reporting by considering options 
such as citizen juries, committee membership, patient review of HTA recommendations, or 
presentation of testimonials (Menon & Stafinski, 2009; Lehoux, 2008a); and  
• Tools such as multi-criteria decision analysis and decision-making frameworks for 
hospital technology approvals can help health care systems to consider the many ways health 
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technologies impact opportunity costs, organizational issues and budgets (Baltussen & Niessen, 
2006; Martin et al., 2016). 
2.4.3 Implementation 
Adoption of innovations is more likely for those that require the least amount of ﬁnancial 
and infrastructure investments (Scott, Pasichnyk, Harstall, & Chojecki, 2015), and normally 
occurs through a procurement procedure that is extremely risk averse, disconnected from 
innovation activities, and focused on cost-containment rather than on value generation 
(Challinor, 2016; Conference Board of Canada, 2011). In general, procurement is treated as an 
administrative function of the health care system that involves blind, competitive bidding to 
ensure fairness among potential candidates (Prada, 2016; Ontario Health Innovation Council, 
2015). An issue with the current competitive model of procurement is that, by deﬁnition, 
innovative technologies will not have comparators with which to compete. Current procurement 
policies that focus on the least expensive item in the short-term are not accommodating to 
innovative technologies, which may have results or value that are more apparent in the long-term 
(Sebastianski et al., 2015). In this sense, Canada is considered a laggard in procurement policy 
innovation and ranks 55th of 140 countries on the Global Competitiveness Index of Government 
Procurement of Advanced Technology (Challinor, 2016; Prada, 2016). Going forward, the 
procurement policy context may be slow to change as needs and priorities for health procurement 
sector have not been identiﬁed (Ontario Health Innovation Council, 2015). 
The procurement process can also be a barrier for small innovation companies when 
group purchasing organizations (GPOs) (e.g., groups of hospitals) extend their buying power 
through procuring supplies in bulk quantities. Smaller innovation companies cannot compete 
with the volume that the GPOs require (Ontario Health Innovation Council, 2015). In Canada, 
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there are a few large GPOs and many smaller payers such as hospitals or clinics, creating a 
fragmented market. (Ontario Health Innovation Council, 2015). This is challenging for local 
innovators to demonstrate and validate the effectiveness of new products, sell to early adopters, 
or spread and scale a technology widely across the system [(Ontario Health Innovation Council, 
2015; Conference Board of Canada, 2007; Conference Board of Canada, 2011). 
Technology transfer ofﬁces (TTOs) are common across academic institutions as vehicles 
to transfer research innovations into the marketplace; however, in some cases their processes 
may hinder health technology adoption. Some TTOs have limited human and ﬁnancial resources, 
and insufﬁcient understanding of health care delivery. With a reward structure, that values 
tangible out- puts such as the number of patents, spinoff companies and royalty income 
generated, TTOs focus on innovations with the most commercial promise (Bubela & Caulfield, 
2010). This can be problematic in the case of public health research that is not patentable (Miller, 
Sanders, & Lehoux, 2009; Bubela & Caulfield, 2010). Focusing on innovations with the greatest 
commercial potential may also be detrimental to those designed for rare conditions or targeted to 
particular user groups, and may limit funding for validation or proof-of-principle studies (Miller 
et al., 2009; Bubela & Caulfield, 2010). In other cases, TTOs may let the personality 
characteristics of innovators inﬂuence their funding decisions by making assumptions about how 
engaged developers are in the commercialization process and choosing not to support those who 
are perceived to be difﬁcult (Miller et al., 2009). 
TTOs also play a major role in negotiating challenging and time-consuming intellectual 
property (IP) agreements, which vary greatly within industry and across academic institutions 
(Ontario Ministry of Research and Innovation, 2015; Miller et al., 2009; Snowdon et al., 2011; 
Bubela, 2010). Different norms regarding commercialization exist between researchers and 
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industry, which may lead researchers to shield innovations from TTOs so as not to risk 
publication delays that can accompany the search for an industry partner or exclusive licensing 
agreements that block access to research tools and methods (Ontario Ministry of Research and 
Innovation, 2015; Bubela, 2010) In other cases, TTOs can be pressured by unrealistic 
expectations regarding outputs from researchers and university administration (Tesfayohannes, 
2007).  
This review found that many strategies and approaches to more effectively facilitate 
implementation of innovations have been identiﬁed; these include: 
• Facilitating alternative proposals that enhance collaboration and give innovative 
technologies access to procurement by considering reforms such as risk-sharing, negotiation, and 
value-based pricing (Snowdon et al., 2011; Challinor, 2016; Prada, 2016; Sebastianski, 2015); 
• Moving to a value-based (as opposed to cost-focused) procurement process that is 
concerned with the life cycle of the technology and integrating budgets and incentives that 
support better patient outcomes (Ontario Health Innovation Council, 2015; Naylor et al., 2015). 
Outcomes could be monitored to support continual reﬁnement of the process; 
• Developing materials for innovators, including a procurement how-to handbook; standard 
bid templates and procurement best practices (MEDEC Canada, 2011); 
 • Encouraging government stimulus to offset the cost of a move to value-based 
procurement, which requires up-front costs in favor of long-term savings (Conference Board of 
Canada, 2011); 
• Developing royalty-sharing incentives between TTOs and a faculty member’s lab 
(Bercovitz & Feldman, 2007); 
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• Developing ﬂexible agreements such as those that enable universities to hold Intellectual 
Property rights on publicly funded research (Ontario Ministry of Research and Innovation, 
2015);  
• Developing metrics for evaluating the effectiveness of technologies that consider societal 
impacts of health innovations as opposed to using standard technology transfer ofﬁce metrics 
such as number of patents, licensing partnerships and intellectual property agreements (Bubela & 
Caulfield, 2010);  
• Encouraging more research on the role that TTOs play in shaping how technologies 
are/are not paired with industry partners impacting development; and 
• Supporting TTOs in better understanding and responding to end-user needs to beneﬁt the 
health care system (Menon & Stafinski, 2008). 
2.4.4 Canadian Policy Context  
The reimbursement hurdles resulting from the thirteen unique provincial and territorial 
jurisdictions create a constrained Canadian policy context. Each has different priorities, privacy 
legislation, provider organizations, centralization models, and intake and procurement systems 
(Snowdon et al., 2011). These multiple jurisdictions create a complicated labyrinth of pathways 
for innovators trying to scale up their technology adoption and diffusion across the country. The 
challenge of multiple jurisdictions is exacerbated by an absence of national level standards and 
strategic priorities in the health innovation sector (Ontario Health Innovation Council, 2015; 
Naylor et al., 2015; MDI2, 2011; Lehoux et al., 2008b).   
Canadian health care system funding is directed toward the delivery of patient care – with 
innovation functions generally falling outside of the scope of most health organizations other 
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than select tertiary providers. Within the federal government, the health and innovation 
departments are siloed with different and often conﬂicting goals: innovation departments seek 
out technologies perceived to be the most proﬁtable, while health departments look to maximize 
patient outcomes and acquire revenue-saving technologies (Lehoux, 2008b; Levin, 2015). Silos 
also lead to different times for intervention in the innovation process (Lehoux, 2008b). For 
example, at the provincial level the innovation department might intervene early with grant 
funding to the innovator, with the health department only intervening later in a technology’s 
development through regulatory or reimbursement action. Silos between the departments that 
fund research and those that regulate it mean that new health technologies can be “pushed” onto 
health systems without an understanding of their usefulness or receptiveness from the health care 
sector (Lehoux, 2008a). As a result, innovations that might be effective in improving health care 
delivery may be ignored while other technologies are developed that do not enhance health care 
or service delivery for Canadians. 
Important facilitators to enable health technology adoption in Canada include: 
• Removing silos between the health and innovation policy departments and encouraging 
better linkages between the two departments’ policy efforts and the analysts who devise them 
will facilitate health technology innovation (Lehoux, 2008b). This bridging and targeted 
ﬁnancing could extend to mobilizing and supplementing the interest and inﬂuence of venture 
capital investors on innovation with that from health policy experts [Lehoux, 2008b] and health 
care providers. Balancing innovation policy with health sector expertise will ensure public 
investment is responsibly allocated to technologies with a high utility for the health care sector; 
and 
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• Developing an innovation ecosystem where public and private stakeholders work 
together to identify, stratify and target investment opportunities in the health technology area 
(Challinor, 2016) that are responsive to unmet public health care needs. An ecosystem approach 
facilitates technology innovation, and results in a return on investment for innovators by helping 
to spread and scale up technologies (Khayat, 2015; Ontario Health Innovation Council, 2015). 
2.4.5. Resources 
A lack of resources constrains technology innovation and adoption, particularly during 
the early, high-risk stages of technology development, when there are very few public and 
private seed capital options available to innovators (MDI 2, 2011; Conference Board of Canada, 
2011). Health science sector innovations are highly impacted by these constrained resources 
because development cycles are long, achieving proof of concept is expensive, and market 
access is regulated (Sebastianski et al., 2015). Working in an environment of constrained 
ﬁnancial and human resources limits ﬂexibility and available funds are quickly depleted in 
situations where projects stall (Sebastianski et al., 2015; Snowdon, Zur, & Shell, 2011). 
Strategic resource allocation is important; however half of Canadian health care decision-
makers report they lack a formal process to do this (Mitton, Dionne, & Donaldson, 2014). The 
resulting risk is that decision-makers may be allocating scarce resources based on historical 
precedent or political factors, which could disadvantage investment in new technologies. 
Additionally, these innovations require signiﬁcant upfront investment, which is at odds with 
tightly managed government funds and a focus on cost containment (Ontario Health technology 
Council, 2015; Sebastianski et al., 2015; Mortenson, Clarke, & Best, 2013). Rigid government 
funding structures do not allow the transfer of funds between and among departments or across 
ﬁscal years. This environment makes it difﬁcult for decision-makers to see past the cost of 
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technology to its potential beneﬁt or value to patient outcomes, especially if value is accrued to 
another department or sector, or only recuperated years after the initial investment (Snowdon et 
al., 2011; McMillan, 2010; Scott, Pasichnyk, Harstall, & Chojecki, 2015; Khayat, 2015).  
The current allocation of resources to physicians who are compensated on a fee-for-
service basis further impedes health technology innovation. There is little incentive for 
physicians to participate in development, testing or procurement processes for new innovations, 
because provider codes are not aligned with these activities (Bégin et al., 2009; Naylor et al 
2015). In addition, there is no incentive to offer services that have good value-for-money, as fee 
codes are based on the costs to deliver the service, not the value a service provides (Husereau & 
Cameron, 2011). Time that physicians might spend working on innovation projects is time taken 
away from their patients, diminishing their income stream. 
Several strategies were identiﬁed to better facilitate the ﬂow of resources to innovators 
and thus improve the adoption of health technologies in Canada: 
• Developing a national medical devices partnership fund (a public private enterprise) to 
generate resources to invest (by funding prototypes, proof of concept research, or pre-market 
evaluations) in promising medical devices (Ontario Health Innovation Council, 2015); 
• Creating research and development tax credits, and optimizing existing innovation-
oriented tax credits incentivize and better accommodate innovators working in the health science 
sector (Snowdon et al., 2011); 
• Scaling up and increasing investment in existing successful funding programs, Canadian 
examples include: British Columbia’s Angel Investor Tax Credit, The Council of Academic 
Hospitals Ontario’s ARTIC (Adopting Research to Improve Care), MaRS EXCITE (Excellence 
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in Clinical Innovation and Technology Evaluation), the Ontario Chief Health Innovation 
Strategist Health Technologies Innovation Fund, and the TEC Edmonton Health Accelerator in 
Alberta (Ontario Health Innovation Council, 2015; Edmonton TEC, 2017; Verma & Bhatia, 
2016; Challinor, 2016);  
• Adopting the Triple Aim philosophy to mobilize health resources around the three goals 
of: population health, improved patient experience, and reduced or stable per capita costs. 
Speciﬁc Triple Aim health system payment reforms include value-based purchasing in 
procurement, pay-for-performance schemes, bundled payment mechanisms, and shared savings 
models between public and private stakeholders to better align incentives to health system goals 
(Verma & Bhatia, 2016); 
• Consider an alternative funding model where health funding is tied to achieving regional 
innovation goals (Conference Board of Canada, 2011); and   
• At the consumer level, programs which combine government funding with private pay to 
increase accessibility of technologies may facilitate their adoption (Schulz, 2015). 
2.4.6 Partnerships/Communication  
In the development stage, understanding and incorporating the needs of patients and 
health care providers is essential to the success of targeted innovations, however technology 
companies consult with these partners inconsistently (Lehoux, 2008b). Innovators struggle to 
gain access to clinician insight to improve the relevance and appropriateness of their 
technologies (Ontario Health Innovation Council, 2015; MDI 2, 2011), and health care 
organizations’ speciﬁc needs and any plans for innovation are not typically externally accessible 
(Conference Board of Canada, 2011). Technology companies also lack important partnerships 
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with venture capital ﬁrms, hospitals, health care providers and universities that would provide 
the mentorship they need to better navigate bureaucracy and access seed funding (Snowdon et 
al., 2011). The disconnect between innovators, health care providers, and payers is problematic 
when it translates into a difference of opinion related to the value of a technology (Lehoux, 
Hivon, Williams-Jones, Miller, & Urbach, 2012). 
Communication at the assessment stage is a barrier for many groups and partnerships. For 
example, the medical device industry is not well connected to the regulators and funding 
agencies who assess their devices (Snowdon et al., 2011). When the two groups communicate, it 
can be challenging as HTA assessment requirements are complex and difﬁcult to translate into 
plain language (Lehoux et al., 2005; Lehoux, 2008a). Relationships between HTA organizations 
and policy makers can be tense and may be conﬂicted by differing motivations and priorities 
(Lee, Marshall, Waddell, Hailey, & Juzwushin, 2003; Abelson et al., 2016). HTA organizations 
are further challenged to successfully incorporate patient and public perspectives into HTA 
reports. This requires organizations to understand and apply appropriate patient engagement 
methodology, and then to incorporate these perspectives in a meaningful and robust way 
(Abelson et al., 2016).  
Recommendations to better facilitate partnerships and communication include: 
• Encouraging, aligning, and managing partnerships and communication between 
stakeholders involved along the innovation pathway – forming partnerships early and seeking 
patient and clinician input on important health system needs (Assasi, Schwartz, Tarride, 
Campbell, & Goeree, 2014; Menon & Stafinski, 2008; Sebastianski et al., 2015; Snowdon et al., 
2011; Lehoux & Blume, 2000);  
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• Involving patients and clinicians in early testing of assistive technologies to increase 
quality, utility, effectiveness and ease of adoption (Lehoux, 2008b);  
• Forming partnership entities, such as Industry Canada’s Networks Centres of Excellence 
(NCE) program, which bring together public and private stakeholders in industry, research and 
health care to better translate research into health technology innovations (Snowdon et al., 2011; 
Lehoux, 2008b; Shultz et al., 2015); and 
• Creating an environment that considers collaboration, trust, information sharing, time, 
and cost, and that provides communication tools to ensure stakeholders understand one another’s 
different roles (Brehaut & Juzwishin, 2005; Shultz et al., 2015; Tsoi et al., 2013; Lehoux, Miller, 
& Daudelin, 2013; Scott, Pasichnyk, Harstall, & Chojecki, 2015).   
2.5 Discussion  
Our scoping review found signiﬁcant research on the policy environment around health 
technologies and medical devices with a focus on existing barriers and facilitators to adoption of 
these innovations. We present a graphic depiction (Fig. 3) depicting the stages along the 
innovation pathway and the crosscutting inﬂuence of the Canadian policy context, resources, and 
partnerships and communication on technology development, assessment, and implementation. 
In addition to these stages, we are aware of emerging areas within the health technology 
assessment literature, which emphasize the importance of evaluating health technologies over 
their life cycle (Scotland & Bryan, 2016; Bryan, Mitton & Donaldson, 2014). Ongoing 
evaluations and delayering innovations play an important role in creating budget ﬂexibility to 
support adoption of new technologies (Keown et al., 2014) and a sustainable system over time. 
Rather than ending at implementation, the innovation pathway requires sustainability. Another 
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emerging theme is the recognition and current effort focused on engaging users in co-creating 
relevant technologies (Holliday, Magee & Walker-Clarke, 2015; Baltalden et al., 2016; 
Greenhalgh, Jackson, Shaw, Janamian, 2016). The meaningful engagement of patients and 
caregivers in the development and adoption of useful innovations has been echoed 
internationally (Keown et al., 2014) and regional innovation ecosystems (Etzkowitz & 
Leyesdorff, 2000) have been proposed as a mechanism through which to engage these users to 
ensure technologies are aligned with health system needs. Though outside the scope of our 
search, we have incorporated these ﬁndings into a revised graphic depiction of Canadian health 
technology innovations, and support an ongoing emphasis of engagement of users throughout the 
innovation process. 
Figure 3: Graphic depiction of innovation stages and crosscutting inﬂuences. 
The inﬂuence of the Canadian policy context found in this study aligns with other 
international ﬁndings that point to the inﬂuence of macro-level factors such as political structures 
and macroeconomic and ﬁscal policies on health innovation diffusion (Keown et al., 2014). 
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Although micro level factors did not emerge strongly in this scoping review, others have 
suggested a focus on the culture at the front lines of health care, which may be more amenable to 
intervention than macro system factors (Keown et al., 2014).  
Despite the many hurdles that exist, Canada is well positioned to successfully implement 
health technologies, with numerous assets including: a highly educated workforce; a stable 
ﬁnancial system; a stable innovation system with relative certainty, a close proximity to lucrative 
American medical device markets; strengths in information technology; a public health care 
system with strong research capacities; a strong track record for conducting clinical trials; and a 
capacity at the local health level, in health care delivery and research (Savage et al., 2009; MDI2, 
2011; Snowdon et al., 2011; Ontario Health Innovation Council, 2015).   
Our ﬁndings will be of interest to three audiences that compose the Triple Helix model of 
innovation (Etzkowitz & Leyesdorff, 2000) including industry, who are addressing health system 
needs through technological innovations; policy-makers, who seek to understand barriers to 
health technology innovation diffusion, and; researchers who are studying the factors inﬂuencing 
health technology innovations and the regulations and policies surrounding them. Results may 
also be of interest to speciﬁc groups such as Aging Gracefully across Environments using 
Technology to Support Wellness, Engagement and Long-Life (AGE-WELL) a federally funded 
research network in Canada. As part of its work, AGE-WELL aims to make recommendations 
for how innovation in health technologies for seniors can be accommodated and stimulated 
within existing policy and regulatory frameworks, as well as how these frameworks might be 
modiﬁed to support and accelerate the safe adoption of promising and effective technologies. 
Our team is part of the AGE-WELL NCE and we have a speciﬁc interest in technologies 
that are particularly relevant for older adults. We found few studies or reports that dealt 
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speciﬁcally with barriers to and facilitators of technology innovation to support healthy aging. 
We see this as an area warranting further investigation; in our own work, we plan to explore 
these topics in consultations with researchers, policy-makers, and industry representatives, as 
well as with older adults and family caregivers. We anticipate that developing and implementing 
technologies for older adults may be particularly challenging. Older adults often experience  
multiple co-morbid conditions, which can make technological design  more complex. For 
example, use of an assistive technology that supports mobility may be compromised by cognitive 
or communication impairments. These health and communication challenges can also make it 
difﬁcult to engage older adults in design processes (McNeil, 2017; McNeil et al., 2016; Newell, 
Arnott, Carmichael, 2007). 
2.6 Strengths & Limitations 
Based on the broad nature of our topic, it was difﬁcult to identify search terms that would 
ensure comprehensive retrieval of relevant sources. As an example, this review identiﬁed a 
number of issues relevant to reimbursement, although we did not explicitly include 
reimbursement as a keyword in the search. Doing so may have generated a more thorough 
understanding of reimbursement- related issues. To some extent, limitations of the search 
strategy could be addressed through the expert consultation phase that has been suggested as an 
optional sixth step in the scoping review process (O’Brien et al, 2016). We are currently 
undertaking an extensive consultation process that will be reported in a separate paper. Through 
Health Technology Assessment international (HTAi), we are also beginning conversations with 
experts from other countries that will allow some comparison of experiences across jurisdictions. 
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We note that while we did not feel a systematic review or realist synthesis would be 
appropriate for our purposes, such a review may be a useful approach for further study of ways 
to address speciﬁc facilitators or barriers identiﬁed in this paper. 
2.7 Conclusions 
Overall, our ﬁndings provide a comprehensive summary of facilitators and barriers to 
technology development, assessment and implementation, and how those stages are crosscut by 
barriers and facilitators in the Canadian policy context, resources and partner- 
ships/communication. There is a lack of literature on barriers to and facilitators of technology 
innovation process to support healthy aging. We suggest future studies may explore these 
barriers and facilitators, particularly as they relate to technologies to support healthy aging. 
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CHAPTER THREE: Stakeholder perspectives on facilitators and barriers to health 
technology innovation and adoption in Canada  
3.1) Introduction 
There are a variety of stakeholders involved in the development, assessment and 
implementation of a health technology. These include technology developers, venture capitalists, 
granting bodies, older adults, end-users, citizens, caregivers, health care providers, policy-
makers, health system administrators and regulators, as well as health care services researchers 
who create or study health technologies and their assessments. All of these different stakeholders 
operate at different levels of the health technology sphere, which we understand to contain 
different jurisdictions each with their own goals, financing and routines.  
This stage of the project is designed to better understand abstract findings from the 
scoping review by generating illustrative examples of specific facilitators and barriers. 
Preliminary work building the search strategy for the scoping review suggests that restricting the 
search strategy to the older adult population does not generate enough results for a fulsome 
review. This stage serves as a way to understand how facilitators and barriers to health 
technology innovation and adoption might affect technologies designed for older adults. This 
objective of this study is to continue to investigate the policy and regulatory barriers to, and 
facilitators of, successful innovation and safe adoption of health technologies in Canada. 
3. 2 Ethics  
Ethics clearance for the qualitative interview process has been obtained under ORE#: 
21006 Policy and Regulatory Issues in Enabling Technological Innovation from the University 
of Waterloo research ethics board (see Appendix A). 
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3.3 Methods 
Semi-structured interviews were conducted with policymakers, innovators, researchers 
and health care providers. A snowball sampling technique was used to generate participants with 
knowledge about health technology innovation and adoption and older adults (Palinkas, Horwitz, 
Green, Wisdom, et al., 2015).  
3.3.1 Types of technologies for older people  
To fully understand how facilitators and barriers to health technology innovation and 
adoption operate on technologies for older adults, some examples of the types of technologies 
available for older people are required. Technologies for older adults include those which can 
help to promote physical fitness, facilitate early diagnosis, enable monitoring of health status, 
increase social interaction, or ensure adequate treatment (Dishman, 2004). The types of 
technologies which are helping older people and their caregivers to achieve these aims include 
telemedicine and tele-homecare, wearable/sensor technologies, ambient smart-home systems, 
assistive robots, intelligent wheelchairs, digital games, and social networking applications 
(Dishman, 2004; Canadian Home Care Association, 2015; Sixsmith, 2013). This range of 
technologies is reflective of those being developed within the AGE-WELL research network 
(AGE-WELL, 2018).  
This research focuses more readily on technologies which are used by older adults and 
caregivers directly at the medical-individual level, than those which are used at the fiscal-
managerial level (such as algorithms which act as decision support and guide care allocation) or 
those technologies which operate at the strategic institutional decision-making system level 
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(where chief executives and boards of directors make choices such as opening a heart surgery 
unit) (Greer, 1985; Varabyova et al., 2017).  
3.3.2 Conceptual framework 
Recognizing the siloed nature of health technology innovation, and as a way to 
demonstrate the numerous and diverse stakeholders relevant to health technology innovation and 
adoption who operate at various levels, I developed a diagram to guide participant recruitment 
(Figure 4). The framework is adapted from the Social Ecological Model, which is often used in 
public health research to demonstrate the ways different social spheres (individual, interpersonal, 
institutional/organizational, community, social structure, policy, systems) have influence over 
individual behavior (Bronfenbrenner, 1992; Gregson, Foerster, Orr, Jones, et al., 2001). The 
social-ecological model arose in the 1990's as a way to understand five levels (intrapersonal, 
interpersonal/primary groups, institutional, community, public policy) which can interact to 
influence health behavior (Golden & Earp, 2012). The Social Ecological Model has been widely 
used to identify level-specific strategies for public health intervention, recognizing that 
individuals are embedded in social, micro, meso and macro level contexts (Golden & Earp, 
2012). By identifying how these contexts interact to influence behavior, interventions can be 
designed which acknowledge these interactions and leverage them to change individual level 
health behavior (Golden & Earp, 2012). 
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Figure 4: Conceptual framework 
This work presumes that policy and regulatory barriers can operate in any of these social 
spheres, which, in health care policy, have different governments responsible for the policies 
operating at each level. The diagram serves as a paradigm or “lens” to consider all of the moving 
parts in a complex policy area.  
Health status is at the centre of the diagram, which includes physical and mental health 
and ability to perform activities of daily living; cognitive health status, ethnicity, gender and 
socioeconomic status are all aspects of older adults’ intrapersonal level that may dictate how a 
health technology policy affects them. Barriers and facilitators to technology adoption can also 
occur at the interpersonal level, or the sphere where family and social support influence 
behavior.  
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The micro-level is the site where local decisions about housing stock take place, and 
about other municipal services such as adult day programs (Marchildon, 2013). Home care 
services are generally allocated and delivered in the micro sphere. At the meso level, provincial 
reimbursement for drugs and medical devices takes place, with different provincial-level bodies 
in existence at each province. This is also the level of government where assistive technology 
programs exist, which impact older adults’ ability to access aids to daily living such as 
wheelchairs, hearing aids and eye glasses. Different research bodies funding health care research 
also reside at the meso, or provincial health care level. At the macro level, there is federal 
jurisdiction for health care research, health human resources and regulation of medical devices 
and pharmaceuticals.  
The interests, institutions and ideas framework (Kingdon, 1984) cuts across each level of 
the framework. Interests include those of policy actors inside and outside of government who act 
to influence or make policy, and are organized into ‘communities, coalitions and networks’ 
(Smith, Mitton, Davidson & Williams, 2014). Institutions include an organization's, formal and 
informal rules (Simeon, 1976; Gauvin, 2014). This includes the jurisdictional issues that exist in 
Canada as a result of being a federation of provinces, with separate mandates for regulation, 
research, and human resource planning at the federal level, and service provision at the 
provincial level (Gauvin, 2014). Ideas include perceptions, knowledge and beliefs about what 
“is” or what “should be” (Gauvin, 2014). This is where research plays a role, and can either be 
used symbolically, for political purposes; conceptually, which enlightens actors; or 
instrumentally, to solve a problem (Lavis, 2002). Values and cultures operate as ideas, both for 
individuals and for societies (Gauvin, 2014). Any policy analysis will have to consider how 
ideas, interests and institutions play out at each level of jurisdiction but also how they play out in 
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terms of older adults and their social support networks and health status, and other intrapersonal 
characteristics such as income and ethnicity.  
The conceptual framework combines two widely used frameworks from policy and 
public health research (Béland, 2016; Golden & Earp, 2012) in order to conceptualize how health 
technology innovation operates at different contexts and track the role of ideas, institutions and 
interests. The framework serves a way to see how policies at different jurisdictional levels can 
impact interpersonal and individual spheres to influence technology innovation and adoption for 
older adults. By conceptualizing where certain policy and regulatory challenges occur and the 
relevant stakeholders involved, the framework creates a foundation for policy change that 
facilitates health technology innovation and adoption. The addition of this diagram helps to 
respond to calls in the literature for the ‘next generation of research’ on health technologies to be 
ecological in nature in order to consider how the interactions between technologies and their 
implementation contexts influences success or failure (Greenhalgh, Robert, Bate, Kyriakidou, 
2004). 
 The framework helped organize recruitment of different stakeholder types. At the macro-
level, health technology regulators and federal policymakers in the health portfolio; arms-length 
agencies such as Canada Health InfoWay and CADTH; as well as not-for-profit stakeholders 
such as MEDEC (lobby group representing Canada’s medical device industry), MaRS (a 
commercialization hub in Toronto, ON offering programs and services for start-up technology 
companies) and the Conference Board of Canada, were contacted for participation.  
At the meso level, provincial policymakers, including those working in assistive device 
programs, those making reimbursement decisions, those working in health technology areas, 
health technology assessment agencies, and health services researchers were contacted for 
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participation. At the micro-level, innovators (both academic and non-academic), regionally based 
HTA agencies, and representatives from the home care sector were contacted for participation. 
Researchers on the AGE-WELL project who are considered ‘insiders’ in health technology 
innovation were contacted to begin the snowball sampling (Palinkas et al., 2015). These insiders 
work as: a consultant in health economics and reimbursement, a provincial policymaker working 
in the area of health technology innovation, and a health technology innovation researcher.  
Older adults and caregivers represent the interpersonal and intra-personal levels of the 
conceptual framework but were not interviewed in this phase of the project. I felt the time and 
abstract nature of the content required an educational component to have older adults participate 
meaningfully, and it was not feasible for me to offer this type of capacity building at this point in 
the project. Using the Change Foundation’s Decision Tool around choosing whether or not to 
pay patients and caregivers for their engagement contribution, the project is in the advisable 
range to consider paying stakeholders for their participation, which was also not feasible for this 
project (The Change Foundation, 2017). The decision tool scores a project based on the impact 
on participants' time, equity, vulnerable population status, challenges and accountability, and 
removes points for positive impact, access, and recognition the engagement could offer 
participants (The Change Foundation, 2017). Due to the nature of the time and challenges 
associated with the project, it was decided to engage older adults and caregivers later in the 
project in a way that would be less resource-intensive and potentially more meaningful for these 
participants (Oliver, Kothari & Mays, 2019). 
Different interview guides were used for each stakeholder group (policymakers, 
researchers, industry representatives and innovators). Each interview guide asks different 
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questions about what institution or company the participant works for, how they evaluate 
technologies, what their research or technology focuses on, as well as what they perceive to be 
facilitators and barriers to health technology innovation and adoption. Each guide asked if a 
technology designed for older adults might go through the stages of innovation differently. The 
last interview questions requested participants to recommend documents, reports or potential 
participants to interview. Interview questions that are not relevant to a participants’ experience 
were skipped. The interview guides were piloted and revised with AGE-WELL affiliated insiders 
for clarity. See Appendix C for the policymaker interview guide, which served as the basis for 
the development of the other types of interview guides. 
Participants were contacted by email, referencing the person who recommended their 
involvement in the study, attaching an information letter, a consent form (Appendix A) and the 
appropriate interview guide.  The consent form asked permission to audio record the interview, 
to use anonymous quotations in theses or publications, and if the participant is interested in 
receiving results of the interview process. Nine researchers, thirteen government employees, 
thirteen industry representatives and eleven innovators (n=46) were interviewed. Each interview 
took about 60 minutes. Recruitment stopped once saturation was reached within each stakeholder 
group, when no new themes emerged, which occurred around the eighth or ninth interview 
(Morse, 1995).  
3.4. Data Analysis  
3.4.1 Introduction  
This research uses framework analysis, which was designed in the 1980s in the UK for 
policy research and is commonly used in health research (Ritchie & Spencer, 2003). This work 
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aligns with the applied policy research tradition, in that certain information is required for 
actionable outcomes - in this case, knowledge about policy and regulatory facilitators and 
barriers is required to make policy change that would enable health technologies’ adoption by 
older adults.    
This method is used to analyze semi-structured interview transcripts with thematic 
analysis, producing a framework matrix in the process to categorize data based on the following 
stages: familiarization; developing a working framework; indexing the framework; charting data 
into a framework matrix; and interpreting data (see figure 4) (Ritchie & Spencer, 2003). In 
framework analysis, themes or categories can be developed in advance of coding as well as 
during coding, as the data dictate (Dixon-Woods, 2011). This flexibility means that framework 
analysis can move between theory-driven and hypothesis-driven approaches (Gale et al, 2013). 
This contributes to transparent coding, and allows for the new work to build on previous work 
(Carroll, Booth and Cooper, 2011). This aligns with the aims of this research to respond to the 
dearth of literature about facilitators and barriers to health technology adoption for older adults. 
Framework analysis can help to define concepts, map the range and nature of phenomena, find 
associations, provide explanations, or develop strategies (Ritchie & Spencer, 2003).   
Figure 5: Stages of Framework Analysis 
Familiarization
Identifying a
thematic
Framework
Indexing Charting Mapping andInterpretation
3.4.2 Familiarization 
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The goal of this stage is to become familiar with the data by reading transcripts, making 
notes about recurring themes or key issues (Ritchie & Spencer, 2003). The interviews were 
recorded and transcribed verbatim. During each interview, I took note of the date, which 
interviewee recommended them, key inferences from each interview, or comments made that 
linked to other interviews. Debriefing with other team members present in the interviews helped 
to make linkages in the data across interviews. Preparing conference presentations on this project 
aided in the familiarization process as I read through each transcript to find quotes that might 
contextualize preliminary themes and findings.   
3.4.3 Identifying a thematic Framework 
In framework analysis, the thematic framework or index is informed by pre-existing 
literature and issues. It is designed to act as a way to parse out the data into manageable chunks 
(Gale et al, 2013). 
A graphic depiction was presented in Chapter two outlining the stages along the 
innovation pathway (development, assessment, implementation, sustainability) and how some 
facilitators and barriers to technology innovation and adoption exist within certain stages, and 
others are common across stages (Canadian policy context, resources, partnerships) (MacNeil et 
al., 2019). This depiction suggests that all technology innovation and adoption efforts should be 
grounded in an effort to co-create technology with end-users. It should be noted that the 
categories of ‘sustainability’ and ‘co-creation’ did not specifically emerge in the data from paper 
one, but were part of the depiction in that they respond to recently emerging trends in health 
technology assessment (Scotland & Bryan, 2016; Bryan, Mitton, & Donaldson, 2014) and health 
care services research (respectively) (Shipee et al, 2013).   
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This was the inspiration for the use of framework analysis to refine this framework and to 
see where the interviewees could shed light on potential issues specific to older adults’ use of 
health technologies. The index contained the following labels: development, assessment, 
implementation, sustainability, policy context, resources, partnerships, co-creation, and 
aging/older adults focus. Multiple coders were used to ensure quality of the data analysis; to 
ensure consistency across coders, a codebook was developed with definitions of each label (see 
Appendix E) (MacQueen, McLellan, Kay, & Millstein, 1998). Coders trialed the codebook by 
using it to code one interview from each stakeholder type. After the trial, coders met with the 
research group and refined the codebook. This process of meeting and discussing results of 
coding is a form of debriefing which enhances the dependability of the findings (Lincoln & 
Guba, 1985).  
3.4.4 Indexing 
Indexing is the process of applying the thematic framework to the data (Ritchie & 
Spencer, 2003). Indexing creates notes within the transcribed interviews based on the labels in 
the thematic framework. Another independent coder and I worked through each of the 46 
transcripts line by line to index portions of text with the labels from the framework: 
development, assessment, implementation, sustainability, policy context, resources, partnerships, 
co-creation, aging/older-adult focus.  
3.4.5 Charting   
Charting is a way of rearranging the data based on the labels of the framework; it is 
thought that by seeing representative excerpts from different interviews on the same label or 
topic, the author can better understand the nature of that label (Ritchie & Spencer, 2003). This 
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process involves more than just physical rearranging of text, but also abstraction and 
synthesizing of the data (Ritchie & Spencer, 2003). Using a thematic approach which identifies, 
analyzes, and reports patterns or themes within data (Braun & Clarke, 2006), I, along with the 
second coder and two other researchers, worked to group all the excerpts related to each label 
together. After this process we created a description (including sub-headings), of the nature of 
the phenomena contained inside each label.  
To address the subthemes contained inside each label, from the perspective of the 
different stakeholders, the charting process featured the label as the title of the chart, the sub-
themes in the columns, and a cell for each stakeholder type at each sub-theme level (See 
Appendix F). In some cases, there were no sub-themes (sustainability, co-creation), and not 
every sub-theme had coverage from every stakeholder type. A blank cell in the chart indicates a 
spot where there was no quotation affiliated with a stakeholder type. The chart was filled in with 
a representative quote and identified as either Innovator, Researcher, Government, or Industry 
representative (Ritchie & Spencer, 2003).  
3.4.6 Mapping and Interpretation  
During the mapping stage, the notes created during the indexing stage and the charts 
created in the charting stage are reviewed to compare perceptions, identify patterns and look to 
explain phenomena occurring within the data (Ritchie & Spencer, 2003). I looked through notes 
and charts to explain facilitators and barriers to technology adoption within each theme 
(development, assessment, implementation, sustainability, co-creation, older adults, Canadian 
policy context, partnerships, resources) from the perspective of different stakeholders.  
3.5. Results 
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Each theme was coded and new sub-themes emerged within each theme. Figure 6 depicts 
a summary of the themes and sub-themes. 
Figure 6: Themes and sub-themes identified through framework analysis 
3.5.1 Older Adults 
Two sub-themes were identified in the older adults theme: aging technology: same 
process and assumptions about older adults. Government, industry and research participants 
agreed that the process of technology adoption was the same for all technologies regardless of 
their target population. One participant noted: 
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“everybody I talk to, no matter whether you’re talking about rapid diagnostic test or an 
assistive device or an app… they all face the same barriers… so I don’t think it will be 
that different”. 
Government and industry stakeholders spoke about negative assumptions among 
policymakers and clinicians about older adults' capacity for technology use as a barrier which 
limits technology adoption:  
   “there is still a cultural barrier in terms of perceptions of what seniors can do in terms of 
technology adoption. I speak with some colleagues and they’re like ‘my grandma’s not 
going to be able to use an iPhone’… I’m like ‘have you given an iPhone to your grandma?’ 
Because if a three-year-old can use it, I’m pretty sure grandma can use it” 
One innovator we interviewed had positive assumptions about aging, which they felt facilitated 
technology adoption:  
“a joke within some of our sales force is that 80 is the new 60 because these people are still 
vibrant and don’t want to give up living in their own homes”.  
Researchers discussed the assumptions about older adults that are built into our measurement tools 
to assess technologies, which may not account for changes in what older adults prioritize. This 
researcher pointed out:  
“I would argue if we were to think about preferences properly we would probably look at 
technologies differently because we value them differently as we age”. 
This theme outlined how technologies for older adults undergo formal processes related to 
adoption, in similar fashion as technologies for other populations. Comments in this theme 
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revealed that technologies for older adults are subject to assumptions (both positive and negative), 
which can help or hinder their adoption.  
3.5.2 Co-Creation 
All stakeholder types felt that co-creation of technologies was a facilitator to technology 
innovation and adoption for older adults, but some stakeholders pointed to problems in how co-
creation is currently achieved. An industry representative contrasted the lucrative market for 
aging-related technologies with the difficulty recruiting patients to participate in their 
development:  
“the only way that Canadian companies will be able to position themselves and 
capitalize on that gross market is…if they can access the clinical and patient 
populations … at hospitals … Because the expertise and the capacities that exist in the 
hospitals can’t be found any place else in the Canadian landscape”. 
A researcher noted that the approaches to integrating patient-preference data into a health 
technology assessment are varied and often completed by proxies:  
“how patient preferences get in, it’s a dog’s breakfast of approaches. So you have a lot 
of, a lot of deliberative decision-making processes, you’ll have a lot of clinicians who will 
identify what patient preferences are… seeking input from patient organizations— 
typically only from patient organizations, and they do their best, or worst, …to gather 
some input, qualitative input, sometimes still too, quasi kind of research. Throw together 
a survey kind of questionnaire, hand it around to their membership...it’s not high-quality 
evidence coming in”. 
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A government interviewee outlined a program which acted as a facilitator of co-creation 
of technology by matching companies with healthcare settings, patients, clinicians, reimbursors, 
and procurement officers. Although all stakeholders viewed co-creation as a facilitator of 
technology adoption for older adults, the comments in the co-creation theme revealed the 
difference between how different stakeholders view co-creation depending on their field. For 
industry representatives, co-creation enhanced the value of technologies created. Researchers 
were concerned with standardizing the ways co-creation is completed, while government 
stakeholders spoke about co-creation as a feature of their program. 
3.5.3 Development  
Three sub-themes emerged related to development: designing relevant technology for 
health care; building capacity through human/financial resources in development; and 
considerations for innovators in the development stage.  
Industry and research representatives spoke about the barriers to designing for healthcare. 
One industry stakeholder discussed the need for innovators to align their technologies with the 
priorities of the health care system:  
     “If you’re innovating, then innovate in the direction of where the health system is 
going…if they’re looking at the strategic priorities of their hospital going in this 
direction, then very likely you will have a buyer”. 
A researcher we interviewed spoke about the need for inexpensive technologies which address 
health system needs:  
“We need to create technologies which the R&D is less costly…that will be more 
affordable and that will tackle system level challenges. Not just add clinical value to what 
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we do already, but to transform health care systems so they can better address today’s 
needs, and ageing is one”. 
An innovator discussed the challenge associated with designing technology for use in 
healthcare due to health information privacy legislation, which can impede access to a patient’s 
health information for clinicians and innovators. This innovator noted a general risk-aversion in 
health care which is bolstered by rigid interpretations of health information privacy laws. A 
government stakeholder noted challenges of deploying new technology in a nursing home 
setting, without support staff present in case any problems arise: 
 “You don't have IT geeks running around an apartment that can reset technology, if 
that's required. Things have to be made entirely foolproof”. 
In this sub-theme, industry and research stakeholders discussed how inexpensive 
technologies and those that align with health system priorities are facilitators to technology 
adoption. Innovators and government stakeholders noted how privacy laws about health 
information and lack of technology support make it challenging to design health technologies for 
health care, which inhibits technology adoption for older adults.  
The second sub-theme, building capacity in development, was acknowledged as a current 
strength of the Canadian ecosystem by an industry representative:  
“we’ve got this really strong engine for R&D that works very well for our system as a 
whole. We’ve got the talent… we’ve got lots of really focused monies and, and, and talent 
that are honing in to the kind of things that would be relevant as our population ages. … 
educationally, knowledge, we’ve got it all”. 
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A researcher contrasted the statements of the industry representative in their description 
of a company that struggled with their capacity during the development stage:  
“one spinoff that created home monitoring…what really hit this spinoff very hard was 
that they could not articulate a business model, it was really hard for them”.  
The researcher goes on to comment on the different types of expertise required to 
commercialize a technology from the expertise which is usually involved in the technical 
development of an innovation. Similarly, an innovator commented on an example where 
inadequate capacity in the development of a technology (a student was asked to develop 
software) led to the failure of the software when deployed in the health care setting.  
Stakeholders held different perspectives about the capacity required in the development 
stage of a technology. An industry stakeholder felt as a sector, Canada has a strong capacity of 
talent and funding in research and development, which acted as a facilitator, as compared with an 
innovator and a researcher who described situations where lack of capacity during development 
impeded technology innovation and adoption.  
The third sub-theme in development was considerations for innovators in the development stage. 
An innovator discussed what they perceived to be a facilitator in their technology development- 
that they were not considered a medical device by Health Canada:  
“because not having cumbersome regulatory oversight allows innovators and 
entrepreneurs to be more flexible especially in the development stages when you’re still 
trying to understand what is the feature set required to deliver value to residents”. 
That innovator went on to say that they felt Health Canada should be liberal in their regulation of 
non-invasive, low-risk technologies to ensure this flexibility for other innovators. 
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An industry representative spoke about their work giving patients access to their health 
data as a suggestion to improve technology development for future innovators:  
“we deal with health solutions at the boundary between the consumer and the health 
system, where information right now doesn’t really flow to the patient about their own 
data, their own body… we’re trying to basically unlock that data and …it’s a flipping 
on its head of data ownership in healthcare”. 
A government representative used Microsoft Excel as an example to show how technologies are 
not always used to their potential:   
“the power of Excel now is amazing… but the average person uses Excel to make tables 
…entrepreneurs have to be aware that in some cases only one third of the functionality 
of your tools will only ever be adopted fully”. 
This sub-theme outlined advice for innovators developing a new technology. An 
innovator advised future innovators to enjoy the freedom that not being a regulated medical 
device can offer to new innovators working to determine the functions of their technology. An 
industry stakeholder encouraged the value of technologies that help patients control their health 
information and a government representative cautioned to innovators that most people do not use 
all capabilities of a new technology.  
3.5.4. Assessment 
There were five sub-themes under the assessment theme: the value of a national 
certificate; assessments do not decide; mismatch between the pace at which a technology is 
developed and the pace at which it is assessed; many categories of evidence to consider when 
evaluating technology; and difficulties assessing complex devices.  
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The sub-theme, value of a national certificate, contains comments from interviewees 
about the benefits or disadvantages to regulatory approval of a technology by Health Canada. A 
government interviewee noted that their group only considers technologies with regulatory 
approval. This could mean that technologies which are not classified as requiring regulatory 
approval may not be assessed in an HTA; this has implications for adoption since the HTA 
makes recommendations for adoption by health care systems. One researcher spoke about the 
value of Health Canada regulatory approval for companies internationally in that the approval 
processes in other countries are somewhat aligned. An innovator pointed out the discrepancy 
between the value for the company whose technology has Health Canada regulatory approval, 
and the value for the health care system:  
“once you put them through the channel… and then say it has, it’s now Health Canada 
approved, I suspect…decreases the accessibility of that product and now it’s maybe 10 
times the cost and …it brings the competitive edge down because very few people can 
compete with that”.  
The innovator suggests the value of the certification increases the perception among investors 
that the company is profitable and thereby legitimizes an increase in price of the technology, 
which in turn makes it harder for other companies to compete in this area, and making the 
technology more expensive for the health care system to purchase and adopt.  
The second sub-theme in assessment was “assessments do not decide”, which includes 
stakeholders’ ideas about the fact that HTA reports simply recommend a technology for adoption 
and it is up to individual health systems to decide whether to action that recommendation or not. 
An industry stakeholder commented on the challenges associated with the elective nature of 
recommendations:  
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“there is no teeth to that recommendation…So the health system itself does not have to 
follow that recommendation. It’s quite optional. And so linking those processes to the 
adoption of innovation … could be greatly improved to helping technologies through 
the system”.  
A researcher suggested that the cost-effectiveness data, that a HTA report uses to generate 
recommendations, are not helpful for decision-makers in health care systems:  
“cost effectiveness tells you nothing about the actual, sticker shock that goes along with 
technology adoption… these technologies involve process changes and organizational 
changes and feasibility of adoption questions from an organizational perspective. It’s 
really very poorly analyzed within an HTA process… often times there is a budget impact 
analysis that is done, but I think they’re quite poorly done which affects the real cost to 
the organizational level to adopt”. 
In this sub-theme, an industry stakeholder addressed a potential misunderstanding about 
HTA recommendations in that they inform adoption decisions, but they do not make them. A 
researcher noted the types of data that are missing from health technology assessments to make 
them operational for health care systems.  
The third sub-theme under assessment was the mismatch between the pace at which a 
technology develops and the pace at which it is assessed. A government interviewee contrasted 
the slow pace of assessment to the academic nature of evidence synthesis inherent in HTA 
production, with the fast-paced nature of health care service delivery where technologies are 
used:  
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“the academic world operates at a standard and at a speed that just isn’t practical 
from the delivery side. The types of things that turn their cranks, that motivate 
them… are not necessarily as relevant to those who are responsible for delivering 
care”. 
An industry representative commented on the slight differences between assessment procedures 
across countries, which leads to separate HTAs being completed when a technology is 
introduced in a new jurisdiction:  
“every jurisdiction, every country – so Canada, the US, Europe, Australia do their 
own thing… it means that if you do bring a product to market in Australia rather 
than launch it in Canada, you have to repeat the process”. 
This stands in contrast to the finding that regulatory certification can facilitate technology 
adoption in another country. As regulatory certification is only concerned with the safety of the 
technology, and roughly the same information is submitted to regulators in different countries. 
HTA is concerned with the clinical and cost effectiveness of a technology, and each country has 
its own set of usual procedures that the new technology would be compared with. This sub-
theme recounts concerns from a government and an industry stakeholder about the speed of the 
HTA process, and whether it is efficient to complete a new HTA every time a technology 
changes jurisdiction.  
The fourth sub-theme under assessment was the many categories of evidence to assess 
with a new technology, which gets at all the different types of evidence tracked in an HTA as 
well as discrepancies or problems when the evidence required by an HTA is not present. A 
government interviewee said:  
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“there is a lot of variability…in what an HTA entails, so what we are trying to do is 
get to a …minimum amount of data that you need as that healthcare setting to say 
‘ok, I am ok with the decision lets purchase this’…And hopefully that evidence 
packages will be enough for the next.. healthcare setting”. 
An industry interviewee commented that relevant evidence is not always collected:  
“ there’s a lack of understanding of what is useful evidence generation, so a lot of 
things… [are] never really captured in a way that provides meaningful evidence on 
which we can make better decisions”. 
An innovator noted that they were torn between industry and academic influence when building 
the evidence base about their technology:  
bridging the gap between academia and industry is …an ongoing issue… we don’t 
wanna go run a $100 000 million dollar study …if at the end of the day, the design of 
the study is so academically focused and doesn’t actually help us prove a case that 
then will result in driving adoption”.  
A researcher postulated the need for different types of data in the case where the traditional 
evidence base is not present:  
“if you’re looking at a medication, quite likely you will find or could do a systematic 
review of … randomized trials with straight forward outcome measures. That… cost 
effectiveness information that could then inform a decision. For many of the technologies 
that we’re considering, the evidence base is not there. And is less likely to get there 
because these may not be the kinds of interventions that would necessarily lend 
themselves to randomized trials…maybe we need to look at different kinds of evidence”. 
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This sub-theme picks up on earlier concerns about HTA informing decision-making, and 
relatedly, what information is required by decision-makers to make decisions about adopting 
new technologies. Government, industry, research and innovator representatives all had 
comments about the balance between how to create the necessary evidence without being overly 
time consuming or costly.   
The fifth sub-theme under assessment is the difficulty associated with classifying 
complex devices. A government interviewee noted the challenges of keeping up with incoming 
technologies seeking Health Canada regulation:  
“everything's innovative … it's new products and used in a way we've never used 
products before…  the sheer challenges in terms of where devices fit right now... There's 
more and more things shoved into each submission, and you're trying to figure out what 
the different component parts are and what's approved and what's not approved… 
moving forward, it's a pharmaceutical, plus a natural health product, plus a device, plus 
it's actually three different types of device in the device …, and how you manage that 
from a regulatory perspective.” 
An innovator commented on the future of medical devices and the potential complexity if 
technology extends to personalized medical devices:  
“we’re getting into a realm where we could actually have individually produced medical 
devices. How on Earth do you figure out whether they are in spec?...From the regulator’s 
point of view this was kind of mind blowing because wow, how cool is this, but at the 
same time … where would be the start, figuring out how to regulate it?”. 
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This sub-theme had two of the most relevant stakeholders in the health technology regulation 
process: government and innovators speaking about the complexity of new health technologies 
and the pressure that puts on regulators.  
3.5.5. Implementation  
Implementation contained four sub-themes: having the right evidence to make 
reimbursement decisions, bureaucratic complexities, value-based procurement, and 
implementation considerations across health care settings.  
The sub-theme, having the right evidence to make reimbursement decisions, describes the 
difference between the types of information that innovators collect about the functionality of 
their technology versus the type of information required to make reimbursement decisions (often 
cost and clinical effectiveness data generated through randomized controlled trials). A 
government interviewee commented about the need to “pull information out of” innovators and 
translate it into metrics that will be relevant to decision-makers.  
That interviewee gave the example where decision-makers were unsure about the value of a 
wound care technology, because innovators had not collected information about the time it took 
to apply the technology. Without knowing how long the new technology took staff to apply, 
decision-makers were not able to compare the technology to existing procedures in wound care 
to know if the new technology was worth adopting and implementing. The government 
interviewee spoke about having to “pull” the time-to-administer information from the innovators, 
as that is the evidence the decision-makers needed to understand the value of the technology. 
 An industry representative spoke about the challenge of responding to pressures from 
clinicians and patients to adopt new technologies:  
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“we just don’t know how to deal with the crowded nature of all these technologies 
dying for attention and all of them equally un-evidenced and unstudied, all of them 
looking equally fine but having nothing specific to make decisions upon. And patients 
and society being very ill-informed of what they’re demanding, generally wanting the 
new and shiny ...and so do clinicians”. 
A researcher commented on the challenge for innovators in that regulators usually require 
different sets of evidence than do HTA producers, and that moving towards better coordination 
between regulatory and HTA bodies could be a facilitator for adoption:  
“coordinate regulatory and reimbursement processes… they need to be both at the table 
because…, especially for the device side, they should be collecting  the evidence that 
they need to get reimbursement decisions”.  
This sub-theme contains comments from government, research and industry stakeholders about 
how different evidence is required across different stages of the innovation pathway in order to 
have health technologies adopted, and the problematic assumption that exists among some 
stakeholders equating new technology with progress, without careful examination of evidence. 
In the second sub-theme, interviewees commented on bureaucratic processes which slow 
technology implementation. An innovator noted that health care systems can be supportive, yet 
slow partners:  
“the health care professionals that we work with are really welcoming new ideas … but 
health care is a very, very long process for changing things. Although they are very 
enthusiastic on a new project to come on board … there’s a lot of protocols to be 
changed to introduce a new product … they can’t actually just make a decision in one 
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day … there’s protocols, processes, people … that need to actually be made aware of it 
- it takes a long time”. 
An industry representative gets at the bureaucratic complexity even within governments:  
“one of the other barriers that might not seem as sort of apparent is, is within 
government, the lack of inter-ministerial sort of coordination and cooperation”. 
A government stakeholder suggests that: 
“building relationships with the healthcare organizations individually and working with 
the ones that are easiest to work with and then that might actually be a faster pathway to 
reimbursement than it is trying to jump through bureaucratic hoops- they’re just not 
business friendly” 
as a method to overcome bureaucratic complexity that impedes technology adoption. In this sub-
theme industry, innovators and government stakeholders acknowledged bureaucratic complexity 
acting as a barrier to technology implementation. Stakeholders offered suggestions as to how to 
manage this complexity: awareness of silos within government; better knowledge of health care 
organizations to understand their process for implementing a new technology and building strong 
relationships with individual health care organizations. 
The third sub-theme under implementation was value-based procurement. The role of 
procurement in Canada is to ‘acquire the supplies and equipment healthcare facilities need to 
function on a daily basis, while addressing clinical needs for quality and policy expectations for 
cost control and regulatory compliance’ (Miller et al, 2019). Group purchasing organizations 
have been created to pool procurement functions across large health regions and in some cases, 
entire provinces (Alberta, British Columbia and New Brunswick) (Snowdon, Zur & Shell, 2011). 
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Group purchasing organizations were designed to create economies of scale by streamlining 
purchasing decisions across multiple health care organizations, but recent comments expressed in 
the literature criticize rigid, cost-focused procurement in Canada’s health care systems (Prada, 
2016; Arshoff, Henshall, Juzwishin & Racette, 2012; Miller et al, 2019). Value-based 
approaches to procurement are promoted as a way to enhance: patient outcomes, longer-term 
health system performance, and innovative products which offer system-wide benefits (Prada, 
2016; Miller at al.,2019). 
Industry and government stakeholders referenced their involvement with value-based 
procurement initiatives in areas such as risk-sharing or pay for performance, where the health 
care system pays a vendor when outcomes that were promised are delivered. Interviewees noted 
that this new way of acquiring services based on outcomes (as opposed to cost) was well-
received by vendors, even those who did not win the contract.  A researcher commented on the 
difficulty even for big, province-wide procurement agencies, which serve all health sectors, to 
think about procurement in home and community care as acute care technology needs crowd out 
technology spending:  
“single province procurement and supply chain and…shared service organizations that 
are serving health organizations … that extend into the home and community care sector, 
even there it’s extremely hard for those procurement agencies to think about adoption in 
the home and community care sector because the, the ones that scream the loudest, the 
tyranny of the acute prevails. So, the highest cost expenditures are still the hips and 
knees. The most influential interests are still the acute care hospitals, the doctors and the 
surgeons”. 
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This sub-theme described interviewees’ positive experiences with value-based 
approaches, but cautioned that these approaches may be more common in an acute care setting 
than in the home and community care sector. 
The final sub-theme was health care implementation, which contained comments about 
the nature of health care systems, which make them more challenging settings in which to deploy 
a technology, than other industries. A government interviewee spoke about the far-reaching 
impacts of introducing a new technology into a complex system: 
“ you have to change how you deliver the care and that’s hard, that’s really hard. It’s 
really slow and costly in the sense of the amount of time and effort needed”. 
An industry stakeholder working in the home and community care sector spoke about the 
challenges associated with introducing a technology without earmarked funding for research or 
evaluation in their budget:  
“some way to tap into dedicated grants or funding that would enable homecare 
organizations to do the testing, do the evaluation and then support knowledge 
dissemination would be incredibly helpful”. 
The industry representative went on to comment: 
 “there’s no mechanism to make it easy for us to do this”.  
A researcher commented that in many cases a technology builds its evidence base according to 
the amount of time it will save health care staff, and cautioned about the human resource 
management implications of comparing a new technology with human delivered care.  
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This sub-theme addressed government concerns about the time and effort required when 
a new technology implicates changes in health care delivery, industry concerns about restrictive 
funding in the home and community care sector and a researcher’s concerns about comparing 
technology-delivered care with human-delivered care.  
3.5.6 Sustainability 
The sustainability theme contained comments from interviewees about the processes that 
exist to ensure technologies are sustainable, including disinvestment processes when 
technologies or procedures are no longer delivering value to the health care system. A 
government interviewee explained the benefits of a health technology management approach:  
 “which is more of a life cycle approach to assessing technologies. It goes a little bit 
beyond an HTA… It would include disinvestment, while the technology is used to 
determine if it's still serving a real purpose or should it be disinvested… what are the 
best ways to use that technology. What should be the conditions for success to reap the 
most benefits from the technology throughout its life cycle”. 
An industry representative spoke about the challenges of technology adoption without health 
technology management:  
“the system I think just really needs to understand how to stop paying for a particular 
technology, de-listing these kind of items so that new things can come in”.  
A government and an industry stakeholder described the features of a health technology 
management approach and the challenges to health technology adoption without a way to ensure 
their sustainability over the long term.  
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3.5.7 Canadian Policy Context 
The Canadian Policy Context theme included comments related to the two subthemes: 
jurisdictional considerations and international comparisons. Interview comments were coded into 
the jurisdictional considerations sub-theme if they touched on issues related to shared jurisdiction 
in health between federal and provincial governments. A government interviewee spoke about 
health care being a provincial jurisdiction and how that leads to variation in which technologies 
are covered or reimbursed across the country. An industry representative added the challenges 
with scaling up a good idea across Canada when the provinces operate so separately:  
“great pilots all over the place that are happening and then they just…stay happening in 
whatever area, or the pilot dies. I think one of the things we’re trying to look at…is how 
do we bring that spread across a jurisdiction. How do you take a good thing happening 
in one community and … how do you take that spread across, but there is no formalized 
process for that in lots of different jurisdictions”. 
An innovator commented on how jurisdictional considerations exacerbate what is already a small 
market in Canada for medical devices:  
“the Canadian model is really messed up because of the interprovincial trade barriers… 
we have a tiny market which we have shrunken even more with these interprovincial 
trade barriers… as a start-up company… I wind up having to pay 10, 20, 30 percent of 
my capital on travel to go to markets where people don’t have enough critical mass that 
it makes sense for you to try and sell them something… there’s no way that the 
Canadian market is remotely big enough to support what I’m doing.” 
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Innovators, industry and government commented how provincial jurisdiction over health 
care creates a fragmented national market where ideas and innovations are difficult and 
expensive to scale nationally leading to variation in what devices are covered by which 
provinces. The international comparisons sub-theme contained comments by interviewees about 
other countries which may be easier or more lucrative for innovators to bring their technologies 
to market. A government interviewee pointed out that North American free-trade laws interact 
with procurement policies, making it hard to favor local innovators:  
“I've heard this… ‘It's easier for me to sell into the US, than it is into my own province.’ 
…A lot of it is procurement rules, because …I can't provide any favoritism, or any 
weighting to say, ‘You're an Ontario-based company.’ Because that's against the North 
American Free Trade laws”. 
An innovator noted that single-payer health care systems in France and Germany attract more 
attention from innovators than being adopted in Canada. An industry representative noted that in 
Europe and the United States there are fast-track processes for approval of medical devices 
which have already been approved that make small changes in materials compared with Canada, 
where there are:  
“substantive barriers especially around class II and class IV medical devices”. 
A researcher also contrasted the difference between Canada and other countries’ medical 
device approval process, and noted that for some companies, Canada is an entry point to the 
North American market: 
“the US is the market that has the gold standard for regulatory approval… they set 
meaningful standards around the regulation of medical devices that are higher than 
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Canada’s and they’re infinitely higher than in Europe. … But Canada is… seen in some 
ways from the regulation of medical devices as the entry place to test out… on the way 
to… or at least can be a quicker entry to the North American market. The FDA has a 
higher standard, so we’re kind of the intermediate, we’re close to the US, but, but we’re 
still easier… maybe it needs to be closer to the FDA, but certainly it doesn’t need to be 
closer to the EU”. 
Stakeholders’ comments reflected on features of other jurisdictions which may make 
them more accessible to innovators. They noted that although Canada may have more stringent 
rules around regulation of high-risk medical devices, it is perceived as a gateway to lucrative 
American medical device markets.   
3.5.8 Resources 
The resources theme contained four sub-themes: funding challenges in home care; hidden 
costs of technology; siloed budgets in health care; and the need to coordinate health care with 
economic development. Funding challenges in home care contained interviewees’ comments 
about resource-related considerations specific to technology adoption in the home and 
community care sector. A researcher commented on the good intentions of resource 
organizations working in home care:  
“this sector is significantly underfunded in every way shape and form, significantly 
under-resourced, massively complicated. No meaningful leadership, you know just a 
nightmare to organize, but deeply mission driven, hundreds of little organizations, 
mission driven, trying to do the best they can”.  
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An innovator added that lack of resources (both time and money) can deter innovators from 
working in the home and community care space:  
“cumbersome policies when it comes to reimbursement, kind of demotivate innovators or 
companies from focusing on the latest innovations in this sector, and so then what ends 
up happening as a result of that… basically all the key stakeholders … are not as 
progressive … not as technology forward, because they just don’t have the money.  
They’re cash strapped and they’re already overburdened and so the barrier…to adopting 
innovation is quite high…so for innovators … in this space, you might have a great 
product that could add a lot of value but there’s no dollars and cents to pay for it and 
nursing staff and administrators… have like ten other priorities that they seem to be 
dealing with and … there’s lots of operators out there…who don’t have the capacity to 
even look at innovations even if they wanted to because they’re just so swamped with 
dealing with the day to day grind of running their business. It’s very, very difficult, it’s 
…disheartening”. 
An industry representative described their experience with successful implementation of 
a technology in home care, despite lack of resources. This interviewee attributed the success to 
the fact that a physical space in the organization was set aside for use to bring together 
innovators, caregivers, and older adults to co-create technologies.  
Interviewees’ comments in this sub-theme focused on the value of co-creation in a 
resource-scarce sector of the health care system, which is focused on service delivery and lacks 
dedicated funding to the research, evaluation and trialing of technologies.   
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The second resource-related sub-theme was: hidden costs of technology, which contained 
comments about the costs of technology adoption beyond the list price of the technology. An 
industry interviewee commented that some products do not fit into normal patterns of use in 
health care and require changes to the way that care is approached to see the benefit promised. 
That interviewee went on to comment about the hidden costs associated with medical devices 
that cannot be used by a single individual:  
“There are a number of medical devices that would be useful for the elderly that cannot 
be applied or used by the patient himself. So, he needs help. And in the homecare 
setting, to provide this support by either a visiting nurse or something like that, it can be 
very, very difficult to do”.  
A government representative spoke about a program they ran which tried to acknowledge 
some of the hidden costs of technology adoption: 
“an eligible expenditure includes any sort of training you might need to …get people in 
your office to be able to use this or even your patients to use it … any sort of culture and 
change management... any sort of supporting technologies so if you need software 
upgrades or … new computers or …a couple of smart phones to actually test out the 
app”. 
Industry stakeholders discussed how technologies which change patterns of service 
delivery, and those which require assistance to be used have hidden costs in time, money or both 
to realize benefits. A government stakeholder recognized these ‘hidden’ costs as eligible 
expenses within their programming.  
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The third sub-theme under resources is titled siloed budgets in health-care. Stakeholders 
commented on how health care funding is allocated and transferred across units, and the impacts 
for a technology which operates across budget silos. 
A government stakeholder noted it can be very challenging to demonstrate value in a 
health care system with siloed budgets:  
“the way the budgets are organized it’s very, very difficult for folks to move resources 
or release resources now that you’ve included this transition cost and getting the new 
technology in place can be challenging…Depending on how it’s implemented you may 
just increase your costs”.  
An industry representative commented that: 
“siloes in the health care system are another huge issue”  
and went on to describe health care funding to be allocated in a way that does not reflect the 
types of patients being served, or their mobility across different sectors of the health care system. 
An innovator added their experience with trying to be compensated for an innovation which 
prevented costs to the health care system: “you have now that gadget that everybody says that 
will save lives, so who's going to pay for it?”. They added: “the savings in the hospital in terms 
of getting people out of the hospital earlier- you can calculate that, but the hospital is not going 
to give you money because you got the person out.”
 Interviewees’ comments reflected agreement that siloed budgets were a barrier to health 
technology adoption in that they made it difficult to: prioritize preventive technologies, 
demonstrate value and treat complex patients. 
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The fourth sub-theme under resources was coordinating the health care system with 
economic development agendas; which contained comments about the value of adopting 
promising local health technologies as a way to make the health care system more of an 
economic driver for governments (as opposed to importing all health technologies from 
companies in other countries). An industry stakeholder commented on this perspective becoming 
more prevalent:  
“The system is being looked at as an economic driver and a way to prop up industry and 
as an industry in and of itself, because it is, it employs 2 million people in Canada and 
could lead to new industries that could drive Canada’s economy. …so, that’s a very, 
very big area”.  
A researcher commented on their efforts to bring local innovations into Canadian health care 
systems:  
“pilot initiatives and experiments around the point 1 percent of—3% of med technology 
adoption. That is, that is the budget allocated to medical technologies in the health care 
system. So fairly small and narrow niche of focus that’s the sweet spot there is to bring 
together health system needs with the commercialization agenda or the economic 
development agenda. So you’re looking for made-in-[province name] technologies seem 
to have actual promise.” 
Industry and research stakeholders reflected the drive to leverage the purchasing power of 
Canada’s single-payer health care system to support local innovation, and how that could 
contribute to Canada’s economic interests.  
3.5.9 Partnerships 
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The partnerships theme contains three sub-themes: partnerships with health care 
stakeholders, innovation ecosystems, strategies to connect partners, and the timing of 
partnerships.  
The partnerships with health care stakeholders contained comments about the value of partnering 
with health care stakeholders to ensure fit and potential for uptake. One industry representative 
commented that health care partnerships are the way forward to ensure adoption:  
“technologies …should [have] the conversation with healthcare administrators and 
senior folks earlier…Otherwise it’s kind of an old-fashioned model to develop 
something and kind of hope for the best… I think the way forward is…having very early 
conversations about what do people need and how is this and is this actually going to 
enjoy uptake”.  
A government official added emphasis to the idea that innovators and health care stakeholders 
should partner early on in technology development:  
“Reach out. Collaborate. We're all condemned to work together. … when you're with 
your little technology and you have an idea… you don't want this policy guy or the 
health research woman who will tell you, ‘You have to tweak it because it won't fly’… 
It's better to have the cold shower right in the beginning and work together than to 
work five years, spend lots of money, make lots of proof of principle and at the end, 
say, ‘Nope. We don't want to’”.  
Industry and government stakeholders commented that the way forward is to develop multi-
stakeholder health care partnerships for development of relevant technologies, which are aligned 
with health care priority issues.   
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The timing of partnerships sub-theme builds on the commentary about the value of 
healthcare partnerships, to include other non-health care stakeholders early in a technology’s 
development. A government stakeholder speaks to the value of early discussions to inform a 
‘regulatory strategy’ for the device:  
“early engagement with regulatory authorities and asking the right questions to 
understand the obligations of an innovator who's entering into this space that's maybe 
uncharted territory for them … looking long-term about aspects related to regulations, 
uptake, and reimbursement. …having those early discussions and developing a 
regulatory strategy early on in the process is something that is very positive … playing 
catch-up after the fact is challenging”. 
An industry stakeholder discussed the value of the medical device industry as a whole working 
closely with governments to better understand each other’s needs. Industry and government 
stakeholders felt multi-stakeholder partnerships helped partners understand each other’s needs 
over the long time period it takes to develop, assess and implement a technology.  
The third sub-theme under partnerships is strategies to connect partners and this sub-
theme contains examples used by interviewees related to connecting relevant stakeholders. A 
government stakeholder spoke about their efforts to bring together researchers, hospitals, 
innovation centers, and the rehabilitation sector to develop an ecosystem to support aging-related 
technologies. An industry representative noted government-created organizations around 
different disease-state or clinical areas as a venue to bring together partners:  
“we’ve been working on an initiative with them to bring in medical technology 
companies, and then the [organization]…will talk to industry about what their health 
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challenges are, and the companies can respond by presenting different technologies 
that will improve the health of that type of patient”. 
An innovator added that technology incubator programs designed to provide them with 
mentorship, advice, and networking opportunities were very helpful to them.  
Government, industry and innovator perspectives cited the value of innovation 
ecosystems, venues or events which bring together multiple partners and technology incubator 
programs as ways to connect partners.  
3.6 Discussion. 
3.6.1 Ideas, Interests, Institutions 
The conceptual framework conceived of numerous interconnected actors operating in the 
health technology innovation policy landscape for older adults in Canada. By collecting 
stakeholder perceptions about what is, and what should be, in the health technology policy arena 
these findings present a set of ideas. The framework helps to understand how many sets of 
interests interact, as facilitators and barriers are relevant at the intrapersonal, interpersonal, 
micro, meso and macro policy levels. These interconnections are complicated by the fact that 
health technologies for older adults may be used, administered, prescribed, regulated, evaluated, 
purchased, invested in, and developed, all by different interests.  
Facilitators and barriers to health technology innovation and adoption for older adults 
operate within a complex web of institutional arrangements. Municipal, regional, provincial and 
federal governments operate with individual mandates for health care and innovation. Private 
stakeholders sell pharmaceuticals, assistive technologies, medical devices, health care services, 
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and insurance. Patient representatives, social movements and charity organizations work to have 
their voices heard. Smith, Mitton, Davidson and Williams (2014) describe this institutional 
complexity: “these increasingly complex arrangements constrain both short and longer-term 
opportunities to reallocate resources as well as confounding decisions concerning who the 
stakeholders are, and how they can be included in the process”. The stakeholder perceptions 
identified ideas and interests and suggested strategies to leverage partners and resources to 
navigate complex institutional arrangements in the health technology policy arena. 
3.6.2 Development 
The findings of this process align with concerns in the literature around designing 
technologies responsive to the needs of Canadian health care systems (Lehoux, Gauthier, 
Williams-Jones, Miller, Fishman, Hivon et al., 2014; Menon & Stafinski, 2011).  Our interviews 
confirm that technology developed without health system expertise is a barrier to adoption and 
use and suggest innovators developing a new technology should seek out health system partners 
and documents to confirm that their technology aligns with health system priorities. Benefits of 
consulting health care partners include: clinician feedback, access to patients, and pilot 
opportunities. Put very simply, we heard: “If you’re innovating, then innovate in the direction of 
where the health system is going”. This may be especially challenging for innovators who are 
funded by partners (either public, private or not-for-profit) who value the potential for revenue 
generation over the potential for a meaningful change in health outcomes.   
3.6.3 Assessment 
As others have found (Culyer, 2014; MEDEC, 2011), this research identified concerns 
about the length of time formal assessment processes can take, which is exacerbated when 
companies have to repeat assessment processes when introducing their technology in a market or 
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jurisdiction. Our interviewees generated new questions about how to support ‘meaningful 
evidence generation’ and what should be done in cases where clinical or cost effectiveness data 
are not available or are unlikely to become available. Our results provide a commentary about 
the future of regulating medical devices, as devices continue to develop at a rapid pace, 
becoming more and more complex and personalized. If device development continues to 
intensify and out-paces assessment processes, it may be relevant for innovators to consider that 
developing a technology that will not be regulated as a medical device can offer flexibility in 
defining the product’s value.   
3.6.4 Implementation & Sustainability 
Our results echo findings in the literature noting the problematic nature of cost-focused 
procurement processes in health care (Prada, 2016; Arshoff, Henshall, Juzwishin & Racette, 
2012; Miller et al, 2019). Processes with an emphasis on values or outcomes ‘de-risk’ the 
investment for the healthcare system in a new technology or innovation, which can be important 
when operating in a publicly funded health care system. As others have noted, (Scotland & 
Bryan, 2017; Bryan, Mitton & Donaldson, 2014), our findings had an emphasis on managing a 
technology throughout its life cycle, and disinvestment as a way to offset spending on new 
technologies. Although interviewees acknowledged the usefulness, in principle, of disinvestment 
to promote sustainability of technologies across their lifespan, they noted challenges in 
implementing a health technology management approach or “how to stop paying for a particular 
technology”. This aligns with the findings of Soril and colleagues (2017) that transitioning to a 
health technology reassessment approach is very difficult. Disinvestments are a form of resource 
allocation and can be a contested endeavor by different health care providers and insurers as they 
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impact volumes of services and the way they are delivered (Smith, Neale, Mitton & Williams, 
2014). Health care systems may require support to know where and how to begin disinvesting. 
3.6.5 Partnerships 
Similar to the findings of Scott, Pasichnyk, Harstall & Chojecki (2015) where the 
technologies with the least amount of support infrastructure were the most likely to be adopted, 
our interviewees noted that change management, support technology, software upgrades, new 
computers and IT support staff during implementation all represent costs beyond the list price of 
a technology which can impede adoption into Canadian health care systems. Partnerships 
between innovators, health technology evaluators and health care systems may be required to 
make all costs of technology adoption apparent.  
3.6.6 Canadian Policy Context 
This work illustrates the frustrations that innovators have when trying to bring a 
technology to market in Canada. Provincial jurisdiction in health care, and the corresponding 
different policies of each health system, exacerbate Canada’s already small market share in the 
medical device arena. Promoting Canada as an entry point to the medical device industry in the 
United States, as one of our interviewees suggested, may provide more incentive for innovators 
to consider bringing their technology to market in Canada. It may be misleading to present 
Canada as a gateway to American markets, since the two health systems are structured quite 
differently, which can impact how well a technology fits in two jurisdictions. Canada’s health 
system is more similar to European health systems such as Germany and the U.K. than the 
American health care system (Lehoux, Miller, Daudelin, Denis, 2017). 
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3.6.7 Resources 
Our interviewees commented on the sheer size of the Canadian health care system and 
the need for governments and policymakers to see health care as a way to drive economic 
development. Relatedly, our interviewees spoke about the opportunity cost to economic 
development when Canadian investments fund the co-design, development, and piloting of 
technologies, which go on to commercialize in other countries. This opportunity cost is 
magnified as Canadian health care systems import 75% of health technologies (International 
Trade Administration, 2019).   
3.6.8 Partnerships 
Different types of partnerships were presented as a way to enable technological 
innovation and adoption in Canada. Given health policy and technology policy operate in 
insulated silos from one another in Canada, with different portfolios, aims, and strategies to 
reach those aims (Henshall & Schuller, 2013; Lehoux, Miller, Daudelin, Denis, 2017) it is not 
surprising that bringing a technology to market in Canada is challenging for innovators, when 
layered with budgetary silos within health care and a lack of inter and intra ministerial 
collaboration within governments (issues which our interviewees brought up). Across 
stakeholder types, our interviewees stressed the importance of collaboration between innovators, 
regulators, HTA bodies, clinicians, patients, reimbursers, procurement staff and health care 
decision makers. The timing of when these partnerships should be formed was undoubtedly early 
in a technology’s development. Stakeholders stressed how much waste could be avoided if 
partnerships leveraged partners’ relevant expertise across the development, assessment, 
implementation and sustainability of a technology. Our findings suggest innovators are receptive 
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and appreciative of venues where they can form partnerships (such as government organized 
entities, or technology incubators) which will help shape the development of their technology.  
3.6.9 Older adults & Co-creation 
This chapter was designed to add insight to aging-related technologies and how they 
might experience barriers and facilitators to health technology innovation and adoption. The 
findings suggest unanimous agreement across stakeholder types that formal innovation and 
adoption processes would be the same regardless of the target population for the technology.  
Our findings show resource constraints specific to innovation and adoption in the home 
and community care sector which are relevant for older adults as they represent 70% of Canadian 
home care clients (Canadian Home Care Association, 2016). An innovator noted that day-to-day 
care delivery activities of home and community care services crowd out the possibility of 
considering or adopting a technology. Our interviewees noted the complexity of the many home 
and community care agencies working separately to deliver care and attributed the lack of 
funding for evaluation and implementation of technologies as related to underfunding of the 
home care sector. 
Interviewees mentioned that negative assumptions persist among policymakers and 
clinicians and about older adults’ capacity for technology use. These assumptions affect the way 
technologies are formally assessed, as value-sets used to estimate changes in health-related 
quality of life are based on representative samples of the general population (Devlin, Shah & 
Buckingham, 2017) and do not consider the ways that preferences change with age, for example 
how emphasis on quality of life as opposed to length of life may change. Other research has 
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shown that older adults feel they are excluded from innovation partnerships due to ageism 
(McNeil et al, 2017).  
Negative assumptions about older adults were contrasted with a strong commitment to 
co-creation of technologies across stakeholder types we interviewed. Governments could play a 
leading role in creating opportunities to link stakeholders across sectors and inform the co-
creation of health technologies for older adults. Opportunities to partner and co-create 
technologies that are relevant to older adults and caregivers and responsive to health system 
needs should take place at the outset of technology development to prevent waste.  
3.7 Strengths & Limitations 
3.7.1 Limitations 
This study used a framework analysis to interpret the findings of 46 qualitative interviews 
on facilitators and barriers related to health technology innovation and adoption for older adults. 
As this method chooses a framework in advance of analyzing data, some have pointed to a 
necessity of getting a good fit between the data and the framework, and the possibility of the 
framework ‘stifling the vividness of insight’ inherent with qualitative analysis (Dixon-Woods, 
2011). The framework method does not address the frequency with each theme arose. Some 
themes were raised in nearly every interview; some in relatively few interviews. The 
categorizations between stakeholder types may be oversimplified as some stakeholders have 
worked across stakeholder types (for example researchers and innovators, or policy-makers and 
researchers).  
As a participant pointed out, there are normative challenges related to asking the research 
question the way I chose to. Asking for facilitators and barriers relies on participants’ subjective 
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definition of good and bad in the health technology policy arena, and stakeholders from different 
sectors (or the same sector) could potentially be in conflict. I have distinguished between 
stakeholder type throughout the results. Older adults did not inform this interview process, but 
will be consulted in a subsequent phase of this work to provide feedback on these findings. 
Innovations operate within social contexts, and communication about new innovations 
between different actors over time influences whether or not an innovation gets diffused widely 
across a system (Rogers, 1995). Although diffusion and widespread use would fall under the 
implementation stage of the innovation pathway developed in this study, I did not study 
specifically the manners in which technologies become used widely or adopted but not used, 
which may have limited the work. 
3.7.2 Strengths 
Framework analysis can be a helpful way to structure a large set of data (Dixon-Woods, 
2011), such as this one, with 46 qualitative interviews ranging from 45-90 minutes each). 
Framework analysis is also ‘an excellent forum for driving forward interdisciplinary 
collaboration’ (Gale et al, 2013, p.6) which may have helped to accommodate the different 
perspectives from four different stakeholder types. 
3.8 Conclusion 
Stakeholder perceptions present a complex arrangement of institutions, interests and 
ideas about facilitators and barriers to health technology innovation. By identifying the layered 
institutional arrangements, this work helps to explain the disintegrated nature of the Canadian 
health care system, and associated challenges with having innovations adopted and used in such 
a system. In many ways, stakeholder comments appear in these interviews as advice to 
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innovators about how to navigate a disintegrated system.  This work offers a discussion, which 
can inform how to move forward in partnership with older adults, caregivers, innovators, 
researchers, policymakers and industry representatives to co-create a more integrated health care 
system enabled by health technologies. 
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CHAPTER FOUR: Ranking policy options to enable health technology innovation and 
adoption in Canada: A multi-stakeholder concept mapping process 
4.1 Introduction 
The earlier stages of this research identified facilitators and barriers to health technology 
innovation and adoption in Canada, as a necessary step in creating an evidence-informed health 
innovation agenda. More research is required to translate facilitators and barriers into policy 
options, and to then understand which of these are the most important, and most feasible. This 
work is in support of the development of a clearly articulated health technology innovation 
agenda, with specific actions for different actors at the different institutional levels, which 
characterize the Canadian health care system (federal, provincial territorial, regional) (Snowdon, 
2017; Padfield, 2017). 
Work has been completed to understand factors that facilitate or constrain health 
technology innovation and diffusion at the front lines of care, based on qualitative interviews 
with healthcare providers and industry representatives in eight countries (Keown, Parston, Patel, 
Rennie Saoud et al, 2014). A systematic review identified the diffusion, dissemination, and 
implementation of innovations within health service organizations (Greenhalgh et al., 2004). 
Other work has been undertaken to understand how to engage older adults in regional health 
innovation ecosystems (McNeil, 2017). What these reports have not covered, is a “whole 
systems approach” to understanding how facilitators and barriers at different institutional levels 
can be translated into viable solutions for policy problems (Greenhalgh et al., 2004). 
Choi and colleagues (Choi, Pang, Lin, Puska, & Sherman et al., 2005) suggest that 
policymakers are specifically interested in policy options, which are agreeable to large 
constituencies of people. Concept mapping has been suggested as a method to integrate 
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viewpoints of a variety of stakeholders to offer insight to the complex, ‘wicked’ problems which 
characterize modern policy-making (Klenk & Hickey, 2011; Trochim & Cabrera, 2005). 
The aim of this study was to use group concept mapping to compile opinions of 
policymakers, researchers, industry stakeholders and innovators to answer: what do experts 
perceive to be the most relevant and feasible policy options to facilitate health technology 
innovation and adoption for older adults? 
4.2 Methods 
4.2.1 Rationale 
Concept mapping is a participatory mixed-methods approach which integrates qualitative 
individual and group processes with multivariate statistics to describe a topic (Rosas & Kane, 
2012). Concept mapping is more participatory than focus groups or other qualitative interviews 
(since concept mapping participants provide and analyze results), and serves as a way to 
structure qualitative data (Burke et al, 2005). The outputs of concept mapping produce a visual 
depiction of the group’s conceptualization, which can be useful for identifying properties of 
complex systems in policy contexts - maps can align vision with action (Trochim & Cabrera, 
2005). Concept mapping has been identified as an important methodology to accommodate the 
complexity of health care systems, and its participatory, structured nature can bridge the different 
perspectives and identified silos in perspectives between innovation policy and health policy in 
Canada (Lehoux, Miller, Daudelin, Denis, 2017). 
4.2.2 Six Stages of Concept Mapping 
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Figure 7: Six stages of Concept Mapping  
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4.2.3 Preparation 
In the preparation or focus formulation stage, the researcher decides who the participants 
are, how they will be recruited, which participants will help to decide focus prompt, and which 
dimensions participants will rate (Trochim & Cabrera, 2005). The focus prompt serves to 
“delimit boundary conditions for ideas or issues to be mapped” (Kane & Trochim, 2007). The 
focus prompt is structured so that participants fill in the blank after the prompt with their 
statements.  
This concept mapping study took place in two phases. In phase one, participants 
completed brainstorming, sorting and rating activities of concept mapping electronically and 
interpreted results in an in-person workshop. In phase two, interviewees were re-engaged to 
complete sorting and rating activities online.  
The framework outlined in Chapter three, which is adapted from the social ecological 
model, identifies relevant stakeholders associated with different social spheres where health 
technology innovation for older adults is created and implemented. An ecological approach to 
research on health technology innovation has been called for in the literature; and research which 
includes members of the Quadruple Helix model of innovation- users, industry, universities and 
public authorities is also increasingly relevant (Greenhalgh et al, 2004; Arnkil et al., 2010). This 
framework guided each phase’s recruitment with the aim to have a representative sample across 
older adults, caregivers, innovators, researchers, policy-makers and industry representatives. 
83 
A committee member and I adapted the wording of the research question (“what do 
experts perceive to be the most relevant and feasible policy options to facilitate health 
technology innovation and adoption for older adults?”) into the following focus prompt: What 
can be done to create a policy and regulatory environment that will support safe adoption of 
effective technologies (especially those for older adults)? 
4.2.4 Recruitment- Phase 1 (March- April 2019) 
An in-person workshop takes advantage of the participatory as well as individual 
components of concept mapping. An opportunity arose to conduct an in-person workshop 
adjacent to a scientific conference that many key stakeholders in the health technology 
innovation arena would be attending. 
Recruitment for phase one used a snowball sampling method beginning with a 
policymaker who had experience working with health technology innovators, researchers and 
industry stakeholders (Palinkas, Horwitz, Green, Wisdom, et al., 2015).  
4.2.5 Recruitment- Phase 2 (July-September 2019) 
Stakeholders who were involved in our interview process (46 industry representatives, 
policymakers, innovators and researchers) were a relevant and appropriate sample for this stage 
of the project. As part of the qualitative interview process, the interview consent form had 
participants indicate whether they would like to be contacted again to receive results of the study. 
This presented an opportunity to reengage those stakeholders in the project.  
We used a four-pronged strategy to increase these stakeholders’ participation in online 
concept mapping, adapted from Dillman (2000). On June 25th every interviewee was contacted 
with a notification email with a brief explanation of the research aims indicating they would 
84 
receive a link to participate in an online concept mapping exercise in coming days. I sought out 
email communication from the interview scheduling process to refer to as a way to remind each 
interviewee (n=46) of their previous contribution to this research. As a way to show appreciation 
for the associated time commitment with completing the concept mapping process (around 45 
minutes), participants were entered into a draw for a gift card ($150 value). 
Interviewees were re-contacted by email four days later with a link to the concept 
mapping exercise, a short description of the activity and its associated time commitment, as well 
as information about the participation draw (Dillman, 2000). The concept mapping exercise was 
piloted with six researchers in Dr. Stolee’s research lab, to understand the time commitment of 
the sorting and the rating activities. In the recruitment email, participants were notified that each 
activity (sorting and rating) would take around 20 minutes, or around 45 minutes if completed 
altogether. Three weeks after the initial contact, participants were emailed a reminder that the 
study would be closing at the end of the week, encouraging their participation. On September 
23rd, participants were thanked for their participation, and the winner of the draw was notified. 
The e-gift-card was sent to their email address. 
4.2.6. Idea generation 
This stage generates answers to or ideas about the focus statement. A brainstorming 
process among participants or coding existing text/literature are common ways to generate 
statements (Trochim & Cabrera, 2005). Most projects have a maximum of 100 statements, the 
internet can be used to gather statements, or it can be completed in-person using pen and paper 
(Kane & Trochim, 2007). 
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Two researchers worked to code the scoping review (Chapter Two) and the qualitative 
interview results (Chapter Three) to generate a list of answers to the focus prompt. Thematic 
analysis of the scoping review generated 69 statements that answered the focus prompt (Hsieh & 
Shannon, 2005). Thematic analysis of the qualitative interview data generated 78 statements that 
answered the focus prompt (Hsieh & Shannon, 2005).  
Researchers used an idea synthesis process (Kane & Trochim, 2007) which: ensures each 
statement only represents one idea, that each statement is relevant to the prompt, that reduces the 
statements to a manageable number, and ensures each statement is clear and understandable for 
participants. The idea synthesis process eliminated irrelevant ideas and removed duplicate ideas, 
concluding with 80 answers to the focus prompt.  
Snowball sampling generated ten stakeholders to participate in a mixed online and in-
person concept mapping process. Six others were contacted for participation but declined. Phase 
one participants were contacted by email and invited to generate additional statements to those 
identified through previous stages of this research. Using the Concept Systems software (2015), 
participants individually and anonymously brainstormed fifteen additional statements, leaving 
the project with 95 statements, which is just under the recommended maximum of 100 
statements (Kane and Trochim, 2007). See Appendix H for a list of statements.  
4.2.7. Structuring ideas 
At this stage, participants decide how the statements are related by completing an 
“unstructured similarity sorting” process – placing ideas in piles and naming them (Kane & 
Trochim, 2007). Concept Systems Incorporated is an electronic software which can organize the 
structuring stage (Kane & Trochim, 2007). Participants are reminded through the software to 
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choose one pile per statement, and encouraged not to place every statement in its own pile. It is 
typical of concept mapping to rate each statement on its relevance to the focus prompt and 
feasibility to accomplish (Kane & Trochim, 2007). As this work was interested in finding 
relevant and feasible policy options, these rating criteria were used. Researchers using concept 
mapping are often interested in how different groups complete concept mapping activities 
differently, and it is common to set up demographic questions which distinguish between groups 
(Trochim & Cabrera, 2005). 
In April 2019, phase 1 participants (n=10) were invited to complete the sorting exercise 
24 hours before the in-person workshop as pre-work. For phase one participants, the rating 
activity took place within the workshop. In July 2019, twelve previous interviewees completed 
both the sorting and the rating activities. The sample of twenty-two participants aligns with 
Rosas and Kane’s (2012) recommended sample size of 20-30 participants.  
4.2.8 Representing ideas 
A similarity matrix is created which shows the number of participants who sorted each 
pair of statements together (Kane & Trochim, 2007). Next, multidimensional scaling takes the 
similarity and places points on a two-dimensional map (called a point map) resulting in a set of 
coordinates for each statement (Kane & Trochim, 2007). Stress tests diagnose the degree to 
which distances on the map vary from values in the similarity matrix. Lower values indicate 
better fit, while higher values mean the data are more complex or that they were not often sorted 
similarly by participants. (Kane & Trochim, 2007). Around 95% of concept mapping projects 
have a stress test value in the range of .205-.365 (Kane & Trochim, 2007). A hierarchical cluster 
analysis of the multidimensional scaling results groups the statements into non-overlapping 
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clusters. The analyst and a small participant advisory group decide the appropriate number of 
clusters, which is normally a function of the amount of detail required in the analysis (Trochim 
& Kane, 2005).  
In this stage, bridging/anchoring analyses are completed to provide the analyst with an 
understanding of which individual statements and clusters of statements are anchored on the 
point map and which bridge across the data (Kane & Trochim, 2007). Bridging and anchoring 
help the analyst to understand the map and the dynamics at play between different sections of the 
map before the interpretation stage. 
5. Interpreting Ideas is usually completed in a facilitated group meeting between the 
analyst and the participants of the concept mapping process, or a sub-group of the participants 
(Kane & Trochim, 2007). In this meeting the analyst presents the maps, discusses the clusters 
and their labels, and goes over the “go-zone map” which is a bi-variate plot of the rating data.  
Phase one participants completed the interpretation stage. The participants were divided 
into two groups with special attention to having policy, research, innovator and industry 
perspectives represented within each group. I worked with a trained facilitator (MK) in concept 
mapping to lead each group through questions about: the number of clusters; the labels of the 
clusters; whether statements were classified properly in go-zones; whether there was overlap 
between statements; and the relationships between the clusters. Clusters were divided between 
the groups.   
4.2.9. Utilizing Ideas 
In this stage where participants put forward ways to use the concept mapping data. 
Common uses of the data are to organize action or program planning, to complete a needs 
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assessment, to organize report writing, or to organize data synthesis and presentation (Kane & 
Trochim, 2007).  
Phase one participants completed the utilization phase using a case example technology 
to ground the discussion (see Appendix K). This process was designed to simulate how these 
statements could be actioned to enhance innovation and adoption of health technologies for older 
adults. Each group was asked to: consider how the statements in the go-zone apply to this 
technology, and to create an actionable objective to promote this technology’s uptake into the 
health care system. Participants were also asked to consider what information is missing from 
this case to be able to act on having it adopted. 
4.3 Ethics 
Ethics approval for the multi-stakeholder concept mapping process was obtained through 
the University of Waterloo Research Ethics Committee (ORE #30529).  
4.4 Results 
4.4.1 Participant information 
For phase one, ten of the 16 invitees participated in sorting, rating and interpretation via 
the workshop. Five policymakers, two innovators, two industry representatives and one 
researcher participated.  
Of the 46 interviewees, two people could not be invited to phase two. One person had 
retired from their role and another person was on an extended leave from their position. Twelve 
of 44 invited people participated in the second phase of concept mapping. Three other 
interviewees created an account to participate in concept mapping but did not complete the 
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exercise. There was very little drop off between sorting and rating exercises. Of the 22 people 
who completed the sorting exercise, 21 participants rated the statements on their relevance, while 
20 users rated the statements on their feasibility.  
4.4.2. Sorting 
Using Concept Systems software, multidimensional scaling is applied to the similarity 
matrix (which identifies how each participant sorted each pair of points), to generate the point 
map, where each of the 95 dots represents one statement from the sort. Statements which appear 
closer together on the map indicate ideas which are similar to each other (Kane & Trochim, 
2007). Hierarchical cluster analysis then grouped the statements in the point map into clusters 
using Ward’s algorithm to create an aggregate of ‘non-overlapping partitions in the data’ (Kane 
& Trochim, 2007).  
The stress value for this analysis is 0.288 after 19 iterations, indicating a good fit between 
the map and data. The stress value falls within the common range (.205-.365) for 95% of concept 
mapping projects (Kane & Trochim, 2007). Stress values are unpredictable below fifteen sorters 
and show diminishing returns for higher than 40 sorters (Rosas & Kane, 2012). Twenty-two sorts 
in this project are adequate for a consistent fit between the data and the point map (Rosas & 
Kane, 2012).  
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Figure 8: Point map 
Participants sorted the 95 statements using between 4 and 14 clusters. For phase one, the 
group decided on a nine-cluster solution during the workshop. After adding phase two 
participants’ data, the Concept Systems software was used to explore an appropriate number of 
clusters for this research. Working with a committee member and another researcher, we used 
the Concept Systems software ® to generate a point replay map for the range of clusters (4-14). 
A seven-cluster concept map was chosen as the best reflection of participants sorting choices.  
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tives 
Figure 9: 7 Cluster Concept Map 
Statements with the lowest bridging values indicate statements which are more of an 
anchor on the point map, meaning many participants sorted that statement with those nearby it, 
and making it representative of the content around that place in the map (Kane & Trochim, 
2007). Low bridging values help to indicate the essence of the cluster and can help with choosing 
a label for the cluster. The software generates ten options for cluster names based on 
participants’ sort data. Using Concept Systems ® software, I created a point bridging map (see 
figure 10) which I cross-referenced with the seven-cluster concept map to give a representative 
name to each of the seven clusters. I was also able to order the statements in each cluster 
according to their bridging value. Table 3 lists the cluster number, and the statement with the 
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lowest bridging value and the final cluster name chosen. By looking at the lowest bridging value 
in each cluster, I was able to see the point, which anchored the cluster. A committee member and 
another researcher reviewed the cluster names.  
Figure 10: Point Bridging map  
Table 3: Bridging Values 
Cluster 
# 
Statement 
# 
Statement with lowest bridging 
value 
Bridging 
Value 
Cluster Name Average 
bridging 
value 
for 
Cluster 
1. 55 More authority for local health 
care agencies to fund 
technologies 0.21 
Legislative & 
regulatory 
0.51 
2. 21 Providing additional 
local/national seed funding or 
venture capital opportunities to 
spur innovation activities and 
0.06 Funding & 
incentives 
0.12 
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decrease dependence on foreign 
investment 
3. 62 Decision timelines around 
adoption are articulated between 
innovators and healthcare system 
payers 
0.28 Processes & 
pathways 
0.36 
4. 13 Define clear pathways that lead 
from real world trials to adoption 
at the start of adoption 
consideration and deliberation 
0.39 System capacity 0.52 
5. 15 
43 
Implementing user experience 
analysis and user acceptance 
testing during evaluation 
Formalizing methods for patient 
involvement in health technology 
assessment 
0.26 
0.26 
Evaluation 0.29 
6. 68 Promote the development of 
innovation ecosystems (which 
can combine resources between 
partners, and link different 
regional partners) 
0.29 Patient & end-
user 
involvement 
0.25 
7. 29 
61 
Innovators/technology 
developers need to better 
understand the practical aspects 
of health delivery (e.g., resulting 
in more relevant technology) 
Encourage innovators to think 
ahead to implementation (where 
will their technology fit and who 
will pay for it) 
0.19 
0.19 
Communication 
channels 
0.50 
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Cluster legend 
Layer Value 
1 0.12 to 0.20 
2 0.20to0.28 
3 0.28 to 0.36 
4 0.36 to 0.44 
5 0.44 to 0. S2 
Figure 11: Cluster Bridging Map 
As seen in figure eleven, clusters one, four, and seven have five layers, and the highest 
bridging values, indicating that they contained points which were sorted in different ways by 
stakeholders. These clusters contained more bridging points, which interacted across the data as 
opposed to anchoring points, which were commonly sorted in the same cluster. Cluster four has 
four layers and Cluster six has two layers indicating some similarity in how participants sorted 
that data. Cluster two has only one layer, demonstrating that the points in that cluster were often 
sorted together.  
Cluster one is titled “legislative and regulatory” and includes fourteen statements about 
macro-level policy actions. This cluster averaged a .51 bridging value, one of the highest of the 
seven clusters, meaning these statements were not always sorted similarly by participants. 
Statements covered a national policy to address costs of telecommunication when used for health 
applications, national level policy alignment between health and innovation portfolios, and better 
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understanding of how international trade agreements impact health innovation and adoption for 
older adults. This cluster is also where statements about health information privacy issues, 
intellectual property agreements and open data policies for health outcome information, were 
located. Statements about value-based procurement fell into this cluster including how to support 
innovative, value-based procurement and how to make these processes accessible to new 
innovators.  
Cluster two is labelled "funding and incentives" and includes 19 statements about 
resource allocation in the health technology innovation arena. Cluster two has an average 
bridging value of 0.12, the lowest of clusters, indicating these statements were very often sorted 
together by participants. This cluster included statements about reforms in health care budgeting 
to: standardize resource allocation; allow for easy transfer of funds across years and across health 
care settings; and focus on patient outcomes. Statements in this cluster also identified specific 
times during the innovation trajectory where resources could be helpful: as venture capital, in 
development, to scale up good ideas, and to off-set the costs associated with value-based 
procurement in health care. Statements in this cluster also mentioned enhancing existing 
innovation-related tax-credits, and creating new innovation-related tax credits. Other statements 
covered how to create incentives to encourage health care providers to participate in innovation, 
including trialing promising technologies. 
Cluster three is labelled "processes and pathways" and includes seven statements about 
pathways to health technology adoption. The average bridging value for this cluster was 0.36 
indicating participants sorted these statements somewhat similarly. Statements included 
comments about the value of communication between stakeholders so that innovation failures are 
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not repeated, so that both parties understand decision timelines, and to ensure both parties 
understand willingness to pay for a technology. This cluster included comments to ensure 
versatile technologies are developed which can be scaled across countries - even those that have 
different levels of publicly funded health care. 
Cluster four is titled "system capacity" and includes eight statements about ways to 
increase health system capacity to support innovation. This cluster had the highest average 
bridging value of all the clusters at 0.52, indicating that participants did not often sort these 
statements together. Increased capacity to recruit patients, co-design technologies, test 
technologies, and implement affordable technologies were topics covered by statements in this 
cluster. Specific strategies such as those which encourage usability and human factors analysis as 
well as those which help consider budget impacts of new technologies and how to dis-invest 
from technologies were included in the statements in this cluster.  
The fifth cluster is labelled evaluation and contains fifteen statements about how 
technologies are evaluated. The average bridging value of these statements was 0.29 indicating 
participants sorted these statements somewhat similarly. Statements in this cluster note that 
technologies should be evidence-based and offer many components of evidence that a health 
technology assessment should consider (outcomes, feasibility, cost-effectiveness, budget and 
care pathway impacts). The statements in this cluster focus on integrating many perspectives into 
health technology assessments, and envision innovators who know what data they need to 
produce to participate in HTA, as well as open access to HTA reports completed in other 
jurisdictions. These statements also list ways to evaluate the opportunity cost of path dependency 
and societal impacts of health technologies. 
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The sixth cluster is titled patient and end-user engagement and contains thirteen 
statements, with a bridging value of 0.25 indicating somewhat similar sorting by participants. 
These statements address the need to have patients define problems which health technologies 
should address, and to involve patients and caregivers across all stages of innovation, including 
policy changes. A few statements in this cluster addressed the need for developing relevant 
technologies that meet health system needs and integrate with existing processes which are 
usable by health care providers - presumably because involving end-users will ensure these 
statements are addressed. This is also the cluster where some comments about older adults 
appeared, touching on the need to bust myths that older adults do not use technology but there is 
still a need to create technologies which are simple and easy to use.  
The seventh cluster in the concept map is titled communication channels and contains 20 
statements discussing ways for partners to work together. This cluster had a high bridging value 
of 0.50 indicating participants did not commonly sort these statements together. The statements 
in this cluster acknowledge transdisciplinary working, promoting innovation ecosystems and 
developing risk-sharing agreements as ways to promote communication. This communication 
channels cluster spoke about bringing together siloed departments at macro and meso levels of 
the health care system, as well as acknowledging that arms-length agencies can act as a hub for 
stakeholders from different sectors.  
4.4.3. Rating 
Relevance 
Twenty-one of the 22 participants rated the 95 points on their relevance to the focus 
prompt. Using Concept Systems Software ®, I created a cluster rating map (See Figure 12) 
which shows on average how relevant the stakeholders perceived the statements to be. The 
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Cluster Legend 
Layer Value 
1 3.84 to 3.91 
2 3.91 to 3.97 
3 3. 97 to 4.04 
4 4.04 to 4.11 
5 4.11 to 4.17 
legislative and regulatory cluster and the patient and end-user engagement cluster are each five 
layers thick, demonstrating high relevance ratings for the statements they contain (4.15/5; and 
4.17/5). System capacity (4.07/5); evaluation (4.06/5); and processes & pathways (4.02/5) were 
the next most relevant clusters. Funding & incentives (3.97/5) and communication channels 
(3.84/5) were the clusters with the lowest average rating of relevance.  
Figure 12: Cluster Rating Map- relevance 
Feasibility 
Twenty out of 22 participants completed the feasibility rating of the 95 statements. Figure 
13 displays the cluster rating map for feasibility, where patient and end-user engagement cluster 
has the most layers (4.46/5) indicating participants perceived these options as (on average) very 
feasible. The evaluation cluster had the next highest feasibility rating (4.18/5), followed closely 
by the communication channels cluster (4.12/5) and system capacity (4.04/5). The funding and 
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Cluster Legend 
Layer Value 
1 3.62 to 3.79 
2 3.79to3.96 
3 3.96 to 4.12 
4 4.12 to 4.29 
5 4.29 to 4.46 
incentives cluster (3.7/5) and the legislative and regulatory cluster (3.62/5) contained statements 
that were perceived to be not very feasible to implement. 
Figure 13: Cluster rating map- feasibility  
4.4.4 Pattern matching 
The pattern-matching graphic is a ladder graph designed to show correlations between 
ratings. This graph (Figure 14) reveals disparities among average cluster ratings in terms of 
relevance and feasibility. The range of scores for relevance was 3.84-4.17 and the range of scores 
for feasibility was between 3.62-4.46. The patient and end-user involvement cluster was rated by 
participants as the most relevant group of statements as well as the easiest group to implement. 
The legislative and regulatory cluster was just behind patient and end-user involvement cluster in 
terms of its relevance to the focus prompt but was rated as the most difficult group of statements 
to implement. The communication channels cluster was rated on average as the least relevant, 
but the third most feasible to implement.  
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Figure 14: Pattern match graph: relevance x feasibility 
4.4.5. Go Zones 
To go further in depth about which statements were rated the most feasible and the most 
relevant, a “go-zone” was created (Figure 15). This type of concept map uses a bivariate graph to 
place statements with higher than average rating scores on both relevance and feasibility into the 
top right quadrant. Statements with scores above average in terms of relevance but below 
average in feasibility appear in the bottom right quadrant. Statements with below average scores 
in relevance but above average scores in feasibility are in the top left corner and statements rated 
below average in both relevance and feasibility.  
Twenty-seven of 95 statements were rated higher than average in terms of relevance and 
feasibility. Six of the 27 go-zone statements came from the evaluation cluster, five statements 
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came from the funding and incentives cluster. Patient and end-user engagement and system 
capacity each had four statements in the go-zone, while three statements came from the 
processes and pathways cluster.  
Legislative and regulatory points in the go zone reflected the need for procurement 
policies that were accessible to smaller companies (65), and a better understanding about how 
international trade agreements can disadvantage local companies (38). Stakeholders also saw 
strategizing about privacy issues working with health information (64) as a relevant and feasible 
policy option.  
In the funding and incentives cluster, stakeholders felt that allocating funds to trial 
technologies in healthcare settings (67) as a relevant, feasible policy option. Policy option 
fourteen was rated highly and suggested subsidies for technologies with a prevention or future 
cost-savings angle (14). Incentives for health care providers to participate in innovation (42) was 
seen as relevant and feasible, as was integrating health care budgets around patient outcomes 
(90) across a continuum of care as opposed to an episode of care (27). Combining government 
and private payer funding to increase technology accessibility was seen as above average in 
terms of relevance but was average in terms of its feasibility rating (34).  
The statements rated as highly relevant and feasible in the processes and pathways cluster 
were supporting innovator/health care operator partnerships (63), clear discussion about 
willingness to pay for a technology (72), and decision timelines (62). 
In the system capacity cluster, the highly relevant and feasible points were resources to 
support patient recruitment for co-creating technologies (35), and enabling the home care sector 
to be more self-sufficient in their funding, testing and implementing of new technologies (50). In 
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the evaluation cluster, it was seen as both relevant and feasible to implement open access to 
existing health technology evaluation reports (86). It was also seen as relevant and doable to 
increase innovators understanding of the data they require to participate in a health technology 
assessment (66). The communication channels cluster included highly relevant, feasibly rated 
statements which listed strategies to bring partners together such as innovation ecosystems (68), 
and trans-disciplinary working (78). Other go-zone points involving communication stressed the 
creation of opportunities to bolster partnerships (19) and to bring innovators, regulators and 
reimbursement representatives together early (26).  
The highly relevant and feasible points which came from the patient and end-user 
engagement cluster included having patients define problems for developers (81), increasing 
awareness of unmet system needs (20), and the possibility of tech adoption beyond acute care 
(40).  
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Figure 15: Go Zone Map- All Statements 
4.4.6 Interpreting ideas 
We conducted an interpretation stage is to discuss the ideas from the concept mapping 
exercise with a sub-group of the participants. Ten people participated in a half-day workshop in 
Edmonton, AB on April 15th, 2019. The workshop took place from 1-4pm, just before the 
opening ceremonies of the Canadian Agency for Drugs and Technology in Health Symposium, 
which many of the participants were attending. 
Format 
The ten participants from phase one were divided into two groups. Group one contained 
one researcher, one innovator, two policymakers and one industry representative, group two 
contained one innovator, three policymakers, and an industry representative. Each group was 
assigned half of the cluster map. Every prompt question (the number of clusters; the labels of the 
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clusters; whether statements were classified properly in go-zones; whether there was overlap 
between statements; and the relationships between the clusters) appeared on a large sheet of chart 
paper, and participants had small post-it notes to post their ideas on the chart. After each 
participant had posted their ideas, they were invited to share them with the group. We concluded 
with a full-group discussion. 
Number of Clusters/Cluster labels 
When asked about the cluster number, the participants chose a nine-cluster solution. 
Participants were concerned with procurement policy issues and questioned why that topic was 
not apparent in the cluster labels. Concept Systems software named one of the clusters 
“contextual adaption” which participants’ felt was jargon, and suggested renaming that cluster 
“patient and user involvement”.  
Gaps in the data  
We also asked this group about gaps in the data, or ideas that could have come out better 
in the statements. Their comments reflected a desire to have the language of ‘technologies for 
health’ as opposed to ‘health technologies’ as a way to include technologies for health and 
wellness, not just those which are regulated by Health Canada. These participants felt that there 
was room for many technologies in the health and wellness space that could prevent health 
decline and promote better health for older adults. They also felt that these technologies could be 
impactful without the need to engage with regulation. Participants expressed that a broader 
perspective on ‘technologies for health’ could lead to development of technologies at more 
diverse price points, increasing accessibility.  
The group discussion brought up that the points are focused on funding and policy 
drivers. Another participant contextualized this statement, saying that we have many supply side 
initiatives which ‘push’ technologies along the innovation pathway and onto the health care 
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system. They added that what is lacking is on the demand-side, which they perceived to be the 
‘pull’ from the health care system. Another participant commented that the points focus on what 
innovators should do differently. They commented that innovators are not resistant to change, it 
is the system which resists change and needs to be nimbler and more adaptable to innovative 
ideas. 
Participants brought up the concept of feasibility, and how to decide what feasibility 
meant in terms of policy options. Some participants brought up that an option could be 
considered more feasible if it did not require a reallocation of resources or “new money”. 
Another participant brought up feasibility in terms of timelines, and questioned whether 
feasibility meant in three years, or five years or ten years. Another participant joked that 
feasibility was a function of how optimistic any person is.   
The go-zone that was created using phase one participants’ data appears in Appendix L. 
The group discussion added some context about certain points. Much of the discussion focused 
on patient and caregiver engagement. Phase one participants perceived that a gap in the 
statements was funding for compensating patient involvement, and they felt that patients should 
be part of policy meetings. Participants felt that family caregivers were not addressed in the 
statements. They commented that there are very few policy initiatives directed towards family 
caregivers who do a great deal of care work, which benefits health care systems and 
governments. Another participant brought up point 64 regarding health data privacy - they felt 
that ownership of health data was in transition and that standards were beginning to emerge to 
support sharing of health data.   
4.4.7. Utilizing ideas 
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Characteristic of the utilizing ideas stage, phase one participants were asked to apply the 
findings from the Go Zone. Given timing constraints, only phase one (10 of 22) participants were 
engaged in this stage. Participants were asked to consider the points in the Go Zone and how 
they would relate to a case example (see Appendix M) technology- an in home monitoring 
solutions compiling older adults’ temporal and spatial movements into data. They were asked to 
create at least one actionable objective to promote this technology’s uptake and they were asked 
what information was missing from this case for it to be considered for uptake. 
 Participants treated the statements in the go zone as advice to the case example 
innovators, and in many cases they qualified the points to make them more detailed. Regarding 
point 15, (“implementing user experience analysis and user acceptance testing during 
evaluation”) they felt that the innovators would need to distinguish between older adults and 
their caregivers, with both being users requiring consent to trial the technology. Regarding point 
80, they felt that innovators would need to explain to health care providers what the benefit of 
integrating this technology would be in order to gain their buy-in. Statement 81 states that 
patients should outline the problem for developers to solve. Participants’ felt that patients could 
be involved in designing the solution as well as the problem.  
The participants were quick to list missing metrics that, if collected, would increase the 
likelihood of this technology being adopted. They were interested in how this technology could 
affect the opportunity cost of falls prevention efforts, related costs of surgery, and quality of life. 
Other missing data included: the cost to implement this technology, the impact to workflows and 
models of care, and training related to the sensors. They also felt there was a role for older adults 
and caregivers to decide on or co-develop meaningful metrics to measure the impact of the case 
example home sensor system. 
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Through preparing, generating, structuring, representing, interpreting, and utilizing ideas 
that were generated through the literature, and in consultation with innovators, policy-makers, 
industry representatives and researchers, concept mapping has helped to organize stakeholder 
perspectives on the most relevant and feasible policy options for innovation and adoption of 
health technologies for older adults. 
4.5 Discussion 
4.5.1 Introduction and Overview 
This work responds to calls in the literature for a ‘whole systems’ approach to health 
innovation policy and provides an evidence-based list of policy options to support the innovation 
and adoption of health technologies for older adults. Multi-dimensional scaling and hierarchical 
cluster analysis of participants’ data create visual maps representative of participants’ thinking, 
and supports the complexity inherent in the health innovation policy arena (Trochim & Cabrera, 
2005).  
This work frames the discussion about how to move forward in health innovation policy 
by distinguishing between relevant and feasible policy options. Twenty-seven of the 95 
statements had above-average ratings in relevance and feasibility indicating a starting point for 
policy interventions to support the innovation and adoption of health technologies for older 
adults. Twenty-one statements were rated below average in both relevance and feasibility, which 
narrows the pool of policy options to consider. Twenty- two statements were rated above average 
in terms of relevance but were perceived by stakeholders as difficult to implement.  
The seven-cluster solution was chosen as the best representation of participants’ sort data, 
and the stress value indicated a good fit between the data and the point map. Twenty-two 
108 
participants are within Kane and Trochim’s recommended number of sorts to validate a concept 
mapping exercise (2007). Kane and Trochim indicate that the sorting stage of concept mapping 
requires the most time and the most expertise, and recommend supplementing recruitment for the 
rating phase if attrition occurs between stages (2007). In contrast, this project saw very little drop 
off between the sorting and rating stages from the twenty-two participants. 
Eight policymakers, eight industry representatives, four innovators, and two researchers 
completed the sorting exercise. One industry representative did not complete the rating exercise, 
meaning twenty-one participants completed the rating exercise. Thirty-two interviewees did not 
respond to a four-pronged email recruitment strategy requesting their participation in an online 
concept mapping exercise. Technology-enabled engagement may facilitate recruitment across 
large geographic areas, but email invitations to participate in research may get lost in busy 
participants’ email inboxes. Online engagement (completing the sorting exercise) allowed phase 
one participants to become familiar with material in the lead up to the in-person workshop. 
Rating took place during the in-person workshop. 
Although this research was designed to find the most relevant and feasible individual 
policy options, the clusters organize the options into understandable policy areas. Each cluster 
will be described and the points which appeared in the go zone will be discussed.  
4.5.2 Legislative & Regulatory Cluster 
The legislative and regulatory cluster had a high bridging value, indicating that these 
points were sorted differently by different participants and bridged across the data. On average, 
participants rated this cluster as more relevant than feasible. Three points from this cluster were 
seen as highly relevant and feasible: better understanding of how competitive bidding can 
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disadvantage local innovators (38); strategies which address privacy issues of health information 
(64); and that procurement processes do not create barriers for small innovation companies (65).  
Participants from the interpretation stage of this research suggested that privacy concerns 
are in transition, and that models were being developed to share protected health information, 
offering some explanation to why this point was seen as relevant and feasible.  
An intergovernmental initiative signals attention to the problems created by current 
health procurement models. The recently announced CAN Health Network is a $20 million 
investment between federal and provincial economic development agencies to support innovative 
procurement models in health care and help to ‘scale up’ Canadian health technology companies, 
making them more competitive with bigger international companies (Innovation, Science, and 
Economic Development Canada, 2019).  
4.5.3 Funding & Incentives  
This cluster had the most statements and was the most anchored, meaning that 
participants very often sorted the points in this cluster together. Participants rated this cluster on 
average as more relevant than feasible, and there were five points that appeared in the go zone. 
Resources to: support technologies which decrease health care costs (14), trial technologies in 
health care settings (67), and create incentives for health care providers to participate in 
innovation (42), were seen as relevant and feasible policy options in funding and incentives. 
Payment reforms to health care budgets such as integrating budgets around patient outcomes (90) 
and funding a continuum of care as opposed to an episode of care (27), may appear in the go 
zone as there are six Bundled Care pilot projects in Ontario to trial this type of funding reform 
(Ontario Ministry of Health, 2018). New tax credits to support innovation (53), and more 
110 
resources to support technology development (83), were seen as neither relevant nor feasible 
points. Discussion during the interpretation session suggested that a clearer definition of what 
feasibility means in terms of resource allocation, and a timeline, could have contributed to more 
precise findings.  
4.5.4 Processes & Pathways 
This was a small cluster with a high bridging value, indicating that these points were 
sorted differently by participants and bridged across the data. Three of the eight points in this 
cluster were in the Go Zone. These three points reflect clear communication about: timelines for 
deciding about whether to adopt a new technology or not (62), and willingness to pay (72). 
Support for collaborations between innovators and health care operators (63) was also rated as 
relevant and feasible. These points about better communication and support for collaboration are 
rather passive and do not imply a great deal of new resources, which could contribute to their 
perception as being easy to act on. Accessible, affordable technologies (2) was seen as relevant 
but not feasible, which may indicate that some participants view technology as costly by nature. 
These stakeholders perceive there is more work that could be done to make technology 
accessible in Canada.  
4.5.5 System Capacity 
Cluster four was another small, bridging cluster indicating these statements served to 
connect other aspects of the map. Three of the eight statements were rated higher than average in 
terms of relevance and feasibility: to define real-world trials which lead to adoption (13); to have 
resources which support patient recruitment for co-design (35); and to better enable the home 
care sector to do their own funding, testing and implementing of technology (50). These points 
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refer to more resources to better build health system capacity, so it is surprising they were sorted 
as separate from the funding and incentives cluster.  
Participants may feel that resources to support co-production of technology are relevant, 
and feasible as stakeholder engagement is becoming a normal part of the granting process 
(Oliver, Kothari & Mays, 2019). Oliver, Kothari & Mays (2019), point out the resource-intensive 
nature of the co-production of research has not fully been acknowledged despite widespread 
interest in co-producing research. 
More support for the home care sector to fund, test and implement technologies aligns 
with calls from Home Care Ontario to empower care providers in planning, implementation and 
evaluation of eHealth technologies (2018). In New Brunswick, the federal and provincial 
government has invested $75 million to support the Healthy Seniors Pilot Project; which 
includes a community information technology strategy (Public Health Agency of Canada, 2019; 
Province of New Brunswick, 2017). At the federal level, the Minister of Health has been 
mandated to encourage the adoption of digital health technology; and to develop performance 
indicators to improve accessibility to home and community care (Trudeau, 2017). The federal 
and provincial interest in having technologically enabled home care sector is clear, which could 
contribute to why participants felt this was a feasible and relevant policy option.  
Participants rating real world trials which lead to adoption as relevant and feasible may 
be in recognition of the trend towards access to evidence development as a tool to aid health 
technology decisions (Chafe, 2010; Carbonneil, 2009; Guerra-Júnior et al, 2017). 
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4.5.6. Evaluation 
The evaluation cluster contains fifteen statements which are fairly anchored on the map, 
meaning they were sorted fairly similarly by participants. On average, participants rated the 
points in this cluster as slightly more feasible than relevant (4.18/5 compared with 4.06/5). Five 
of the statements fell into the Go Zone indicating participants perceived them to be relevant and 
feasible. Participants felt that innovator understanding of what data they need to participate in 
health technology assessment (66), and assessment processes more generally (30), were 
considered relevant and feasible. Stakeholders’ felt that technology assessment incorporating 
many different evidence types was also relevant and feasible (88) and they felt user experience 
and user acceptance should be among those metrics (15).  
These findings may indicate that our participants perceive that innovator communities 
and assessment communities could work more closely to better understand each other’s 
requirements, which is a relatively low-cost endeavor.  
4.5.7. Patient & End-user Engagement  
The thirteen statements in the patient and end-user engagement cluster had a relatively 
low bridging value, indicating they were often sorted together by participants. Four statements 
were rated by participants as relevant and feasible: having patients define problems for 
developers (81), building awareness of unmet health system priorities (20), encouraging health 
technology innovators to think ahead to implementation (61), and increasing awareness of health 
technology implementation beyond acute care (40). These statements suggest patient 
engagement may not be enough when the health technology is embedded in a complex health 
care system with various actors beyond patients and caregivers. 
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These findings align with the move towards responsible innovation in health, which is 
defined by Silva, Lehoux, Miller & Denis (2018, p.5) as:  
“a collaborative endeavor wherein stakeholders are committed to clarify and meet a set of 
ethical, social and environmental principles, values and requirements when they design, 
finance, produce, distribute, use and discard sociotechnical solutions to address the needs 
and challenges of health systems in a sustainable way”. 
In this conception, any health technology operates in an environment among many 
individuals (investors, regulators, developers, users, policymakers and providers) and other 
technologies (Silva et al, 2018). Silos between health and innovation policy could be bridged; 
health care settings could be more integrated; innovators would be aware of health system 
problems as well as how their technology would fit in this environment; and technologies could 
consider health equity implications as well as minimize environmental impact (Silva et al.,2018) 
4.5.8 Communication Channels 
The communication channels cluster contained 20 statements that were sorted somewhat 
similarly by participants. On average, participants saw this cluster as less relevant than feasible, 
but it still contained five statements in the go zone. These statements centered around developing 
innovation ecosystems and sharing resources between different ecosystem partners (68). 
Transdisciplinary working within ecosystems (78) and creation of other strategies to promote 
communication and information sharing (19) were also seen as relevant and feasible actions by 
this stakeholder group. Channels to connect innovators with regulators and reimbursement 
representatives (26) and materials that would support innovators who are pursuing traditional 
procurement methods (28) were also seen as relevant and feasible by participants. 
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4.5.9. Pattern Matching 
The pattern-matching graph illustrates how participants’ viewed the feasibility of 
different clusters of policy options. Patient and end-user involvement was viewed as the most 
relevant and the most feasible place to start any policy intervention. This aligns with previous 
work on engaging older adults in regional innovation ecosystems (McNeil, 2018). Ensuring 
technologies respond to health system needs; allowing patients to define problems, conceptualize 
solutions, co-developing meaningful metrics to demonstrate value, and have patients attend 
policy meetings were some of the ways our stakeholders felt engagement could be undertaken. 
Our phase one participants pointed out that family caregivers’ contributions to older adults’ 
health, and special policies supporting family caregivers’ technology use may be missing from 
these policy statements. Adler & Mehta have pointed out that caregivers’ and patients’ needs for 
technology differ, for example, caregivers might prioritize safety, while older adults prioritize 
autonomy (2010). This can lead to different ways of engaging with technology, which may 
require separate engagement from patients. Resources are required to support relationship 
building needed for meaningful participation of patients and caregivers in technology 
development, assessment and implementation initiatives. 
Policy scholars may provide some insight as to why the legislative and regulatory 
category was ranked second highest in relevance but last in terms of feasibility. Large social 
programs such as Medicare create “lock in effects” which recreate institutional logics in a path 
dependent way which is only responsive to an external shock (Pierson, 2000; Béland, 2016). 
Shared jurisdiction between federal and provincial governments in health care is compounded by 
silos between health policy and innovation policy efforts at both the federal and provincial levels 
(Lehoux, Miller, Daudelin, & Denis, 2018). Stakeholders in this concept mapping exercise may 
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take these arrangements and silos as static. Programs such as the CAN Health Network can 
organize federal-provincial stakeholders to make procurement more innovative and accessible to 
Canadian health technology companies.  
Evaluation was seen as an area that was as relevant as it is feasible; much of the feasible, 
relevant points addressed increasing knowledge among innovators about how health technology 
assessment works, and how to create data which will allow for a health technology assessment to 
be completed. In the interpretation session, participants noted that it is important to consider all 
health and wellness technologies and the role that both regulated and non-regulated health 
technologies can play in helping older adults live independently in their homes. They felt that 
metrics which demonstrate cost savings across different departments (emergency, surgery, 
mental health) would make it easier for policy makers to decide to implement them.   
4.6 Strengths and Limitations 
4.6.1. Limitations 
Although this work recruited an appropriate number of stakeholders according to concept 
mapping recommendations (Kane & Trochim, 2007), only twelve of 44 people from the 
interview stage were recruited to participate in online concept mapping. This led to the 
underrepresentation of innovators (4/22) and researchers (2/22) as compared with industry (8/22) 
and policy-maker (8/22) stakeholders. These categorizations may not reflect the dynamic roles of 
participants who may conduct research in a policy role, or those who are academic-innovators.  
Despite the four-pronged approach to phase two recruitment (Dillman, 2000), e-mail 
bounce-backs during the recruitment period (June-August) indicated that some participants were 
on holiday. Software problems were an issue for other participants. One participant reported that 
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they could not participate, as the Concept Systems ® software does not currently function on cell 
phones or tablets. Another participant reported that the font size of the statements in the software 
was challenging to read. Another participant found it time consuming to have to rate each of the 
95 policy options individually (in two separate pages) on relevance and feasibility, and suggested 
having both rankings available simultaneously in the same screen. 
Older adults and caregivers are notably absent from this concept mapping process. Other 
research has used card-sorting with success as an alternative to computer-based concept mapping 
with older adults (McNeil, 2018; Wilberforce et al, 2018). Behrens et al. (2019) successfully 
used computer-based concept-mapping with a small group of community-dwelling older adults 
and caregivers (n=3). Additional resources would be required to adequately support the 
recruitment and whole participation of older adults and caregivers in computer-based concept-
mapping of a policy project. Older adults and caregivers were consulted on the results of this 
concept mapping exercise, and this is reported in a subsequent chapter.  
Ninety-five statements in this concept mapping exercise were near the recommended 
maximum of 100 (Kane & Trochim). The time commitment of the entire exercise was 45 
minutes. While the statements reflect the diversity of policy approaches that can be taken to 
enhance the innovation and adoption of health technologies for older adults, it may have been 
burdensome for some participants. This may explain the three participants who created an 
account in the software, but did not complete the sorting or rating.  
4.6.2. Strengths 
Ideally, the interpretation and utilization stages of concept mapping would be completed 
at the end of data collection. The mix of in-person and online participation was a strength of this 
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research and the Concept Systems ® software allowed for almost real-time analysis of rating 
data, which phase one participants completed during the workshop. Concept mapping is 
‘inherently a systems methodology’, which allowed for the collection and organization of 
stakeholder perspectives on an evidence-based list of policy options. The software houses this 
project and can be repeated on up to 100 participants. Future work could include the use of 
Concept Systems ® software as a decision-support for policymakers if a policy intervention to 
support health technology innovation and adoption became a priority.  
4.7 Conclusion 
Twenty-two stakeholders completed a concept mapping exercise to sort and rate 
evidence-based policy options and to show which of 95 statements rated highest in terms of 
relevance and feasibility. This works frames any discussion about where to start in terms of a 
policy intervention in health innovation technology: better engagement of patients, caregivers 
and end-users of technology. This work has also outlined areas where change may be more 
difficult or require more collaboration from diverse stakeholders, such as making legislative or 
regulatory changes. 
118 
CHAPTER FIVE: Discussing Health Technology Policy Questions with Older Adults and 
Caregivers 
5.1 Introduction 
Collaborative research is an umbrella term for a variety of research practices including 
co-production, co-design, co-creation, stakeholder and public engagement, 
participation/involvement and integrated knowledge translation (Fransman, 2018). Collaborative 
research has moved into the mainstream as government funding agencies mandate engagement 
and or integrated knowledge translation in grant proposals (Oliver, Kothari, Mays, 2019). As an 
extension of the goals of Chapter 6, (to collect stakeholder perspectives about the relevant and 
feasible policy options to support health technology innovation and adoption), this research seeks 
the perspectives of older adults and caregivers on key policy issues relevant to health technology 
innovation and adoption for older adults. 
5.2 Methods 
Older adults were engaged using focus group methodology to gather their perspectives 
about key issues in health technology and innovation policy (Patton, 2002). Thematic analysis 
(Braun & Clarke, 2006) was used to recode Chapters 4 and 5 to discern key themes. Some of the 
key themes included: timing of engagement of end-users of technology; role of end-users in 
evaluation of technologies; value-based as opposed to cost-focused principles in acquiring new 
technology; deploying technology in different settings; who should pay for health technologies; 
data ownership in health technologies; how could ineffective technologies be de-funded; 
ensuring relevant technology gets developed.  
119 
 Next, the key themes were re-worded to create discussion questions. This coding process 
generated thirteen discussion questions. The case example (used in the interpretation and 
utilization stages of Chapter 6- see Appendix #) was chosen to frame the discussion with older 
adults and caregivers, as a way to make health technology policy and regulatory issues less 
abstract. The case example discusses a home monitoring technology that creates data about older 
adults by tracking their temporal and spatial movements which can be used for a variety of 
purposes. A committee member and another researcher reviewed the questions.  
Focus groups are seen as foundational research method in participatory research, acting 
as a bridging strategy between scientific research and local knowledge (Cornwall & Jewkes, 
1995). Focus groups are an important way to gather perspectives on a topic within a social 
context (Patton, 2002). Focus groups are characteristic of the experience-based co-design 
literature, which is a set of procedures used to engage patients in health service improvements 
(The Point of Care Foundation, 2019).  
The Seniors Helping As Research Partners (SHARP) group is composed of sixty older 
adults and caregivers who live in Kitchener, Waterloo and Guelph. The Geriatric Health Systems 
(GHS) Research Group partners with SHARP on health related research projects, community 
events, and to share information related to the health care system. In line with McNeil et al. 
(2016), this project was guided by the principle that the type of engagement should be defined by 
the older adults, and revisited throughout the project. 
I worked with a SHARP Network member who had expertise as a legislator, in business, 
in health care, and in community supports to design the materials and structure of the focus 
group session. I met Mr. C at a SHARP event at the assisted living facility where he lives, where 
he took interest in my technology policy work.  
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I reached out to Mr. C by email to ask if he would meet me to comment on the discussion 
questions and the structure of the event. I met Mr. C with the research coordinator for the 
SHARP group in his home. Mr. C has trouble seeing so the case example and the questions were 
printed in a large font for the meeting.  
Mr. C approved of the case example and said there was a similar technology being 
considered by his facility, which he felt would help participants visualize the case example. He 
suggested I read the case example out loud in case participants were slow to read or had trouble 
seeing.  He felt that slides, although not necessary, might be conducive to keeping participants on 
topic, or helping to redirect conversation towards the discussion questions I wanted to explore 
during the session. He felt that a focus group style session with ten or fewer older adults would 
be familiar and appropriate for SHARP members to participate in this research.  
Mr. C’s comments helped to eliminate some of the discussion questions, and to re-order 
the questions with the aim to generate discussion early in the session and ‘get people talking’. 
Some questions were removed after meeting with Mr. C, as he felt they were too complex. The 
removed questions covered what role older adults and caregivers could play in identifying 
processes or technologies to disinvest in; should university offices help to link academic 
innovators with older adults and caregivers; and how could older adults and caregivers help 
health care systems identify valuable technologies.  
Seven discussion questions were prioritized for the 60-minute focus group (See Appendix 
M). Mr. C suggested the term ‘solution’ to be used with ‘technology’ to be clear to participants 
in the recruitment email. He recommended avoiding the term ‘policy’ in the recruitment email to 
the SHARP group, as he felt it might be misleading to the group and suggest that the session was 
to solicit political views. Going back to the case example, we used the language 
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‘technology/solution to help older adults live independently in their homes’ in the recruitment 
email (See Appendix J).  
Fourteen older adults and caregivers were invited to the session. The session was audio-
recorded and transcribed verbatim. Two independent researchers used NVivo 12 (2019) to code 
the transcript using an emergent coding strategy (Patton, 2002). The two researchers met to 
discuss codes and group them into themes.   
5.3 Results 
Four older adults participated in the focus group session. Two of the older people lived in 
the assisted living facility where the session was held, and two lived in the community. Two of 
the four older people were caregivers for a parent or spouse. Two coders identified five themes, 
which emerged throughout the focus group: integration, reporting relationships, varied abilities, 
government as a hub, and cost vs. benefit. 
5.3.1 Integration: “For us to just buy a piece of equipment and put it in the house, we need… We 
need help to attach it to the right people.” 
The older adults felt that the benefit of the case example technology would be if it were 
integrated with the wider health care system, and could transfer the information it collects to 
health care providers in different settings. One participant noted: 
 “They should be very pleased to be able to get that kind of information back to the team” 
as a way to help a care team schedule and allocate care, for patients who have rapidly changing 
health states which require different amounts of support. Another participant noted this could be 
helpful to interface between family doctors and acute care, and noted different software would 
need to be able to communicate with each other.  
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Participants also felt that certain partnerships which stack the expertise of multiple 
different fields could increase the integration between a technology and the wider health care 
system. An older adult commented:  
“just the understanding that I, as an engineer have this piece of information, and that’s 
my specialty. Well, there’s so much more to that. I need to have all these people bring 
their specialty and their expertise and together we can create something”.  
Participants felt that current levels of health system integration could be supplemented by a 
home-monitoring system which was designed by multiple types of expertise and was 
interoperable across health care settings.  
5.3.2 Reporting relationships: “I’m not totally enthusiastic about the long-distance response 
systems” 
Focus group participants contrasted the home monitoring system of the case example 
with the call system which was in use at the facility where two of the participants lived. The call 
system was a button which was worn on the resident and pressed if they needed help, which 
would alert a staff member who could follow up in-person. One older person stressed the 
importance of this in-person follow up:  
“we’re losing this - in-home, simple, cozy - which I like because it’s very important 
when someone has a problem that someone is with them. It doesn’t matter to me 
whether that person has medical [experience] … it’s a matter of comfort, knowing that 
someone can come and stay with you”. 
Alternatively, another participant felt that a remote system could be helpful for people with 
diabetes, or high blood-pressure, in that it could report worrisome changes in real-time to health 
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care providers. The participants valued the preventive component of the case example 
technology, but recognized that: 
“health plans don’t pay for prevention”. The older adults were skeptical about who would 
receive the information generated by the case example technology and what they would 
do with it: “maybe the family doctor will get it or their office staff will get it. Will they 
respond? Nobody knows”. 
Ultimately, they felt that a monitoring system, even if it reported remotely, would be adequate if 
it enabled the person to live with dignity in their own homes as opposed to moving to an 
institutional setting.  
Older adults contrasted the differences between monitoring for acute conditions and 
preventive monitoring, and who should be responsible with acting on data generated by home 
monitoring systems in this theme. 
5.3.3. Varied Abilities: “we could go out and find you ten people at ten different levels of 
knowledge in terms of using the equipment” 
The participants acknowledged some assumptions about older people’s technology use 
are rooted in truth, and outlined vast differences in older adults’ interest in and capacity for 
technology use. They felt with time, education and awareness, ageist attitudes about older adults’ 
technology use would dissipate. 
The participants felt there were many different levels of ability and interest in technology 
among older adults, which can lead to stereotypes. The group covered a variety of reasons why 
there might be negative assumptions about older adults’ technology use. First, they admitted that: 
 “what we’re saying is that some of those negative assumptions are well-founded”.  
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This participant was a caregiver and said that her parents’ capacity for technology use is very 
limited at their current stage, even though they used computers earlier on in their lives. The 
caregivers in the group said that older adults’ reluctance to accept technology presented to them 
by their caregiver as encroaching on their independence:  
“I don’t need a babysitter, I don’t need that thing that you put around my neck”. 
Other participants agreed that there are some cases where technology should be “hands-off”, or 
very passive and in the background. The participants described other situations where an older 
adult was paranoid about the use of technology, or had a fear of being “connected” because of 
the risk of their information being hacked, but how that person still used a computer for their 
own record-keeping. 
The older adults suggested education and awareness of the diversity of older adults as the 
primary strategy to overcome ageist attitudes about older adults’ technology use:  
“it’s like any other group…I think if they’ve [got to] develop to the level of what the 
person needs”. 
One participant outlined her own technology use, as it differs from younger people:  
“and I think I do pretty well on a computer and on my tablet but I don’t carry them 
around with me. So, I don’t have that constant input that younger people have”. 
Participants went on to comment that for people with ageist attitudes currently, their attitudes 
will change quickly as technology savvy baby boomers age, and technology use becomes 
mainstream: 
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“it’s going to take care of itself, within a decade easily…I’m saying that you know, over 
time this will change quite quickly and dramatically”. 
5.3.4 Government as a hub: “they could be the focal point…. It would be part of the 
responsibility” 
This group felt that governments should be at the center of any health-oriented 
technology solution. They felt government actors could assist those who need support to access 
technology, share information about consumer technologies, which are working well, and hold 
access as part-owners of health information.  
Some of the participants felt that governments should be co-payers with older adults of a 
home monitoring system such as the case example. They saw a role for health insurance as well 
but were less certain about how something preventive in nature could be insured.  The 
participants felt that the ownership of the data generated by a technology should be offered as a 
feature they could pay extra for or choose to opt out of.  
Participants agreed that governments play a central role in identifying disadvantaged 
groups of people:  
“We have low income families, we have new immigrants - a number of layers of obstacles that 
people might not know about it. So, how can we level the playing field, even before the 
payment”. 
The focus group participants felt that by identifying disadvantaged groups, governments would 
have knowledge of and ability to help groups of people who may have difficulties accessing 
useful technology.  
126 
The group also discussed the role for governments in disseminating information about 
consumer technologies which are working well in the community. One of the caregivers 
described a technology she found online to organize and distribute medication to her mother, 
which was working well. She went on to mention three different types of health care providers 
who had been in her mother’s home inquiring about the technology – they had commented that 
they did not know it existed. Another participant commented this was shameful that information 
was not better shared inside health regions about things which are working well for patients.  
Focus group participants felt that governments should be a hub of information about 
technologies and a source of funding to level the playing field for disadvantaged groups, 
including enabling their access to technologies. 
5.3.5 Cost vs. Benefit: “that’s a hard formula, right?” 
The participants spoke about the benefits of a monitoring technology such as the case 
example, as well as the costs, and the affordability of technologies. They spoke about the cost of 
the system to be implemented in the facility, and they anticipated that the cost would be 
prohibitive for some residents who might need it:  
“it’s going to be $80 for installation, 50 bucks a month for monitoring. So, there’s going 
to be… a big decision on part of individuals. Do they want to get it or not, and I suspect 
that some of them will skip it because of the cost, when they could use it”.
 One participant added that for the amount of money that the system was going to cost 
individuals they could afford to hire more staff, which would be preferable to them than a remote 
monitoring technology. The participants noted the system they were implementing would 
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implicate local emergency services to respond to an event such as a fall; they said the emergency 
services were already over-extended and importing services from other health regions to keep up 
with demand.  
They also pointed out that any new technology has a cost to install and a cost for upkeep; 
they also noted that the updates continue. They wondered if accessing updates for the technology 
would include ongoing costs. Participants also noted how costs can be challenging to measure. A 
participant noted the challenges associated with finding the right formula to measure all the ways 
a technology such as the case example could save the health care system money:  
“if you can do that benefit analysis where, if you’re monitoring people that you’re 
avoiding those emergency calls, and in an expensive long-term care home where the 
government has to pay anyways… but then that’s a hard formula, right? Have to figure 
out what the benefit is, the value is down the road, how much it might reduce the 
number of beds needed” 
The cost implications of the case example were especially relevant for the group, since 
they were facing a similar decision about a technology in the facility where two of the 
participants lived. They outlined the installation costs as well as the ongoing costs of technology 
implementation, and the challenges associated with measuring the benefits to the health care 
system as well as the costs. They also noted the strain that monitoring systems can put on local 
EMS services.  
5.4 Discussion 
A small focus group interview was conducted to discuss key issues in health technology 
innovation and adoption with older adults and caregivers. Aligned with efforts to engage older 
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adults and caregivers (McNeil et al., 2016) and principles of partnership readiness for 
community-based research (Andrews et al., 2012), I worked with an older adult to design the 
recruitment materials, questions and the format of the session.  
5.4.1. Recruitment 
Working with an older adult familiar with the SHARP group and some of the policy 
issues relevant to health technology innovation and adoption helped me to design appropriate 
recruitment materials. Focus groups are familiar to the SHARP group and are seen as desirable 
for that reason. More detail in recruitment materials may be required if a new or unfamiliar 
methodology or form of engagement is to be used with a community group. Given that this focus 
group was conducted within two weeks of a federal election, I was advised not to have the word 
‘policy’ play too prominently in the marketing for the session. This may speak to perceptions 
about policy and politics which are important to distinguish in advance of a community research 
endeavor.  
Questions about disinvestment, value-based procurement and the role of technology 
transfer offices were removed from the question list as they were deemed too complex. These 
topics may require more background information in order for participants to engage 
meaningfully with them. There have been efforts to involve citizens in specific disinvestment 
deliberations using illustrative case studies, which could inform future work on older adult and 
caregiver perspectives about disinvestment decisions (Watt et al, 2012).  
Nevertheless, one of the key themes of the session was the tension between costs and 
benefits of a home monitoring technology. The discussion covered the value of a home 
monitoring technology which could save the health care system money in the long-term or by 
preventing undesirable outcomes.  
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Older adults pointed out the contrast between a piece of equipment in a home and one 
which is connected to the right people inside the health care system. They perceived the latter as 
more valuable, and felt that health care providers’ decisions about care allocations could be 
simplified with continuous, real-time information about patients with rapidly-changing health 
care states such as diabetes or hypertension. They envisioned an interoperable technology as a 
way to enable communication between different health care settings. This finding aligns with the 
mandate of Canada Health InfoWay to improve access for Canadians to digital health and 
‘interoperable health solutions’ which connect patients to their health information across care 
providers (Canada Health InfoWay, 2019).  
Participants idealized that a technology could surmount issues of health system 
integration but brought up a tension between the information created by a technology and the 
responsibility that information creates for action. Participants were skeptical of what family 
doctors would do with information generated by the case example technology. They also felt that 
in emergency situations, such as a fall, an in-person response is preferable than a remote 
response via the telephone. They thought that ideally, a home monitoring technology would be 
able to have different reactions for an acute emergency as opposed to a long-term change in 
behavior indicative of a change in health status. 
Older adults identified issues of paranoia, declining health status, and desire for 
independence as mediators in older adults’ interest and capacity for use of technology. Care 
recipients can be reluctant to accept technologies proposed by caregivers if they are seen as 
encroaching on their independence, aligning with the findings of Mattison et al. about the stigma 
associated with needing an assistive technology (2019). They felt that technology should be 
designed to address all the different needs and levels of capability they described.  
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The focus group participants felt governments should be central in coordinating access to 
health technologies. They saw a role for government co-payment of health technologies, aligning 
with the finding that willingness to pay for technologies increases when governments are co-
payers (Schultz et al. 2015). Older adults and caregivers thought that governments were a natural 
intermediary between disadvantaged groups and technology access. Mattison et al, describe 
efforts to improve coordination between health and social sectors of service provision as a way 
to enhance access to assistive technologies in Canada (2019).     
The participants in this focus group were attuned to the difficulties in demonstrating 
value for a home monitoring system, which is aligned with CADTH’s inconclusive findings 
about the safety, efficacy and availability of home monitoring technologies in Canada (2019). 
Older adults and caregivers outlined a societal benefit which could be accrued if a home 
monitoring technology decreased the need for long-term care beds, which would benefit 
government. This broad set of societal benefits has been outlined as specifically challenging to 
measure (Menon, 2009).  
Older adults also allude to the tension between a technology they purchase individually in 
an assisted-living facility which decreases the need for staff, but increases the demands on local 
services. Questions of ethics and equity may arise, if private care homes download care 
responsibilities to opt-in technologies which implicate responses from local health care systems.  
5.5 Strengths and Limitations 
I worked with an older adult to design a focus group to discuss issues related to 
technology adoption for older adults. This work sits in a niche among work on patient 
engagement in health care (Andrews et al, 2012); McNeil et al, 2016), citizen engagement in 
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health policy (Abelson et al., 2013; Li et al., 2015; Menon & Stafinski, 2008) and end-user 
involvement in technology development (Viswanathan et al., 2017; MacGillivray et al., 2019). 
There are not best practices for engaging older adults and caregivers on policy research about 
health technology innovation and adoption.  
The strength of this work is having older adult and caregiver perspectives on policy 
issues presented along with those of industry, innovators, policymakers and researchers. Ideally, 
older adults and caregivers work with researchers to define the scope, research questions, 
methodology, and knowledge translation at the outset of a project (McNeil et.al, 2016). This 
research engaged older people and caregivers near the conclusion of the research project. This 
might be viewed as tokenistic, but it also gave prominence to the perspectives of older adults and 
caregivers. 
More resources would be required to recruit, prepare, and engage older adults and 
caregivers at the project’s outset than were available to this project. Game simulation is a 
resource-intense method to structure a deliberative session, which is seen as non-threatening, and 
can prompt deeper thinking about health policy issues (Li et al., 2015).  
The case example described a technology to support living independently in the home, as 
did the language used in the recruitment materials. Although this terminology was recommended 
by an older adult stakeholder, it may have limited the discussion to similar types of technologies 
which support older adults in their homes, as opposed to the full range of health technologies 
(devices, medications, processes, vaccines and systems).  
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5.6 Conclusion  
An older adult helped to design a focus group session to discuss key policy issues in 
health technology innovation and adoption for older adults. The discussion was anchored by a 
case example technology to which older adults and caregivers were able to relate well. Older 
adults and caregivers desired technologies which are integrated with health system actors, and 
see technology as a way to bridge silos between care settings for example, primary care and 
acute care. Participants brought up questions about who has the responsibility to respond to 
information generated by a home monitoring system, and how those responses should be 
conducted. They emphasized the heterogeneity of older adults and range of interest and capacity 
for technology use. Governments were seen as a hub to coordinate access to, and information 
about, technologies which could work well for older people and caregivers. Older adults and 
caregivers were attuned to the challenges of accounting for all the costs and benefits a home 
monitoring system could offer.  
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CHAPTER SIX: SUMMARY AND GENERAL DISCUSSION 
6.1 Thesis Summary 
This study sought to document and understand facilitators and barriers to health technology 
adoption in Canada across all stages of innovation; understand how these facilitators and barriers 
might impact technologies for older adults and caregivers, (such as those being developed inside 
the AGE-WELL research network); and to engage diverse stakeholders to create an evidence-
informed policy agenda for health technology innovation for older adults. To achieve these aims, 
a scoping review; 46 qualitative interviews; a group Concept Mapping exercise; and a focus 
group interview were conducted.  
The scoping review found that supporting health technology innovation requires attention 
across all phases of innovation: development, assessment and implementation. Silos between 
health and innovation policies impact how scarce resources are allocated, what partnerships get 
formed (and those that do not), what technologies get developed (Lehoux et al., 2014), how they 
are evaluated and which populations they target (Lehoux et al, 2000). Innovation ecosystems 
were proposed as a mechanism to engage stakeholders across silos in health and innovation 
policy (Etzkowitz & Leyesdorff, 2000). This review highlighted the value of evaluation across 
all stages of a health technology’s life cycle to increase health system sustainability (Scotland & 
Bryan, 2016; Bryan, Mitton & Donaldson, 2014). 
To provide illustrative examples of findings from the scoping review, a series of qualitative 
interviews were conducted with policymakers, innovators, industry representatives and 
researchers. Elements from the graphic depiction in the scoping review (development, 
assessment, implementation, partnerships, resources, Canadian policy context) guided data 
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analysis using Ritchie and Spencer’s Framework analysis method (2003) to identify multiple 
perspectives on facilitators and barriers across each stakeholder type.  
In line with Kingdon’s work (1984), this study highlighted a complex interplay between 
ideas, institutions and interests in health technology policy in Canada. Our findings highlighted 
challenges associated with innovating in a fragmented health care system. In such a system, 
health care actors lack capacity to consider, adopt and integrate technologies, even those with the 
potential to improve health outcomes for older adults. Again, partnerships were identified as a 
way to integrate promising innovations into Canadian health care systems. Mechanisms are 
required to support meaningful, sustained partnerships between patients and end-users, 
caregivers, health care providers, policy-makers, decision-makers, and industry representatives 
to ensure technologies meet health system needs. These are especially important when 
considering that technologies, unlike medications, implicate a whole host of actors: health 
technologies for older adults may be used, administered, prescribed, regulated, evaluated, 
purchased, invested in, and developed, all by different interests (Lehoux et al, 2012). 
Findings from the first two stages of this study reinforced the need for a ‘whole systems’ 
approach to health technology innovation (Greenhalgh et al., 2004). Stakeholder perspectives 
were gathered on which of the 95 policy options identified in earlier stages of the research were 
likely to be the most relevant and feasible policy options to enable the innovation and adoption 
of health technologies for older adults. Participants sorted options into clusters and rated policy 
options as part of a six stage Concept Mapping process. As part of the process, a workshop to 
discuss how to implement the most relevant and most feasible options was conducted.  
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 Stakeholders perceived policy options related to end-user and patient engagement to be 
both the most relevant and feasible options to support technology innovation for older adults. 
Legislative and regulatory policy options were deemed very relevant but less feasible to 
implement, reflecting the complex institutional arrangements and ‘lock-in’ effects of large social 
programs which only change incrementally (Pierson, 2000; Béland, 2016). These institutional 
arrangements include multiple decision nodes in health care, contributing to a complex 
disordered technology adoption process, which does not respond well to efforts to control it 
(Scott, 2015). The single highest rated policy option was: “encourage innovators to think ahead 
to implementation, where their technology will fit and who will pay”. This policy action 
statement can be considered advice to new innovators to consider the whole system which affects 
the adoption of the technology.  
 Orienting health technologies for older adults towards a consumer purchase ‘pathway’ may 
appear to be a solution to bypass the complexities of the Canadian health care system (AGE-
WELL, 2019). Alternatively, there may be problems of equity, access and waste if health 
technologies are oriented solely for consumer purchase (Lehoux et al, 2012, Lehoux 2014b). A 
move towards responsible innovation in health would suggest a move away from technologies 
for consumer purchase, and that a variety of factors be considered in the development of any new 
health technology: inclusivity; responsiveness to health system needs; ethical, social and legal 
issues; environmental value; and economic value or frugality (Silva et al., 2018). 
A focus group interview with older adults and caregivers was conducted to discuss key issues 
in health technology innovation and adoption. This interview generated findings in five themes: 
integration, reporting relationships, varied abilities, government as a hub, and cost vs. benefit. 
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Older adults and caregivers contrasted technologies operating independently from the health care 
system with those which are integrated, and preferred the latter. This group alluded to the 
challenges of consumer technologies which operate independently from the health care system, 
but implicate a system response, and which can strain emergency services. 
Although the older adults outlined challenges with demonstrating benefits of a technology 
which operates in a home and prevents (as opposed to treats) poor outcomes, they felt that the 
data generated would be very valuable to aid in care decisions. They felt that the data would be 
worth it to care providers to merit the investment by governments. Focus group participants felt 
that governments were a focal point in the relationship between older adults, caregivers, the 
health care system and technologies. They felt governments should play a role leveling the 
playing field for disadvantaged groups, coordinating access to health technologies, through the 
creation of cost-sharing programs, and spreading information and awareness about technologies 
which work well. 
6.2 Implications 
6.2.1 Federal Policy Implications 
Pan Canadian Health Organizations 
Health care and innovation were relatively absent from party platforms in the recent federal 
election. Under the previous federal government, three ministers were mandated to look 
individually at innovation, home care services, and access to digital health. It is not clear if new 
mandates for these ministers will prioritize these topics.  
Information from this study may be relevant to policy actions prioritized in light of the 
findings of the External Review of Federally Funded Pan-Canadian Health Organizations. This 
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report creates four scenarios for change in how the federal government funds agencies with 
mandates relevant to health technology innovation such as the Canadian Agency for Drugs and 
Technology in Health (CADTH), the Canadian Foundation for Healthcare Improvement (CFHI), 
Canada Health Infoway and the Canadian Institute for Health Information (CIHI). Scenario two 
identifies innovation as a catalyst for change in health care financing and delivery, which is 
aligned with calls in the scoping review for bundled payments, value-based procurement, and 
pay for performance schemes characteristic of the Triple Aim (Verma & Bhatia, 2016; Forest & 
Martin, 2018). Scenario three relies on fostering engagement across clinicians, researchers, 
provincial and territorial stakeholders, policy makers, and the public to create transformative 
health care change in Canada (Forest & Martin, 2018). The need for diverse partnerships and co-
designed strategies to health care service and delivery echo findings from this research. It may be 
of interest that a group of relevant stakeholders rated policy options promoting engagement of 
patients and end-users as both the most relevant and most feasible to implement of seven distinct 
policy clusters.  
Forest and Martin view the federal government as possessing the necessary legal and 
financial tools to play a central role in catalyzing innovation in health care (Forest & Martin, 
2018). Findings from this research support federal policy intervention to enable health 
technology innovation and adoption for older adults, but encourage the alignment of health 
innovation efforts with innovation policy efforts (MacNeil et al, 2019; Lehoux et al, 2017).  
This report encouraged governments to consider revising the basket of health care services 
that are publicly funded in Canada to include mental health and home care services (Forest & 
Martin, 2018). Findings from this research indicate challenges specific to innovation in the home 
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and community care sector, which should be considered if federal policy action in home and 
community care is prioritized.  
AGE-WELL Network Centre of Excellence  
This study is part of a project affiliated with AGE-WELL, a federally funded research 
network on technology and aging. Findings from this research are relevant to members of AGE-
WELL including innovators, researchers, industry representatives, policymakers, older adults, 
caregivers, and students. The findings of this study can be instructive for new grantees of the 
AGE-WELL network. This work has supported the creation of websites, process maps, or 
consultations for innovators, to help innovators navigate policies and regulations relevant to their 
technologies for older adults.   
There is an ongoing tension between what constitutes meaningful evidence for decision-
makers, and the resources (time and money) required to produce high-quality evaluations of 
promising health technologies. Our findings are supportive of ongoing partnerships between 
those with expertise in evaluation of technologies, and technology innovators, such as CADTH’s 
recent mandate to broaden its assessment capacities and re-evaluate technologies to ensure they 
are being used appropriately in a way that creates value for healthcare systems (CADTH, 2018).  
6.2.2. Provincial Policy Implications 
Stakeholders we interviewed mentioned investment programs such as Alberta Innovates, and 
technology incubators such as MaRS in Ontario, as exemplary in supporting health technology 
innovation in Canada. Both of these programs saw their funding frozen or withdrawn with recent 
government changes in these provinces (CBC, 2019). Findings from this study which were seen 
as highly feasible, may be of interest to governments who wish to support health technology 
innovation through smaller investments than tax credits.  
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6.2.3. International Policy Implications 
Health technology assessment international (HTAi) is the global scientific and 
professional society for users and producers of HTA. HTAi sponsors an interest group on patient 
engagement in HTA, which is focused on standardizing methodologies of involvement. Findings 
of this research related to measuring impact of technologies for older people may be of interest to 
this group. This study has informed recent collaborations in the HTA community among 
international policymakers, reflecting on special considerations for aging-related technologies 
and how to best incorporate older adults’ perspectives in HTA processes (Juzwishin et al., 2018). 
6.2.3. Targeted Areas for Next Steps 
The conceptual framework developed in Chapter Three will be used to structure policy 
recommendations for different institutional levels. At the interpersonal/intrapersonal level, these 
findings suggest that older adults and caregivers should define problems for technology 
developers to address. Resources are required to help recruit patients to co-design innovations, 
and sustain their involvement across the innovation pathway. Efforts to bring older people and 
caregivers into the co-design of innovation should acknowledge the varied abilities and levels of 
interest in using technology. Early and late adopters of technology exist among any age group 
(Rogers, 1995) and perhaps this continuum could be used to typify technology users in a way 
that acknowledges differences, but does not attribute differences among them solely to age.  
At the micro-level, where regional health organizations sit, this research supports the 
empowering of the home care sector to fund, test and implement new technologies. This may 
require dedicated resources so that home care agencies do not have to allocate funds designed for 
care delivery to technology activities. This may also necessitate new expertise or human 
resources designed to support these activities, as there may be a shortage of economic evaluation 
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expertise in evaluating integrated care interventions which span home and community care and 
acute care (Knai et a., 2013).  
This research supports regional collaboration of academic, industry, citizen, clinical, and 
government stakeholders. The innovation ecosystem model (Etzkowitz & Leyesdorff, 2000).  
was presented throughout the work as a mechanism to support collaboration, and noted a 
transdisciplinary working style is required to ensure stakeholders with different backgrounds and 
interests work productively with one another. Extending the model of innovation ecosystems 
means installing and sustaining mechanisms for resource-sharing, communication and 
information-sharing to build trust. In talking with older adults and caregivers, their perception of 
governments as a hub between health care, citizens and researchers was clear. Governments can 
play an important role in convening stakeholders, ensuring access to technology for 
underprivileged older people, and building awareness about technologies which are working well 
in community settings. 
Many of the policy recommendations are focused at the meso or provincial level which 
corresponds with provincial jurisdiction over health care delivery. This research supports 
changes to funding models so that health care budgets are integrated across years, departments 
and health care settings, such as those which fund a continuum of care as opposed to an episode 
of care. These funding changes would have impacts on how the health care system procures new 
technologies and would be responsive to technologies which offer benefits in terms of 
prevention, or decreased health care costs. Province-specific materials should be designed for 
innovators to aid them in participating in traditional models of procurement (competitive bidding 
models).  
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At the meso-level, resources are required to build the evidence base for new technologies 
such as: real world trials, trials which have health care provider participation, assessments of 
decision-makers’ willingness to pay for a new technology, and studies which capture user 
experience/user acceptance.        
The federal government plays an important role in raising awareness, and many of the 
policy recommendations to come out of this project have to do with building awareness among 
innovators. The federal government is in a unique position to demand that health technology 
innovations respond to demonstrated health system needs, given that their innovation program 
supports tens of millions of dollars in innovation granting programs. This includes building 
awareness among innovators of: health system priorities; how their technology fits with existing 
systems, workflows and scopes of practice; and what types of studies they need to conduct to 
ensure their technology can produce clinical and cost-effectiveness data for HTA.  At the macro-
level, the federal government can support programs which help to build expertise in health 
economics, which is in high demand (Kaambwa & Frew, 2013). This expertise can help to 
answer questions of willingness to pay, cost as opposed to value, and how to generate 
meaningful evidence for health technologies for older adults. New trainees in health economics 
can support innovators and health care systems from development through to sustainability and 
disinvestment of promising technology.  
6.3 Future Research Directions 
Future directions for this work include sharing results through traditional academic means 
including journal publications, conference posters and presentations. The older adults in the 
focus group interview were interested to see how the focus group information would be used in 
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this study. One of the first steps will be to re-engage this group to discern what format the 
follow-up should take. 
Many of the stakeholders who were engaged in the interview process expressed interest in 
being re-contacted with results of the study. Briefing notes will be created summarizing the 
results of the interview process to share with stakeholders. The findings of the Concept Mapping 
process are specifically relevant for policy stakeholders and briefing notes summarizing the 
policy options in the Go Zone will be created and shared with stakeholders.  
The findings of the Concept Mapping process will be shared through a workshop with policy 
actors within the AGE-WELL network who have a mandate to promote policy action in health 
technology innovation.  
6.4  Conclusions 
Jurisdictional issues lead to a complex network of institutions and stakeholders in the 
health technology and innovation policy arena in Canada. Policymakers, innovators, industry 
representatives, older adults and caregivers contributed to an understanding of policy and 
regulatory facilitators and barriers. Multiple stakeholders were engaged to rank policy options, 
forming the basis for an evidence-based health technology innovation policy agenda with special 
attention to health technologies for older adults.  
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APPENDICES 
APPENDIX A: SEARCH TERMS FOR SCOPING REVIEW 
Canad*[Title/Abstract] AND (technolog*[Title/Abstract] OR medical devic*[Title/Abstract]) 
AND (((governmen*[Title/Abstract] OR polic*[Title/Abstract] OR 
regulat*[Title/Abstract] OR approval process*[Title/Abstract] OR 
marketing[Title/Abstract] OR decision making[Title/Abstract] OR health technology 
assessment[Title/Abstract])) OR health technology assessment[MeSH Terms]) NOT 
(drug*[Title/Abstract] OR vaccin*[Title/Abstract] OR genetic*[Title/Abstract] OR 
pharmaceutical*[Title/Abstract]) AND (("2000/01/01"[PDat] : "2015/09/18"[PData])) 
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APPENDIX B: INFORMED CONSENT- INTERVIEWEES 
CONSENT FORM 
By signing this consent form, you are not waiving your legal rights or releasing the 
investigator(s) or involved institution(s) from their legal and professional responsibilities.  
I have read the information presented in the information letter about a study being conducted by 
Dr. Paul Stolee, Melissa Koch and Maggie MacNeil from the School of Public Health and Health 
Systems at the University of Waterloo. I have had the opportunity to ask any questions related to 
this study, to receive satisfactory answers to my questions, and any additional details I wanted. 
I am aware that I have the option of allowing my interview to be audio recorded to ensure an 
accurate recording of my responses. 
I am also aware that excerpts from the interview may be included in the thesis and/or 
publications to come from this research, with the understanding that the quotations will be 
anonymous.  
I was informed that I may withdraw my consent at any time without penalty by advising the 
researcher.   
This project has been reviewed by, and received ethics clearance through a University of 
Waterloo Research Ethics Committee.  I was informed that if I have any comments or concerns 
resulting from my participation in this study, I may contact the Director, Office of Research 
Ethics at 519-888-4567 ext. 36005.  
With full knowledge of all foregoing, I agree, of my own free will, to participate in this study. 
☐YES   ☐NO   
I agree to have my interview audio recorded. 
☐YES   ☐NO   
I agree to the use of anonymous quotations in any thesis or publication that comes of this 
research. 
☐YES   ☐NO 
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______________________________________________________________________________ 
______ 
_________________________________ 
Participant Name: ____________________________ (Please print)   
Participant Signature: ____________________________  
Only for consents obtained verbally: 
Participant Name: ____________________________ (Please print)   
Interviewer Name: ________________________________ (Please print) 
Interviewer Signature: ____________________________ Date: ___________________ 
When this study is completed, we will write a summary of the results. Would you be interested 
in receiving a copy? 
☐YES, please e-mail me a summary of the results. My e-mail address is:  
☐YES, please mail me a summary of the results. My mailing address is:  
☐NO, I do not wish to receive a summary of results 
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______________________________________________________________________ 
APPENDIX C: INFORMED CONSENT – OLDER ADULTS  
CONSENT FORM FOR FOCUS GROUP 
By signing this consent form, you are not waiving your legal rights or releasing the 
investigator(s) or involved institution(s) from their legal and professional responsibilities.  
I have read the information presented in the information letter about a focus group session being 
facilitated by Dr. Paul Stolee, Melissa Koch and Maggie MacNeil from the School of Public 
Health and Health Systems at the University of Waterloo. I have had the opportunity to ask any 
questions related to this focus group, to receive satisfactory answers to my questions, and any 
additional details I wanted.  
I am aware that the focus group session will be audio recorded to ensure an accurate recording of 
my responses.   
I am also aware that excerpts from the focus group may be included in the thesis and/or 
publications to come from this research, with the understanding that the quotations will be 
anonymous.  
I was informed that I may withdraw my consent at any time without penalty by advising the 
facilitator of this decision.   
This study has been reviewed and received ethics clearance through a University of Waterloo 
Research Ethics Committee (ORE# 30529). If you have questions for the Committee contact the 
Office of Research Ethics, at 1-519-888-4567 ext. 36005 or ore- ceo@uwaterloo.ca. 
With full knowledge of all foregoing, I agree, of my own free will, to participate in this session 
and to keep in confidence information that could identify specific participants and/or information 
they provided. 
YES   NO   
I agree to the use of anonymous quotations in any thesis or publication that comes of this 
research. 
YES   NO 
Participant Name: ____________________________ (Please print)   
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______________________________________________________________________________ 
______ 
_________________________________ 
_________________________________ 
Participant Signature: ____________________________  
Witness Name (1): ________________________________ (Please print) 
Witness Signature (1): ____________________________ Date: ___________________ 
Only for consents obtained verbally: 
Participant Name: ____________________________ (Please print)   
Witness Name (1): ________________________________ (Please print) 
Witness Signature (1): ____________________________ Date: ___________________ 
Witness Name (2): ________________________________ (Please print) 
Witness Signature (2): ____________________________ Date: ___________________ 
When this focus group session is completed, we will write an executive summary of the results. 
Would you be interested in receiving a copy? 
YES, please e-mail me a summary of the results. My e-mail address is:  
YES, please mail me a summary of the results. My mailing address is: 
NO, I do not wish to receive a summary of results 
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APPENDIX D: SEMI-STRUCTURED INTERVIEW GUIDE  
 PRI-TECH: Policy and Regulatory Issues in Enabling Technological Innovation  
Interview Guide Questions 
Date:  
1. Could you please describe your current role (in the federal/provincial/territorial ministry, 
department, or organization)? 
2. What technologies do you look at and how do you decide which ones to consider?  
3. What is your involvement in policy-making, planning or decision-making related to 
regulations and adoption of other health technologies? 
4. Can you walk us through the process, from submission to approval, and do you have any 
guidelines or frameworks that guide this?  
5. Do you have any policy, regulatory or reimbursement frameworks for technologies related to 
aging? 
6. How does the reimbursement and adoption process for aging-related technologies differ from 
other health technologies? 
7. In the medical device or health technology industry, what is working well in terms of: 
(Facilitators) 
a. Regulatory processes  
b. Approval/reimbursement? 
8. What could be improved? (Barriers)  
a. In the regulatory process? 
b. In the approval/ reimbursement process? 
9. Are you working on identifying potential policy or research priorities related to regulations, 
adoption and reimbursement in health technologies? 
10. Are there any documents or summarized reports that you would be able to share with us? 
11. Have you heard of _______ (AGE-WELL Technology)? What factors would influence the 
feasibility of this technology getting regulatory approval? 
a. What factors could influence its adoption for reimbursement by the province? 
12. Do you have any recommendations of other policy-makers, innovators, or industry 
representatives you think we should speak with? 
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APPENDIX E: FEEDBACK LETTER 
FEEDBACK LETTER (for Focus Groups) 
Seniors Helping as Research Partners (SHARP) Network 
Principal Investigator: Paul Stolee, PhD 
Co-investigators: Maggie MacNeil, Melissa Koch  
Thank you for your participation in our project! The results of the focus groups will be used to 
inform the PRI-TECH project. The PRI-TECH (Policy and Regulatory Issues in Enabling Health 
Technology), is a project funded by AGE-WELL which explores current policy, regulatory, and 
health system issues relevant to the evaluation, approval, regulation and reimbursement of 
technologies to support healthy aging. 
A. PURPOSE 
The aims of the focus groups were to understand older adults and caregivers perspectives on 
areas of potential policy change including: building supportive partnerships for health 
technologies for older adults; patient and user involvement in technologies for older adults; and 
education and awareness about technologies for older adults. 
B. SUMMARY OF FOCUS GROUP FINDINGS 
C. CONFIDENTIALITY AND DATA SECRUITY  
Your identity is considered completely confidential by the researchers. The results of the focus groups have 
been anonymized. Specific comments and statements are not directly identifiable in any reporting of the 
results. Your name and contact information will be remain confidential. Only the research team will have 
access to the data collected and all members of the research team have signed an agreement to maintain 
confidentiality. All paper documents are secured in a locked filing cabinet at all times and electronic files are 
maintained on a password-protected computer. All data will be retained for seven years; at this time, all 
electronic data files will be permanently deleted and any papers of the raw data will be destroyed. 
D. QUESTIONS  
If at any time you have questions about this research project, or wish to obtain a results summary of 
the findings, please contact the Principal Investigator:  
Paul Stolee, PhD, School of Public Health and Health Systems, University of Waterloo, Waterloo, Ontario, 
519-888-4567 ext.35879, stolee@uwaterloo.ca  
Should you have any questions or concerns arising from your participation in this study, please contact Dr. 
Susan Sykes, Director, Office of Research Ethics, University of Waterloo, at (519) 888-4567 ext.36005, 
ssykes@uwaterloo.ca. 
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APPENDIX F: INTERVIEW CODE BOOK 
Development: Research, device prototyping (include talk of finances for development, 
stakeholder engagement during development) 
The innovation process generally begins with research and development of an innovation. 
Research should inform the innovator about the problem, existing solutions and the target 
population, or end-user. The initial research should show evidence in support of the clinical 
effectiveness of the innovation. This research may be necessary for obtaining regulatory licences 
and approval. The research and development phase continues throughout the entire innovation 
process to ensure that the product remains competitive with similar innovations, and maintains 
end-user interest.  
Assessment: Regulatory approval, health technology assessment, other evaluation processes, 
data requirements/issues 
It is important to determine whether or not the health technology will be considered a ‘medical 
device’ early in the innovation process. In Canada, health technologies that are considered 
‘medical devices’ under the Food and Drugs Act, Medical Device Regulations, must be licensed 
by Health Canada. In order to obtain a medical device license, innovators must submit an 
application to Health Canada containing the evidence obtained from the research phase, along 
with application documentation. This manual will help innovators determine if their technology 
requires a medical device license in Canada.  
Health Technology Assessment is a process in which the technology is evaluated for social, 
economic, organizational and ethical issues in order to inform policy decisions. Health 
Technology Assessment requires evidence on the therapeutic and cost effectiveness of the device. 
The outcome of the HTA process is used to inform hospitals, regional health authorities, 
provincial programs such as the Assistive Devices Program in Ontario, Alberta’s Aids to Daily 
Living Program (AADL), BC’s PharmaCare Prosthetic and Orthotic Program, or Quebec’s 
Régie de l’assurance maladie du Québec (RAMQ) and third party payers about the technology, 
allowing them to determine whether or not the device will be reimbursed.  
Implementation: Implementation plan, adoption, diffusion, reimbursement  
If the device is reimbursed decisions around procurement and adoption can be made. In the 
procurement and adoption phase, group purchasing arrangements are made by Shared Service 
Organizations (SSOs) or provincial level Group Purchasing Organizations (GPOs). 
Alternatively, regional health authorities, government initiatives, research facilities, teaching 
hospitals and health care practitioners may provide smaller scale procurement initiatives. 
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Sustainability: Reinvest, disinvestment, reevaluating existing technology within the system, 
health technology management, evaluating if there is better technology to do the same job  
(e.g. if grant-funds pay for initial hardware and software, will the partnership organization 
continue paying on-going upgrade and maintenance costs after the grant-funds are spent? This 
question extends to whether and how the organization aligns structure and processes to 
incorporate the new technology, sustainability depends on intelligent adoption of technologies 
that enable gains in population-based needs and outcomes) 
Policy Context: Aspects/specifics of the policy context  
 Federal 
 Provincial 
 Regional  
 International 
(e.g. multiple provincial/territorial jurisdictions, comparisons to international contexts, etc.) 
Resources: Human, financial, considering the continuum of care (home/acute care resources) 
 (e.g. technology investment, venture capital, government expenditures), information resources 
Partnerships: partnerships/communication between a variety of stakeholders, organizations or 
members of groups (e.g.. Experts and academics that partner within AGE-WELL) 
clinicians/health care providers, patients, industry, policy makers, payers etc….  
User or Consumer Co-Creation: Developers engaging the end-users throughout innovation 
processes, consulting about the design or development of the process 
Aging/Older Adult Focus: Technology for older adults, technology not solving the aging 
problem, technology not specific to aging, misconceptions for technology for older adults 
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APPENDIX G: CHARTING FOR FRAMEWORK ANALYSIS 
Older Adult 
Subtheme: a) aging tech: same process b) assumptions about older adults 
Government “Generally… everybody I talk to no matter whether you’re 
talking about or rapid diagnostic test or an assistive device 
or an app… they all seem to face some of the same barriers... 
so I don’t think it will be that different” 
“there is still a cultural barrier in terms of perceptions of what seniors can do 
in terms of technology adoption… I speak with some colleagues …and they’re 
like … my grandma’s not going to be able to use an iPhone… I’m like have 
you given an iPhone to your grandma? Because if a three-year-old can use it 
I’m pretty sure grandma can use it as long as she can see it and hear it… “ 
Industry “So a lot of technologies that I have in mind, or that I am 
seeing, are not shaped to… especially focus on the old” 
“You know, you also hear in terms of clinician resistance. … They’re 
passively telling you l… I’m not really there….”Well I’d like it, but I see 
mostly senior patients, and they’d never be able to use it.” 
Innovator “ this cohort of people who are in the baby boomer years and they’re getting 
older except they don’t want to think that they’re older … as a joke within 
some of our sales force that 80 is the new 60 because some of these people are 
still vibrant don’t want to give up living in their own homes …” 
Researcher 
“I do not know of any and I would be quite surprised if there 
was anything that is aging specific because even when you 
open it up to overall health we kind of lack those things at 
this point” 
“how do you manage this patient, which may take into account age, 
because…patient preferences change when you age. A .02 increase or 
decrease in mortality isn’t usually very important to somebody that is 75, 
being out of pain is hugely important to them. ... so I would argue if we were 
to think about preferences, properly and actually consider that in the equation 
you would probably look at technologies differently because we value them 
differently as we age “ 
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Partnerships 
Subtheme: a) partnerships with health care 
stakeholders 
c) strategies to connect partners  d) involving the right stakeholders at the 
right time 
Government Reach out. Collaborate. We're all 
condemned to work together. … when 
you're with your little technology and you 
have an idea… you don't want this policy 
guy or the health research woman who will 
tell you, "This won't fly…"You have to 
tweak it because it won't fly." 
… It's better to have the cold shower right 
in the beginning and work together than to 
work five years, spend lots of money, make 
lots of proof of principle and at the end, 
say, "Nope. We don't want to."  
“Part of what we're doing … is …trying to 
develop an ecosystem, talking to researchers, 
understand the early technologies… talking 
to [the hospital], talking to rehab, the 
innovation center …There are 
technologies… that could be focused on a 
long term care home, or could be used in the 
home… and we don't have a handle on all 
the challenges of deploying it at home.”  
“innovators, people that are coming out 
with these new technologies, …early 
engagement with regulatory authorities and 
asking the right questions to understand the 
obligations of an innovator who's entering 
into this space that's maybe uncharted 
territory for them … looking long-term 
about aspects related to regulations, uptake, 
and reimbursement. …having those early 
discussions and developing a regulatory 
strategy early on in the process is something 
that is very positive … playing catch-up 
after the fact is challenging.” 
Industry “it seems to me that technologies that were 
identified should [have] the conversation 
with healthcare administrators and senior 
folks earlier…Otherwise it’s kind of an old 
fashioned model to develop something and 
kind of hope for the best… I think the way 
forward is…having very early 
conversations about what do people need 
and how is this and is this actually going to 
enjoy uptake” 
“So the SCNs in Alberta are these 
organizations that the government created 
that look at different sort of disease states or 
clinical areas, like diabetes, cardiovascular, 
that sort of thing…we’ve been working on an 
initiative with them to bring in medical 
technology companies, and um and then the 
Strategic Clinical Network…will talk to 
industry about what their health challenges 
are, and the companies can respond by 
presenting different technologies that will 
improve the health of that type of patient.” 
“The number one thing working well right 
now is that in the last five years, we have 
industry is at the table with governments - 
you know, this is sort of new to the industry. 
The medical technology industry historically 
hasn’t had dialogue with government in the 
way that it has in the last few years” 
Innovator “there’s a lot of different programs for 
entrepreneurs in Toronto specifically...  on 
campus at UofT, there’s 5 or 6 campus run 
accelerators that provide mentorship and 
advice and then we’re also part of.… another 
Toronto based accelerator. … that’s been, 
quite helpful too and. that’s all been very 
helpful….  People willing to make 
introductions and provide feedback and 
mentorship and all those things are really 
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critical for life sciences and health science 
start ups.” 
Researcher 
CANADIAN POLICY CONTEXT 
Subtheme: a) jurisdictional considerations b) international comparisons 
Government “one of the barriers is healthcare delivery is a provincial 
responsibility so there will then be a fair degree of diversity in 
what’s covered across the country so any kind of standard that 
you might want to believe in…aids to daily living and that sort of 
thing will tend to be somewhat more fragmented.” 
“I've heard this… "It's easier for me to sell into the US, than it is into my 
own province." …A lot of it is procurement rules, because …I can't 
provide any favoritism, or any weighting to say, "You're an Ontario-
based company." Because that's against the North American Free Trade 
laws”. 
Industry “one of the last ones is probably scaling up good initiatives, 
right? … great pilots all over the place that are happening and 
then they just…stay happening in whatever area, or the pilot 
dies. I think one of the things we’re trying to look at…is how do 
we bring that spread across a jurisdiction. How do you take a 
good thing happening in one community and … how do you take 
that spread across, but there is no formalized process for that in 
lots of different jurisdictions” 
“in the United States or the European Union market…you can very 
quickly get approval and then start using your thing...we put substantive 
barriers especially around class II and class IV medical devices. Even 
ones that might just simply be the same idea in principle but using a 
different material but a material that’s already been tested. You could 
theoretically see a much faster approval certain types of technologies in 
the states, because of their fast track process” 
Innovator “the Canadian model is really messed up because of the 
interprovincial trade barriers… we have a tiny market which we 
have shrunken even more with these interprovincial trade 
barriers… as a start-up company… I wind up having to pay 10, 
20, 30 percent of my capital on travel to go to markets where 
people don’t have enough critical mass that it makes sense for 
you to try and sell them something… there’s no way that the 
Canadian market is remotely big enough to support what I’m 
doing.” 
“some of the hard-core innovators were like “we don’t care about 
getting our product adopted in Canada, tell us how to get it adopted in 
Germany”.  So, there’s definitely some countries that…have a single 
payer model that the innovators seem to be interested in…French, 
Germany are much better models” 
Researcher “the US is the market that has the gold standard for regulatory 
approval… they still have standards, they set meaningful standards 
around the regulation of medical devices that are higher than Canada’s 
and they’re infinitely higher than in Europe. … But Canada is… seen in 
some ways from the regulation of medical devices as the entry place to 
test out… on the way to… or at least can be a quicker entry to the North 
American market. The FDA has a higher standard, so we’re kind of the 
intermediate, we’re close to the US, but, but we’re still easier… maybe it 
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needs to be closer to the FDA, but certainly id doesn’t need to be closer 
to the EU.” 
Development 
Subtheme: a) designing for health care c) building capacity through human/financial 
resources in development 
d) considerations for innovators in the 
development stage 
Government “we don't have a full handle on all the 
challenges of deploying it at home…Simple 
things, if you've got a technology deployed 
in the long term care owners, and there's a 
power failure, A that the long term care 
home might have a generator, in a home, 
you don't have that. It's gone, who resets it? 
You don't have IT geeks running around an 
apartment that can reset technology, if 
that's required. Things have to be made 
entirely foolproof, entirely power failure 
proof, entirely suited for people that are 
not technically inclined to do what they 
need to do. That's a challenge in and of 
itself” 
“There's not a poll from the healthcare 
system right now saying, "Here's what we 
really need." On the one hand you have 
companies or academics working away on 
something that they think is cool. Then on 
the other end of the line you've got people 
who are like, "Well, it might be cool, but it 
doesn't actually help me solve the problems 
that I have right now." Then in the middle, 
you've got the regulator who's going, 
"Well, here's how I classify it and will 
approve it"” 
“And I try to remind people about how … the 
power of Excel now is amazing like you can 
do a Monte Carlo analysis on Excel… but the 
average person uses Excel to make tables 
…entrepreneurs have to be aware that in 
some cases only one third of the functionality 
of your tools will only ever be adopted fully” 
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Industry “what happens is Health Quality 
Ontario…reported on what their areas of 
quality improvement are, what the strategic 
direction would be…and there’s an annual 
report that’s been generated out of that. … 
as an innovator, if I was to provide them 
with that tool and say “If your innovating, 
then innovate in the direction of where the 
health system is going. So they’re 
improving these areas, and if they’re 
looking at the strategic priorities of their 
hospital going in this direction, they’re 
very likely you will have a buyer for 
technology if you’re looking to address 
their problems. So this whole, looking at, 
look at the systems needs and then innovate 
in that direction would be an important 
thing” 
one of the great things that we have going for 
us in our ecosystem is just, the R&D capacity 
that we have … there’s a lot of support … in 
terms of funding, and just the regional 
innovation centres…many others that are there 
to facilitate, that are there to … take those 
ideation creation, … stage companies, through 
the continuum… we’ve got this really strong 
engine I think for R&D. I think that works very 
well for our system as a whole. Umm, I think 
we’ve got the talent… we’ve got lots of really 
focused monies and, and, and talent that are 
honing in to the kind of things that would be 
relevant as our population ages. … 
educationally, knowledge, we’ve got it all. 
The other bottleneck we work on is, we deal 
with health solutions that are at the boundary 
between the consumer and the health system, 
where information right now doesn’t really 
flow to the patient about their own data, their 
own body. It’s kind of stuck in silos and 
prisons… we’re trying to basically unlock that 
data and …its a flipping on it’s head of data 
ownership in healthcare. 
Innovator …to work in the health industry personal 
information sharing is a challenge. You’ve 
got to comply to HIPAA or PHIPA … 
people interpret this in different ways in 
different organizations and often people 
will use this as a barrier to block changes 
… entrepreneurs like me … have great 
ideas that could make health care progress 
faster but because of this limitation or risk 
adverse type protocols it’s very difficult to 
involve and to support those types of 
entrepreneurs …in Ontario or in Canada 
many, many systems exist to manage 
personal data … for caregivers or care 
professionals with ability to treat a patient 
and have access to all the data is extremely 
difficult …often I find good ideas will die 
because people are just not able to 
overcome those major barriers – Innovator 
7  
But I have noticed that many people from the 
healthcare sector do not appreciate how 
unwieldy the software can be….I hear, ‘we will 
get a student to build this’ and sometimes it is a 
small thing that can be built and sometimes it’s 
not and the assumptions that are made about 
how the software behaves is completely 
unrealistic. …there is a gap on both sides and 
many times the failure of software… is because 
there was not enough resources allocated to it 
and there was not enough knowledge allocated 
to it to be developed properly. 
Health Canada has ruled out that we are not 
a medical device…which I think is actually a 
positive in a sense because not having 
cumbersome regulatory oversight allows 
innovators and entrepreneurs to be more 
flexible especially in the development stages 
when you’re still trying to understand, you 
know what is the feature set required to 
deliver value to residents…  if Health 
Canada’s more liberal with the way they look 
at kind of non-invasive devices that pose a 
low risk to residents… that’s probably a 
positive. 
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Researcher from a policy perspective we need to do 
technologies differently…We need to create 
technologies which the RND is less 
costly…And that will be more affordable 
and that will tackle system level challenges, 
not just add, clinical value to what we do 
already. But to transform health care 
systems so they can better address today’s 
needs and ageing is one… I don’t know 
how people will tackle this 
Uh in our research we’ve looked at uh one 
spinoff that created home monitoring And, and 
what really hit this spinoff very hard was that 
they could not articulate a business model, uh 
it was really hard for them, they, they had a 
great team they really worked closely with 
clinicians and, and the whole idea was to 
reduce unnecessary uh hospitalization and, 
emergency room visit 
Assessment 
Subtheme: a) value of a national 
certificate  
b) assessments don’t 
decide/consider 
consequences  
c) mismatch 
between the pace a 
tech develops and 
pace of assessment  
d) many categories of 
evidence when assessing 
tech.  
g) difficulty classifying complex 
devices 
Government we would only review a 
device or technology that 
has been approved by 
Health Canada, so that’s 
obviously one big 
consideration. It has to 
have Health Canada 
approval.  
… 
 while we might say 
that this appears to be 
very appropriate and 
the evidence supports 
inductiveness and the 
model seems to support 
that we might get a lot 
of savings from this, it 
is not up to us to make 
that decision. We might 
put it forward and say 
that this is a positive 
decision, but at the end 
of the day it is not up to 
us, or our process, or 
one of the issues is 
timeliness, that’s a 
very slow process 
both in collecting 
the evidence… the 
academic world 
operates at a 
standard and at a 
speed that just isn’t 
practical from the 
delivery side. The 
types of things that 
turn their cranks, 
that motivate them, 
that they get 
motivated for doing 
you talk to one person 
and they’re like yeah 
you have to do 
randomized control 
trials you talk to another 
person no you don’t 
need to do an 
RCT…there is a lot of 
variability…In what an 
HTA entails, so what we 
are trying to do is get to 
a minimum viable 
product … to the HTA… 
what is the minimum 
amount of data that you 
need as that healthcare 
everything's innovative … it's new 
products and used in a way we've 
never used products before…  the 
sheer challenges in terms of where 
devices fit right now... There's 
more and more things shoved into 
each submission, and you're trying 
to figure out what the different 
component parts are and what's 
approved and what's not 
approved… moving forward, it's a 
pharmaceutical, plus a natural 
health product, plus a device, plus 
it's actually three different types of 
device in the device …, and how 
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the advisory committee 
to make the decision 
that this is gonna 
happen. 
are not necessarily 
as relevant to those 
who are responsible 
for delivering care. 
…it’s impossible to 
come up with 
recommendations 
that will apply to 
sites across the 
province or across 
the country.  
setting to say ‘ok I am 
ok with the decision lets 
purchase this’ 
…And hopefully that 
evidence packages will 
be enough for the next.. 
healthcare setting 
you manage that from a regulatory 
perspective. 
Industry Agencies … do a good 
job of health 
technology assessments 
.. But … there is no 
teeth to that 
recommendation…So 
the health system itself 
does not have to follow 
that recommendation. 
It’s quite optional. And 
so linking those 
processes to the 
adoption of innovation 
… could be greatly 
improved to helping 
technologies through 
the system. 
on reimbursement and 
approval… we put all 
our eggs in the basket 
of a funding decision 
being the be-all and 
end-all, and its just not 
even close to the 
beginning. You know, if 
you’ve met the 
evidence threshold to 
make the decision 
“This should be 
every jurisdiction, 
every country – so 
Canada, the US, 
Europe, Australia 
do their own thing… 
it means that if you 
do bring a product 
to market in 
Australia rather 
than launch it in 
Canada, you have to 
repeat the process 
… that is not 
encouraging 
innovators to come 
to certain markets  
there’s a lack of 
understanding of what is 
useful evidence 
generation, so a lot of 
things enter for the 
purpose of gaining 
experience, but is never 
really captured in a way 
that provides 
meaningful evidence on 
which we can make 
better decisions and I 
think that’s a huge 
opportunity loss. And by 
the time its past the 
point of …we’ve kind of 
lost our ability to study 
it in a  naïve sense in 
order to capture any of 
the signals from the 
noise so I think we need 
to work on that – it’s 
one of the biggest 
barriers 
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funded” … well that 
has nothing to do with 
adoption and ultimate 
value capture. So I 
mean that’s a big 
problem…, we equate 
a reimbursement 
decision making with 
use and they’re totally 
not! And so we have a 
terrible, terrible track 
record of access, and 
ultimate use by patients 
and clinicians of 
technologies that are 
frankly, standards of 
care in most countries 
Innovator the difficulty with going 
through health Canada 
…once you put them 
through the channel, if you 
package it into a hardware 
of some kind and then say 
it has, it’s now health 
Canada approved, I 
suspect…decreases the 
accessibility of that 
product and now is maybe 
10 times the cost and …it 
brings the competitive 
edge down because very 
few people can compete 
with that. - 
we hypothesized that it 
would be great to work 
with research 
institutions and 
professors who are 
prominent in the field,… 
but we found I think 
there’s been a lot of 
issues with that 
approach, … bridging 
the gap between 
academia and industry 
is …an ongoing issue… 
we don’t wanna go run 
a $100 000, million 
dollar study …if at the 
end of the day, you know 
the design of the study is 
so academically focused 
and doesn’t actually 
help us prove a case 
we’re getting into a realm 
where we could actually have 
individually produced medical 
devices. How on Earth do you 
figure out whether they are in 
spec?...From the regulator’s point 
of view this was kind of mind 
blowing because wow, how cool is 
this, but at the same time … where 
would be the start, figuring out 
how to regulate it. 
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that then will result in 
driving adoption 
Researcher Health Canada certainly 
sees themselves on the 
med tech regulatory 
pathway … The Health 
Canada regulatory 
approval process is pretty 
efficient… never mind 
small guys – for the small 
guys everything is 
impossible…  
cost effectiveness tells 
you nothing about the 
actual, sticker shock 
that goes along with 
technology adoption… 
these technologies 
involve process 
changes and 
organizational changes 
and feasibility of 
adoption questions 
from an organizational 
perspective. Its really 
very poorly analyzed 
within an HTA 
process… often times 
there is a budget 
impact analysis that is 
done, but I think 
they’re quite poorly 
done which effect to 
the real cost to the 
organizational level to 
adopt, certainly, any 
kind of meaningfully 
complex technology. 
or a lot of technologies 
we’ve looked at they 
would not have the 
evidence base nor be 
likely to get it. So if 
you’re looking at a 
medication or a certain 
type of medical 
procedure. Quite likely 
you will find or could do 
a systematic review of a 
number of regressively 
down randomized trials 
with straight forward 
outcome measures. That 
could you know cost 
effectiveness 
information that could 
then inform a decision. 
For many of the 
technologies that we’re 
considering the you 
know the evidence base / 
is not there. And is less 
likely to get there 
because these are they 
may not be the kinds of 
intermission that would 
necessarily lead 
themselves to 
randomized trials for 
example. And maybe we 
need to look at different 
kinds of evidence. – 
Implementation 
188 
Subtheme: a) having the right evidence to 
make reimbursement 
decisions  
b) bureaucratic complexities  d) value-based procurement  e) implementation considerations 
across HC settings 
Government Unless you can show that 
these devices actually save 
money based on what you’re 
already doing… It’s actually 
sitting down with the 
innovators and saying…Is 
there any way we can save 
time here?” … they often 
don’t think about that right off 
a lot of companies they think 
that that’s the ultimate goal: to 
get reimbursement but I’ve 
been trying to impress upon 
them is that reimbursement is 
not the magic bullet that they 
think that it is… in some ways 
they’re better off actually 
forgetting about 
reimbursement and actually 
we put…we're trying to do an 
outcome based RFP, here's the 
outcome: we want to reduce 
caregiver stress. …We tried to 
have a balance of being 
prescriptive, yet being open. 
Ultimately, I do think it worked 
out, I think we've got a good 
solution… We did debriefs with 
the other fourteen that didn't 
you have to change how you 
deliver the care and that’s hard, 
that’s really hard. It’s really slow 
and costly in the sense of the 
amount of time and effort needed 
and a lot of people are just too 
busy or too focused on their 
immediate needs that they just 
can’t free up enough mind share 
to work through how on earth are 
the bat. They’re so into their 
little device and they already 
think it’s wonderful … it’s 
almost like it’s your job to 
establish that dialogue and 
almost pull that information 
out of them … you go back to 
them and say “these are what 
I’ve come up with as potential 
benefits … I can see these as 
drawback. What am I 
missing?”  
building relationships with the 
healthcare organizations 
individually and working with 
the ones that are easiest to 
work with and then that might 
actually be faster pathway to 
reimbursement than it is trying 
to jump through bureaucratic 
hoops they’re just not business 
friendly 
win, and they had different 
opinions as to the process, most 
liked it being open. … a lot of 
the respondents didn't 
understand what we were 
getting at when we said…"We 
want to see a reduction in 
caregiver stress." The typical 
response back, … "We can help 
you measure caregivers' stress 
in this fashion." Good, but that 
doesn’t tell me how you're going 
to reduce it. … A few of them 
we going to change our workflow 
around this. 
understood, "We can improve 
caregivers' stress through these 
features of our product." They 
were very explicit, that was one 
reason why they won the bid. 
Industry The other barrier is that we 
just don’t know how to deal 
with the crowded nature of all 
these technologies dying for 
attention and all of them 
equally un-evidenced and 
unstudied, all of them looking 
equally fine but having 
nothing specific to make 
first to get to the market in 
general like the Health Canada 
approval… and then the 
second step, which is the 
approval for reimbursement in 
the provinces that is even more 
complicated …you cannot say 
that health technology 
assessment that leads to 
we have a unit …that works on 
outcome-based financing … the 
government is sort of tired of 
paying for things without really 
knowing if they get the value. So 
we pay for activities …to resolve 
that…  called value-based 
healthcare, or outcomes based 
financing, or outcomes based 
to kind of create a way for 
technology to be assessed and 
disseminated for homecare…there 
is no funding available from the 
ministry for research… for an 
organization like ours to do 
testing or to work with vendors, 
we don’t actually get funding for 
that.  And, it’s really a big issue, 
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decisions upon. And patients 
and society being very ill 
informed of what they’re 
demanding, generally wanting 
the new and shiny ...and so do 
clinicians. But our biggest 
barrier is that we just don’t 
have information to advice 
which technologies should 
and should not be used… and 
it’ll only get worse. 
purchasing decisions in 
Ontario would for the same 
product also qualify the 
product for being reimbursed 
in another province. … one of 
the other barriers that might 
not seem as sort of apparent is, 
is within government, the lack 
of inter-ministerial sort of 
coordination and cooperation 
payment. Also called pay for 
performance. In a technology 
room that’s called risk 
sharing… the idea would be you 
don’t pay the company … a 
penny until you actually get the 
results of the value that they 
their clinical trial suggests 
should have happened in the 
real world 
because – Because you’re taking 
money away from other things 
you wanna do to invest in this and 
you’ve got lots of competing 
priorities. So, some way to tap 
into dedicated grants or funding 
that would enable homecare 
organizations to do the testing, do 
the evaluation and then support 
knowledge dissemination would 
be incredibly helpful.  …there’s 
no mechanism to make it easy for 
us to do this. 
Innovator the health care professionals 
that we work with are really 
welcoming new ideas … but 
health care is a very, very long 
process for changing things. 
Although they are very 
enthusiastic on a new project 
to come on board … there’s a 
lot of protocols to be changed 
to introduce a new product … 
they can’t actually just make a 
decision in one day … there’s 
protocols, processes, people … 
that need to actually be made 
aware of it- it takes a long 
time.  
Researcher I think that time to synthesize, 
or coordinate regulatory and 
reimbursement processes, um 
I think Health Canada should, 
should get more in line with 
um, CADTH and they need to 
be both at the table because I 
think um, especially for the 
device side they should be 
collecting um, the evidence 
not just low tech versus high 
tech …its not just the 
magnitude of the spend… Its 
also the power of the 
purchase…there are 
established players with a seat 
at various tables and their 
interests therefore, not 
necessarily in any nefarious 
way, are heard, and so 
physicians and surgeons, the 
Places like Alberta, BC, with the 
big province-wide procurement 
agencies, and procurement 
organizations…. single province 
procurement and supply chain 
and, in BCs case shared service 
organizations that are serving 
health organizations … they’re 
serving health systems, …  that 
extend into the home and 
community care sector, even 
if the technology is not costly and, 
small, residential or hospice 
organizations could buy it, then 
it’s a matter of how do you 
convince this organization, that 
the device will pay off in, in one 
way or the other meaning… and 
this is where it’s tricky…Because, 
if you make the argument that the 
technology will reduce the need 
for a, nurse, nursing staff or a 
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that they need to get tools that they use and their there I think its extremely hard number of people taking care of 
reimbursement um decisions mechanism, to get them used. If 
they’re home and community 
care, its just a total… So yes 
you’re in the messiest space of 
all for technology adoption. 
for those procurement agencies 
to think about adoption in the 
home and community care 
sector because the, the ones that 
scream the loudest, The tyranny 
of the acute prevail. So the 
highest cost expenditures are 
still the Hips and Knees. The 
most influential interests are still 
the acute care hospitals, the 
doctors and the surgeons. So in 
their efforts, they get pulled. 
Now their doing two things, I 
think BCs initiative with value 
analysis teams, they’ve hooked 
procurement in some extent to 
the provincial wound care 
expert team in BC. Their 
capacity to bring some collective 
purchasing expertise to bear in 
aligning technology expenditure 
with clinical need 
the elderly think you are entering 
a very dangerous zone because 
what you do is put the technology 
against human delivered care… 
And you put this invention with 
how human resources are 
managed.. And…it will be 
tempting… to do what will save 
costs 
Sustainability 
Government …One other area of interest is health technology management…which is more of a life cycle approach to assessing technologies. It goes a 
little bit beyond an HTA… It would include disinvestment, while the technology is used to determine if it's still serving a real purpose or 
should it be disinvested… what are the best ways to use that technology. What should be the conditions for success to reap the most benefits 
from the technology throughout its life cycle.”  
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Industry “so the biggest one is the lack of organization and coordination. A lot of stuff just comes in and is never properly evaluated and by virtue of 
entering the hospital it is very difficult to get it back out again” 
“the system I think just really needs to understand how to stop paying for a particular technology, de-listing these kind of items so that new 
things can come in. 
it’s not the assessment, it’s the health technology management. Because part of the problem with our system is that it never goes back to 
review the old stuff … So I think we need to take a look at how we’re going to be exiting technologies that no longer 
meet our needs.” 
Innovator 
Researcher 
Co-creation 
Sub-theme: a) end-user involvement throughout innovation process 
Government “we have an element of co-design built into this program …(we) will be working with companies … and matching them with healthcare 
settings … to build evaluation projects. So the idea is that they have 6 -18 months to try out the technology in the in the actual clinical 
setting… and they form teams … the entrepreneurs… the clinicians…patients …whoever the end users are...the health procurement 
professionals- so the people …who would actually be filling out the paperwork to be actually buying this product” 
Industry the medical device sector has… some pretty big money in it…But the home health and wellbeing sector which a lot of those aging stuff … 
is really by far, [an] exponentially larger market and the only way that Canadian companies will be able to, position themselves and 
capitalize on that gross market is…if they can access the clinical and patient populations … at hospitals … Because the expertise and the 
capacities that exist in the hospitals can’t be found any place else in the Canadian landscape 
Innovator 
192 
Researcher “how patient preferences get in, it’s a dog’s breakfast of approaches. So you have a lot of, a lot of deliberative decision making processes, 
you’ll have a lot of clinicians who will identify what patient preferences are…This is to my mind, quite an inadequate process in seeking 
input from patient organizations—typically only from patient organizations, and they do their best, or worst, …to gather some input, 
qualitative input, sometimes still too, quasi kind of research. Throw together a survey kind of questionnaire, hand it around to their 
membership. Umm, so it’s not high quality evidence coming in, but some evidence is kind of brought to bear through those kind of patient 
input processes. 
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Resources 
Subtheme: a) funding challenges: homecare b) hidden costs of tech c) siloed budgets in health care  d) need to coordinate health 
tech. with economic 
development and consider that 
adopting tech can save the 
health care system money 
Government “… an eligible (program) 
expenditure includes any 
sort of training you might 
need to …get people in your 
office to be able to use this 
or even your patients to use 
it … any sort of culture and 
change management... any 
sort of supporting 
technologies so if you need 
software upgrades or … 
new computers or …a 
couple of smart phones to 
actually test out the app, 
that is also an eligible 
expense” – Government 9  
The cascading implications 
of changes in workflow is 
one of the things I think we 
need to get better at around 
the operational impact of 
the technologies… 
the way the budgets are organized 
it’s very, very difficult for folks to 
move resources or release 
resources now that you’ve included 
this transition cost and getting the 
new technology in place can be 
challenging…Depending on how 
it’s implemented you may just 
increase your costs and may get 
the benefit. Like if it’s done well 
you’ll get the benefits but a lot of 
the times the benefits are obtained 
outside of that area… 
Industry …our public delivery system, 
especially in home care is they 
sort of put their hands in [the 
air] and say “Oh I can’t do 
innovation” and he challenged 
that and he set up an innovation 
center, the first one ever in a 
homecare agency in our 
province and they’re out there 
to find the best of stuff that’s 
gonna help people live well at 
home, that are older. And they 
“and there are products 
that would not fit into this 
pattern of use as it is 
traditionally developed in 
the health care system… the 
health care system is too 
rigid and has a problem to 
adapt… the benefit of a 
product sometimes requires 
a change in how the the 
care is being approached” 
siloes in the health care system are 
another huge issue … health care 
is funded in this country based on 
primarily global budgets that are 
not reflective of the types of 
patients that are being treated and 
the volume of patients being 
treated and so hospitals are really 
disincentivized to really, to frankly 
want to have patients and all 
patients are looked at like a cost. 
The system is being looked at as 
an economic driver and a way 
to prop up industry and as an 
industry in and of itself, because 
it is, it employs 2 million people 
in Canada and could lead to 
new industries that could drive 
Canada’s economy. …so, that’s 
a very, very big area 
have a rebuilt an entire home in 
their center and they have 
…different gadgets that are 
There are a number of 
medical devices that would 
be useful for the elderly that 
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being tested… when they 
validate it, that it works, then 
they help the company be 
around the table and the 
patients and their families and 
work out all the bugs in a safe 
environment. Then they make it 
available …to any home care 
agency, so its scaled for the 
whole province.  
cannot be applied or used 
by the patient himself. So he 
needs help. And in the 
homecare setting, to 
provide this support by 
either a visiting nurse or 
something like that, it can 
be very, very difficult to do 
… certain products just 
need a second person to 
make this product work on 
the patient who needs the 
care. 
195 
Innovator cumbersome policies when it 
comes to reimbursement, kind of 
demotivate innovators or 
companies from focusing on the 
latest innovations in this sector, 
and so then what ends up 
happening as a result of that… 
basically all the key 
stakeholders … are not as 
progressive … not as tech 
forward, because they just don’t 
have the money.  They’re cash 
strapped and they’re already 
overburdened and so the 
barrier…to adopting innovation 
is quite high…so for innovators 
… in this space, you might have 
a great product that could add a 
lot of value but there’s no 
dollars and cents to pay for it 
and nursing staff and 
administrators… have like ten 
other priorities that they seem to 
be dealing with and, … there’s 
lots of operators out there in the 
nursing home space who don’t 
have the capacity to even look at 
innovations even if they wanted 
to because they’re just so 
swamped with dealing with the 
day to day grind of running their 
business. It’s very, very difficult, 
it’s …disheartening. 
“you have now that gadget that 
everybody says that will save lives, 
so who's going to pay for it…How 
to tie in… the savings in the 
hospital in terms of getting people 
out of the hospital earlier. You can 
calculate that, but the hospital is 
not going to give you money 
because you got the person out. …. 
“ 
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Researcher “this sector is significantly 
underfunded in every way shape 
and form, significantly under-
resourced, massively 
complicated. No meaningful 
leadership, you know just a 
nightmare to organize, but 
deeply mission driven, hundreds 
of little organizations, mission 
driven, trying to do the best they 
can”-  
So, I’ve, so in my advisory 
capacity then, I look at 
technologies with respect to, 
say, innovation procurement, 
where we’re looking for, ummm, 
you know that sweet spot of— 
and that—those are specifically 
funded by the ministry 
government and social services 
to support umm, you know, pilot 
initiatives and experiments 
around the, I don’t know, point 
1 percent of—3% of med tech 
adoption. That is, that is the 
budget allocated to medical 
technologies in the health care 
system. So fairly small and 
narrow niche of focus that’s the 
sweet spot there is to bring 
together health system needs 
with, um, the commercialization 
agenda or the innovation, um, 
the economic development 
agenda. So you’re looking for 
made-in-Ontario technologies 
seem to have actual promise. 
And I’d say that’s a niche from 
an HTA perspective. 
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network in technology and aging whose aim is to help older Canadians to maintain their 
independence, health and quality of life through accessible technologies that increase their safety 
and security, support their independent living, and enhance their social participation. 
Your participation in this study is entirely voluntary, so it is up to you to decide whether or 
not to take part in this study. Before you decide, it is important for you to understand what the 
research study involves. This letter will provide you with information about the study. It will 
explain the purpose of the research, your role in the research and potential benefits, risks and 
discomforts.  
Please take the time to read the following information carefully.  
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Who is conducting the study?  
This study is being conducted by: Dr. Paul Stolee, Maggie MacNeil and Melissa Koch from the 
School of Public Health and Health Systems at the University of Waterloo.  
What is the purpose of the study? 
This project will examine current policy and regulatory frameworks and processes that are 
relevant to the licensing, approval, regulation, reimbursement and evaluation of new 
technologies and innovations resulting from AGE-WELL and others involved in developing 
health technologies. Recommendations will be made for how innovation in health technologies 
for seniors can be accommodated and stimulated within existing policy and regulatory 
frameworks, as well as how these frameworks might be modified to support safe and timely 
adoption of promising and effective technologies. This understanding will be valuable in 
supporting the successful innovation and commercialization activities of AGE-WELL to the 
study aims to uncover the steps required for AGE-WELL and other technologies to be approved 
for licensing and marketing in different Canadian provinces. 
What will happen? 
You are being invited to participate in a workshop to learn from your knowledge/expertise in 
policy and regulatory issues related to new technologies and innovations. The workshop will be 
3 hours in length. You will be asked to sort, rank and rate policy options, which have emerged 
through the earlier stages of the research project. The goal of this process is to create an 
actionable policy agenda for health technology innovation in Canada, specific to older adults. 
Where will the study take place? 
The workshop will take place in-person at a convenient location. 
Will the study help you or others?  
We hope to understand the regulatory and policy frameworks/processes that guide the 
implementation of new technologies. The knowledge gained through this study will directly help 
the commercialization and dissemination activities of AGE-WELL technologies that are being 
developed for older adults, and others involved in technology innovation. We hope to make 
recommendations for how innovation in health technologies for seniors can best be 
accommodated and stimulated within existing policy and regulatory frameworks which will help 
those within and beyond the network. 
Will the study harm you?  
There are no known risks to participating in this study. 
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What do you get for being in the study? 
We are not providing any remuneration. 
Is your participation voluntary? 
Your participation in the study is completely voluntary and you may choose to withdraw from 
participating at any time. You can decline to participate in the study without penalty. If you agree 
to participate, you will be able to talk about whatever you are comfortable. If there is a question 
you do not want to answer, you may say, “I don’t want to answer that question.” Given the group 
format of this session we will ask you to keep in confidence information that identifies or could 
potentially identify a participant and/or his/her comments. 
Can you change your mind or decide not to answer a question? 
You can change your mind and stop being part of the study at any time. If you decide to leave the study, 
all of the data collected from you will be immediately destroyed.  
What will happen to your information? 
All personal information you give during the conversation will be held in confidence. Your 
information will be kept in a locked filing cabinet at the University of Waterloo, School of 
Public Health and Health Systems, and will be accessed only by members of the research team. 
Your name will not appear on any of the data. Only the project team will have access to entire 
focus group transcripts. With your permission, anonymous quotations may be used in the 
following way(s): 
 in teaching and demonstration materials 
 in scholarly papers, articles and other publications, and 
 in presentations at academic, health care conferences  
Electronic files containing study data will be password-protected, and will be destroyed after 
7years. Data files will remain anonymous such that no names will be associated with the data. 
Each participant will be assigned an identification number, which will be used to organize the 
data. There are no conditions under which the confidentiality of data cannot be guaranteed.  
Who can I contact if I have any questions? 
If you have questions about the research or about your role in the study, please feel free to 
contact Dr. Paul Stolee by phone at (519) 888 4567 x 35879 or by e-mail (stolee@uwaterloo.ca) 
or Maggie MacNeil (Margaret.macneil@uwaterloo.ca). This study has been reviewed and 
received ethics clearance through a University of Waterloo Research Ethics Committee 
(ORE#30529). If you have questions for the Committee contact the Office of Research Ethics, at 
1-519-888-4567 ext. 36005 or ore-ceo@uwaterloo.ca. 
What will happen after the study is over? 
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The researchers will ask if you would like to be contacted in the future to go over the findings 
and give your opinions on the results. If you do not want to be contacted in the future, you may 
indicate this preference.  
Conclusion 
We are excited about this study and are looking forward to listening to your experiences and 
insights regarding policy and regulatory frameworks that impact the medical device and health 
technology industry. We sincerely hope that you will consider participating.  
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APPENDIX I: POINTS DIVIDED BY CLUSTER 
Cluster 1: Legislative & regulatory 
1. National policy to contain costs of telecommunication charges when used for health applications. 
6. Make public (open data) generic and non identifiable data on costs, prices, quantity, utilization, quality, experience, etc of 
health care system consumption, production and outcomes available to industry, citizens, researchers and innovators. 
7. Develop a procurement stream with tools and mechanisms that is independent of the day to day procurement processes 
that discourages innovative procurement. Innovate procurement within accountable and responsible limits agreed to all 
parties 
25. Developing flexible agreements such as those that enable universities to hold Intellectual Property rights on publicly 
funded research 
31. Develop national level standards and strategic priorities in health innovation, encourage better alignment between these 
two federal departments and their policy efforts 
37. Health system need to be connected with economic development agenda with hospitals viewed as industrial development 
sites 
38. Understanding how current competitive bidding processes can disadvantage small, local innovators (Ex. NAFTA) 
44. Procurement reforms like risk-sharing, negotiation and value-based pricing 
45. Moving to a value-based (as opposed to cost-focused) procurement process that is concerned with the life cycle of the 
technology 
51. Reduce bureaucratic complexities within healthcare setting that slow implementation 
55. More authority for local health care agencies to fund technologies 
64. Strategies which address privacy issues working with health information 
65. Procurement processes that do not create barriers for smaller innovation companies 
91. Policy and regulatory processes align with the pace of technology development 
Cluster 2: Funding & incentives 
8. Develop a standardized template, structure and process with contracts or agreement for how organizations can carry out 
"trade offs" among budgets and departmental budgets in order to achieve improved outcomes for clients and health care 
delivery 
14. Provide subsidies and/or funding support for technologies that have the potential to offset downstream healthcare costs 
16. Payment reforms such as pay for performance schemes 
17. Scale up and increase investment in existing successful funding programs (e.g. MaRS EXCITE and TECH Edmonton 
Health Accelerator) 
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21. Providing additional local/national seed funding or venture capital opportunities to spur innovation activities and 
decrease dependence on foreign investment 
22. Federal or other resources to support innovation (e.g. developing a national medical devices partnership fund) 
27. Payment reforms such as funding based on a patients continuum of care instead of episodic treatment 
34. Programs that combine government funding with private pay to increase accessibility of technologies 
39. Government funding structures that allow the transfer of funds between and among departments or across fiscal years. 
42. Create incentives for health care providers to participate in innovation activities 
46. A formal process for strategic resource allocation in health care setting 
53. Create new innovation oriented tax credits 
67. Allocation of funds to support the trialing of technologies in health care settings 
75. Optimize existing innovation oriented tax credits 
79. Health care funding that is flexible to transfer between years or departments 
82. Government stimulus to offset the cost of a move to value-based procurement (ie which requires up-front costs in favor 
of long-term savings) 
83. More resources during the early, high risk stages of technology development 
90. Integrating health care budgets and incentives that support better patient outcomes 
Cluster 3: Processes & pathways 
2. Technologies are accessible in Canada (obtainable, affordable). 
9. Be prepared to describe and explain the challenges and issues associated with failures in innovation so that mistakes are 
not repeated. Published literature has an aversion to negative results. 
49. Develop strategies to help innovators scale technologies between different countries 
54. Encourage development of technologies which respond to health care needs present in both publically funded and user-
pay health care systems 
62. Decision timelines around adoption are articulated between innovators and healthcare system payers 
63. Support for collaborations between innovators and health care operators 
72. Clear communication between decision-makers and innovators about willingness to pay 
Cluster 4: System capacity  
12. Develop and provide structure, processes and funding to encourage and expect usability analysis and human factor 
analysis to be used in supporting innovation with safe adoption of effective technologies. Results, whether + - or neutral to 
be public 
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13. Define clear pathways that lead from real world trials to adoption at the start of adoption consideration and deliberation 
32. Products which allow for private and public sales 
35. Resources to support patient recruitment for co-creation of technologies 
50. Enable the home care sector to fund, test and implement new technologies 
59. Tools that help health care systems consider the ways health technologies impact opportunity costs, organizational issues 
and budgets 
70. Better understanding of health technology management and ways to disinvest 
85. Encourage the development of affordable technology 
Cluster 5: Evaluation 
3. Ensure technologies are evidence-based. 
5. Develop methods, processes, techniques, monitoring and reporting mechanisms to demonstrate the negative consequences 
to the health of the public of the opportunity cost and financial losses due to an inability to innovate from the path 
dependency 
10. Emphasize the necessity for innovative technologies to demonstrate and report on the direct line of sight between the 
innovation and clinical, quality and or cost effectiveness of the innovation in the health care setting and as a benefit to the 
clients 
15. Implementing user experience analysis and user acceptance testing during evaluation 
18. Recognizing that technologies need to be adapted to various healthcare settings 
30. Encourage innovators to think ahead to assessment (what data do they need) 
43. Formalizing methods for patient involvement in health technology assessment 
48. Health technology assessments are relevant and understandable for a particular context 
57. Health technology assessment processes align with the timelines of decision-makers 
66. Innovators understand the data they need to produce to participate in health technology assessment 
84. Alternative approaches to assessment for promising technologies (e.g. allow for adoption and assessment to occur 
simultaneously) 
86. Open access to, and contextualization of, existing evaluations of health technologies 
88. Technology assessments are designed to incorporate a variety of metrics or evidence types (e.g outcomes, feasibility, 
cost effectiveness, budget and care pathway impacts) 
93. Technology assessments are designed to incorporate a variety of perspectives (e.g. social, ethical, legal, patient 
preference) 
95. Developing metrics for evaluating the effectiveness of technologies that consider societal impacts of health innovations 
as opposed to using metrics such as number of patents, licensing partnerships and intellectual property agreements 
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Cluster 6: Patient & end-user involvement 
20. Build awareness and understanding among developers of unmet health system priorities (e.g. so technologies are driven 
by health system need) 
23. Technology that has a useful interface for care providers that fit with existing technology and processes 
29. Innovators/technology developers need to better understand the practical aspects of health delivery (e.g. resulting in 
more relevant technology) 
33. Encourage the development of simple and easy to use technology for older adults 
40. Increase awareness of implementation in health care settings besides acute care (e.g. home care and long-term care) 
56. Involvement of patients across all stages of innovation 
58. Create opportunities for innovators to consult with clients, health care professionals early (ie slow iterative development 
stage to understand target population) 
60. Involvement of patients and caregivers in policy/process change 
61. Encourage innovators to think ahead to implementation (where will their tech fit and who will pay) 
80. Understanding health care provider perspectives about integrating technology in their work 
81. Have patients define problems for developers to address 
87. Bust myths about older adults and technology (e.g. their willingness and ability to use it) 
92. Increase awareness that HTA recommendation does not guarantee widespread adoption 
Cluster 7: Communication channels 
4. Work with unions and associations representing health care workers in reviewing labour contracts with a view to 
identifying and amending clauses and serve as a disincentive or barrier to facilitating safe and effective diffusion of health 
care innovation 
11. Develop and raise awareness and understanding of risk sharing agreement templates that could be adopted by health care 
delivery organizations, innovators and industry. 
19. Strategies to bolster partnerships between stakeholders (tools to promote communication, information sharing and reduce 
duplication) 
24. Earlier consideration and understanding by innovators of the regulatory process 
26. Create opportunities for innovators to consult with regulators, reimbursers early 
28. Developing materials for innovators, including a procurement how-to-handbook; standard bid templates and 
procurement best practices 
36. Understanding professional college policies on scope of practice before introducing a new technology 
41. Build the business skills of innovators 
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47. Acknowledging the time and cost associated with training staff to use a new technology 
52. Policy makers need to better understand the practical aspects of health care delivery (e.g. resulting in the development of 
innovation policies that are reflective of the needs of the health care system) 
68. Promote the development of innovation ecosystems (which can combine resources between partners, and link different 
regional partners) 
69. Promote early engagement between medical device industry and regulators at Health Canada 
71. Encourage better linkages between innovation departments, and their health policy directions in different provinces 
73. Understanding how new technology engages with existing legislation (e.g. regulatory processes and software, 
multicomponent devices etc) 
74. Support technology transfer offices in better understanding and responding to end-user needs to benefit the health care 
system 
76. Acknowledge the role that arms-length agencies can play linking partners from different sectors (innovators, regional 
partners, institutions, governments, international partners) 
77. Develop strategies to help innovators scale technologies between different jurisdictions (i.e. provinces) 
78. Encourage transdisciplinary working within ecosystem partnerships 
89. Promote partnerships between technology companies and venture capital firms 
94. Strategic plans of health care organizations are externally accessible 
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APPENDIX J: GO ZONE STATEMENTS 
3. Ensure technologies are evidence-based. 
10. Emphasize the necessity for innovative technologies to demonstrate and report on the direct line of sight 
between the innovation and clinical, quality and or cost effectiveness of the innovation in the health care setting and 
as a benefit to the clients 
13. Define clear pathways that lead from real world trials to adoption at the start of adoption consideration and 
deliberation 
14. Provide subsidies and/or funding support for technologies that have the potential to offset downstream 
healthcare costs 
15. Implementing user experience analysis and user acceptance testing during evaluation 
20. Build awareness and understanding among developers of unmet health system priorities (e.g. so technologies are 
driven by health system need) 
26. Create opportunities for innovators to consult with regulators, reimbursers early 
28. Developing materials for innovators, including a procurement how-to-handbook; standard bid templates and 
procurement best practices 
30. Encourage innovators to think ahead to assessment (what data do they need) 
35. Resources to support patient recruitment for co-creation of technologies 
38. Understanding how current competitive bidding processes can disadvantage small, local innovators (Ex. 
NAFTA) 
40. Increase awareness of implementation in health care settings besides acute care (e.g. home care and long-term 
care) 
47. Acknowledging the time and cost associated with training staff to use a new technology 
50. Enable the home care sector to fund, test and implement new technologies 
56. Involvement of patients across all stages of innovation 
58. Create opportunities for innovators to consult with clients, health care professionals early (ie slow iterative 
development stage to understand target population) 
60. Involvement of patients and caregivers in policy/process change 
61. Encourage innovators to think ahead to implementation (where will their tech fit and who will pay) 
63. Support for collaborations between innovators and health care operators 
64. Strategies which address privacy issues working with health information 
66. Innovators understand the data they need to produce to participate in health technology assessment 
67. Allocation of funds to support the trialing of technologies in health care settings 
80. Understanding health care provider perspectives about integrating technology in their work 
81. Have patients define problems for developers to address 
86. Open access to, and contextualization of, existing evaluations of health technologies 
88. Technology assessments are designed to incorporate a variety of metrics or evidence types (e.g outcomes, 
feasibility, cost effectiveness, budget and care pathway impacts) 
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95. Developing metrics for evaluating the effectiveness of technologies that consider societal impacts of health 
innovations as opposed to using metrics such as number of patents, licensing partnerships and intellectual property 
agreements 
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APPENDIX K: CASE EXAMPLE 
A group of proactive and community-minded Senior Citizens, Family & Caregivers, Home Care 
clinicians and Senior Administrators have become aware of a new home sensor system that may 
enable independent living for those with advancing age and increased health needs.   
The sensor system has the ability to send alerts to caregivers by tracking and reporting older 
adults’ temporal and spatial movement patterns.  There is potential for these movement patterns 
to then be monitored and compiled as data.   
Interventions could be established from this data to mitigate other health risks or declining health 
states.  To make a well-informed decision, a multiplicity of issues needs to be considered. 
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APPENDIX M: PHASE ONE PARTICIPANTS’ GO ZONE  
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APPENDIX N: FINAL QUESTION LIST FOR FOCUS GROUP 
1. What challenges exist to installing a technology in an older person’s home as compared to 
a hospital or a retirement home? 
2. Who should pay for health technologies such as the one identified in the case example? 
3. Who should own older adults’ health information? 
4. What could be done to help companies developing technologies like the case example to 
understand our health care system? 
5. How can we make technologies inclusive for disadvantaged groups of older adults? 
(ex. low-income, visible minority groups, new immigrants, indigenous, sexual minorities) 
6. How should we address negative assumptions about older adults’ technology use? 
7. How could we ensure the technological solutions that are developed are what our health 
care system needs? 
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